










The handle  http://hdl.handle.net/1887/92369 holds various files of this Leiden University 
dissertation. 
 
Author: Meeuwis, S.H.   
Title: Placebo and nocebo effects in itch : from conditioning to psychophysiological 
effects 







Placebo and nocebo effects in itch 













Author:   Stefanie Meeuwis 
Cover design:   Céline Meeuwis 
Printing:   GVO Drukkers & Vormgevers BV 
 
© Copyright Stefanie Meeuwis, 2020 
All rights reserved. No part of this thesis may be reproduced or transmitted in any form or 
by any means without written permission from the author. 
 
The research presented in this thesis was carried out at the Health, Medical and 
Neuropsychology Unit of Leiden University, Leiden, the Netherlands. The research was 
funded by a Consolidator Grant from the European Research Council (ERC), granted to 








Placebo and nocebo effects in itch 
From conditioning to psychophysiological effects 
 
Proefschrift 
Ter verkrijging van 
de graad van Doctor aan de Universiteit Leiden, 
op gezag van Rector Magnificus prof. mr. C.J.J.M. Stolker, 
volgens besluit van het College voor Promoties 
te verdedigen op woensdag 3 juni 2020 
klokke 13.45 uur 
 
door 
Stefanie Helena Meeuwis 





Prof. dr. A.W.M. Evers 
 
Copromotoren: 
Dr. H. van Middendorp 
Dr. D.S. Veldhuijzen 
 
Promotiecommissie: 
Prof. dr. J.F. Brosschot 
Prof. dr. M.H. Vermeer 
Prof. dr. M.L. Peters (Universiteit Maastricht)  
 
 
TABLE OF CONTENT 
 
Chapter 1.  General introduction         7 
 
Chapter 2.  Placebo and nocebo effects across itch and dermatological   23 
conditions: a systematic review  
Chapter 3.  Antipruritic placebo effects by conditioning H1-antihistamine               99 
Chapter 4.  Placebo effects of open-label verbal suggestions on itch              151 
Chapter 5.  Effects of open- and closed-label nocebo and placebo               171 
suggestions on itch and itch expectations 
Chapter 6.  Open- and closed-label placebo and nocebo suggestions              203 
about a sham transdermal patch: effects on itch 
 
Chapter 7.  Summary and General Discussion                 243 
 
  Nederlandse samenvatting                 271 
  Curriculum Vitae                  279 





















Placebos are inert substances (e.g., sugar pills) or other types of inert treatment forms [1]. 
Particularly in the field of medicine, placebos are used as a tool to which active 
pharmacological substances can be compared [2]. The rule of thumb involved is as follows: 
you have two groups of people (‘A’ and ‘B’), give ‘A’ the real medicine, and give ‘B’ 
placebos instead – any improvement of ‘A’ over ‘B’ is indicative of whether the real 
medicine is effective [2,3]. At first glance, this appears very straightforward indeed. 
However, while simply looking at the difference between groups ‘A’ and ‘B’ in a clinical 
trial paints a clear picture of the efficacy of a specific medicine, it is also somewhat limited: 
this difference does not tell a patient exactly how much improvement to expect after taking 
said medication. For that, comparisons to a ‘starting point’ or baseline value are needed, 
and here the previously clear picture becomes blurry. Studies show improvement of 
symptoms within the control groups of clinical trials – so for the people who are taking 
placebos – across a wide range of medical conditions [4]. This type of improvement is 
generally attributed to contextual or nonspecific treatment factors. Moreover, these factors 
impact outcomes within the treatment groups of clinical trials as well: so the total 
improvement following medication use would then be the sum of the specific effects of the 
medication and the nonspecific treatment factors [2,3,5]. In reality this may be even more 
complex however. Research has shown that nonspecific treatment factors can interact with 
the efficacy of medication – and that the efficacy of medication can likewise impact 
nonspecific treatment factors, such as placebo effects [2-4].  
 
Placebo and nocebo effects: concepts and definitions 
Placebo effects are part of the nonspecific treatment factors that can impact or interact with 
the efficacy of medication, and may make up a significant portion of what makes a 
treatment effective. They are defined as beneficial treatment outcomes that cannot be 
attributed to active treatment components [6]. Rather, these effects are attributed to 
expectations of beneficial or positive treatment outcomes [7-11]. It is important to 
emphasize the difference between placebos and placebo effects: where placebos refer to 
inert treatments (e.g., sugar pills) that can be given to a person, placebo effects refer to 
positive reactions a person can show in response to inert substances or as part of active 
treatments, with these reactions being elicited by expectations of benefit [1,6]. Unravelling 
the specific mechanisms that underlie placebo effects and investigating their impact is 
important for two reasons: 1) this knowledge may help to improve research on the efficacy 
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of (new) treatments, and 2) knowing how placebo effects can be elicited may help to 
develop strategies to maximize them in clinical practice, which could then lead towards 
enhanced treatment outcomes, optimized medication use, and reduced side effect 
occurrences [6]. Placebo effects are attributed to expectancy and can be elicited by a variety 
of factors, for example, but not limited to: information about a treatment, previous 
experiences with treatments or otherwise learned associations of treatment and 
improvement, general beliefs about medicine, aspects of the patient-provider relationship, 
and other social or contextual cues [7-11]. On the opposite side of the spectrum are nocebo 
effects: negative or adverse treatment outcomes that are attributed to non-active treatment 
components [12,13]. Researchers have spent the last decades unravelling the mechanisms 
behind placebo and nocebo effects, and have identified three main mechanisms through 
which these effects may be induced: associative learning (i.e., conditioning), instructional 
learning (e.g., through verbal suggestions), and social or observational learning (e.g., by 
social cues in the environment) [14-16]. These different types of learning are proposed to 
shape an individual’s expectations about treatment either positively (in case of a placebo 
effect) or negatively (in case of a nocebo effect). Theoretical models of the placebo effect, 
for example the response expectancy model [17] and the learning model of placebo effects 
[18], state that these modulated expectations can then influence the experience of symptoms 
of disease [19]. 
Both placebo and nocebo effects have been found to significantly impact health-related 
outcomes. For example, placebo effects have been found to reduce itch and other somatic 
symptoms such as pain, dyspnea, fatigue and nausea [20], and research shows that they can 
impact physiological parameters as well, for example, immune or endocrine responses [21-
23]. Nocebo effects in contrast have been found to increase the experience of somatic 
symptoms, to result in increased side effects, or to result in reduced treatment efficacy 
[12,13]. One area in which placebo and nocebo effects may be relevant is that of 
dermatology [24].  
 
Placebo and nocebo effects in dermatology: effects on itch 
Itch, or pruritus, is commonly described as an unpleasant sensation that evokes the urge to 
scratch, and is considered chronic if it lasts for over six weeks [25-28]. This symptom is a 
key marker of most cutaneous conditions, for example allergic disorders, atopic dermatitis 
or eczema, urticaria, psoriasis, and lichen simplex [29, 30]. Listed as the fourth leading 
10 
 
world-wide cause of non-fatal disease burden, skin diseases have a major social, societal 
and economic impact [31]. Especially in skin diseases, the burden of itch is high, with an 
estimated lifetime prevalence of itch set at 100 percent for patients (whereas in the general 
population, estimated prevalence ranges from 7-22%) [32]. Finding strategies to reduce this 
burden of disease therefore remains a priority for scientific research. In addition, itch is a 
common symptom for non-dermatological conditions. It has been often reported in 
systemic, uraemic, neurological, or endocrine diseases (for example, kidney failure, 
multiple sclerosis, or diabetes mellitus), and is also prevalent in some psychiatric conditions 
[28,33,34]. For these conditions, itch often also has a considerable impact on quality of life 
and wellbeing of patients [34]. 
Depending on the origin of the itch sensations, different classifications can be identified 
[33,35]. A common classification of itch is by the pathway through which it is evoked: 
histaminergic, or non-histaminergic [36,37]. Although several signaling chemicals are 
known to evoke itch, histamine is investigated most frequently [27,28]. Treatment of 
histaminergic itch often consists of systemic treatment with H1-receptor antagonists, 
commonly referred to as antihistamines, or topical agents such as corticosteroids. However, 
these treatments usually  have low efficacy or result in significant side effects [33,37], thus 
increasing the need for formal investigation into approaches by which the efficacy of 
existing treatments may be enhanced. Moreover, considering the broad range of conditions 
for which itch occurs and its debilitating nature, it is important to find ways to reduce this 
symptom and thereby positively impact patients’ wellbeing. One of the ways to do this is 
by strategically using placebo effect mechanisms [24].  
 
Strategies for inducing placebo and nocebo effects 
Studies on the phenomenon of ‘contagious itch’ – itch that is induced by visual, auditory or 
other contextual cues – show that social and psychological factors can play an active role in 
determining the severity of itch that is experienced by patients [38-40]. Contagious itch 
therefore may indicate that placebo and nocebo effects could potentially play a large role in 
itch. Moreover, while most studies on placebo and nocebo effects focus on pain and pain-
related conditions (for a review of placebo and nocebo effects in pain see, for example, 
[41]), there is also evidence that these effects occur in itch. A meta-analysis shows that in 
control arms of clinical trials with patients suffering from dermatological conditions, over 
30 percent of itch reduction can be attributed to placebo effects [42]. In addition, several 
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studies have investigated whether placebo and nocebo effects for itch can be experimentally 
elicited by associative or instructional learning.  
 
Associative learning: classical and pharmacological conditioning 
Originally described by Pavlov, classical conditioning entails the learning process by which 
(new) associations between stimuli are formed [43,44]. In short, an association is made by 
presenting an initially neutral stimulus (thereafter the conditioned stimulus, CS) together 
with an unconditioned stimulus (UCS) that is known to elicit a certain response 
(unconditioned response, UR). After the CS and UCS have been presented together, the CS 
will then elicit a response that is similar to the UR by itself, even when the UCS is not 
presented (this is known as the conditioned response, CR; see Figure 1) [22,44]. Studies 
show that these classical conditioning procedures can be used to modify itch levels in 
healthy volunteers. To illustrate, one recent study investigated effects of conditioning on 
itch by combining visual cues (i.e., various colors) with high and low levels of itch. After 
these CS’s and UCS’s were repeatedly paired together in a learning phase, the visual cues 
were then found to influence the amount of itch that participants reported when they were 
presented together with a medium level of itch during a testing (evocation) phase [45]. 
Learned associations like these could be what drives the placebo effect: positive 
expectations trigger actual symptom reduction when certain visual cues are presented. The 
type of classical conditioning that was investigated in the study described above [45] has 
been found to occur mostly on a cognitive level however – in other words, the association 
between CS and UCS needs to be made consciously by participants and, more importantly, 
the UCS consists of changes in itch that are made by manipulating the experimental 
procedure (i.e., exogenous change). Placebo effects may also be learned by conditioning 
responses on a more endogenous level: through classical conditioning of pharmacological 
responses [46,47]. In studies investigating conditioned pharmacological effects, the UCS 
typically is a substance known to elicit a certain physiological response, such as an active 
medicine [23,24]. For example, patients can learn that treatment cues (e.g., the color of a 
pill; CS) belonging to a pharmacologically active substance (painkiller, UCS) are 
associated with certain treatment effects (pain reduction; UR). These treatment cues could 
then prompt the same response (CR), which is what we know as the placebo effect (i.e., itch 
or pain reduction after taking a colored pill, even when active pharmacological substances 




Figure 1. Schematic overview of (A) Pavlovian and (B) pharmacological conditioning: before conditioning, the (initially 
neutral) to-be conditioned stimulus (CS) causes no response. During conditioning, the CS is coupled with an unconditioned 
stimulus (UCS), that elicits an innate (unconditioned) response (UCR). After conditioning, the CS provokes a similar (conditioned) 
response (CR), even in the absence of the UCS.  
 
Research demonstrates that it is possible to modulate immune functioning with 
pharmacological conditioning [47-50]. For example, studies show that, after having been 
conditioned with the immunosuppressive drug cyclosporine A as UCS, a saccharin solution 
can significantly reduce blood serum levels of interleukins, and thereby reduce the 
physiological response to immune challenges (e.g., viruses or allergens) in animal and 
human models of allergy [49,50]. Likewise, this type of conditioning can also increase 
immune responses, for example when a CS is coupled with a substance that challenges or 
sensitizes immune functioning, such as an allergen. Allergic responses were found to be 
sensitive to these conditioning effects [51-53]. For example, cases are known where 
patients who are allergic to roses have developed allergic asthma attack when presented 
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with artificial roses [54]. Such learned allergic responses to inert stimuli may exacerbate 
existing allergic disorders, which could be interpreted as a nocebo effect. There is also 
evidence that conditioned immunosuppression can be used to reduce allergic symptoms that 
are elicited through histaminergic pathways [55,56]. Goebel and colleagues [55] found that 
conditioning with the antihistamine desloratadine (UCS) could influence the basophil 
response to dust mite allergens on a level comparable to actual drug effects in humans, 
although they did show that effects of conditioning on self-reported allergic symptoms 
(including itch) and skin response to dust mite were less evident.  
A second study complemented these findings by showing that allergic symptoms and 
physical responses to histamine reduced in both the conditioned and sham-conditioned (i.e., 
receiving a CS without UCS) groups compared to a natural history (i.e., no intervention) 
group [56]. Given that not only the conditioned group but also the sham-conditioned group 
showed reduced symptoms, it is likely that these reductions can be attributed to factors 
other than pharmacological conditioning [56]. Taken together, these two studies show 
mixed evidence for the efficacy of antipruritic conditioning of the effects of antihistamines 
for allergy [55,56]. However, as noted by the authors of both studies, a number of factors 
may have impacted study findings, such as elicitation of symptoms through non-
histaminergic pathways, regression to the mean, receiving an intervention (regardless of 
this being a sham or active intervention), or potentially, participants’ own previous 
experiences with antihistamines. More research is needed in order to unravel whether 
conditioning of antihistamines is possible in humans. 
 
Instructional learning: the impact of positive and negative verbal suggestions 
Where conditioning may largely rely on one’s ability to associate one cue with another 
(which would then impact expectancy), another type of placebo and nocebo effect induction 
often used in laboratory settings is to alter expectancy by instructional learning. This type 
of learning does not rely on prior experience (as associative learning does) or on 
observations of others (as social learning does), but on communication of information or 
advice [57-61]. Placebo and nocebo effects can be elicited by instructional learning, for 
example when suggestive information is given about the effectiveness of a certain treatment 
(i.e., verbal suggestions) [14,16,22]. These suggestions can elicit positive or negative 
expectations, which would then in turn impact symptom perception [14]. Previous studies 
have shown that verbal suggestions can influence somatic symptoms, for example of pain, 
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fatigue, and nausea [20]. Evidence for the efficacy of verbal suggestions in itch varies: 
some studies show that placebo and nocebo effects in itch can be elicited by verbal 
suggestions [62-65], whereas others show mixed evidence, with suggestions eliciting 
nocebo but not placebo effects [66], or fail to show effects on itch of verbal suggestions 
alone [45,67,68]. Moreover, the methods used to elicit itch vary across studies and only a 
few have investigated histaminergic itch induction. A single study indicated that nocebo 
responses to verbal suggestions in physical responses to histamine (i.e., wheal or flare 
response) could be provoked [63], however, most studies report finding no significant 
changes in physical parameters following verbal suggestions [62,67,69]. Considering the 
mixed evidence, more research is needed to investigate whether placebo and nocebo effects 
could be induced for itch specifically through verbal suggestions.  
Across studies variations in the type of verbal suggestions that are employed to elicit 
placebo and nocebo effects are found. For example, some studies give suggestions of high 
or low itch because of changes in the pain or itch induction method (also known as placebo- 
and nocebo-like responses) [45,66,70], whereas others give suggestions about a dummy 
treatment (e.g., an inert cream) provided alongside the pain or itch induction [62,67,69]. 
More research is needed in order to identify how and under which circumstances verbal 
suggestions may elicit placebo and nocebo effects. It should be clarified what type of 
information and which environmental cues can elicit placebo effects, as this knowledge 
could be used in clinical practice by health care providers, for instance to maximize positive 
expectations while informing patients who start new treatments. Knowing which manner of 
information provision may or may not be helpful could then be used to improve patient-
provider communication, and by that enhance placebo effects and prevent nocebo effects in 
clinical practice.  
 
Open-label placebo effects 
Knowing how to best inform patients about treatments, and using this knowledge to 
improve patient-provider communication may be a potential strategy for utilizing placebo 
and nocebo effects mechanisms to improve healthcare. At a first glance it appears that this 
might in fact be the only way to use the knowledge on placebo and nocebo effects in 
clinical practice in an ethical and non-deceptive way [71,72]. After all, any use of inert 
substances or covert changes in medication dosages – which are common techniques used 
to study placebo and nocebo responses in laboratory experiments – would be considered 
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unethical in clinical practice as these involve deception [73]. Patients should be fully 
informed about which treatment they receive, and any attempt to circumvent this could 
harm a patient or challenge their autonomy. Because of this, the means by which placebo 
and nocebo effects are traditionally investigated in the laboratory (i.e. by providing inert 
substances under guise of an active treatment) cannot be immediately translated to clinical 
practice. In the last decade, however, research has shown that it may be possible to induce 
placebo effects in clinical practice without involving deception [74-76].  
It has been found that providing inert pills to patients alongside a rationale that explains 
how subsequently elicited placebo effects could impact symptomatology can reduce self-
reported symptoms for patients suffering from irritable bowel syndrome [77], chronic low 
back pain [78], attention deficit hyperactivity disorder [79], and allergic rhinitis [80,81]. 
Most of these aptly dubbed ‘open-label’ placebo effects are elicited on top of treatment as 
usual. Because of this it remains unclear by which aspects (or combinations thereof) open-
label placebo effects are elicited [75]. For example, it may be possible that the effects of the 
open-label placebos are evoked by the provided explanation (instructional learning), or that 
the inert pills alone are enough to elicit improvements in symptomatology (through 
classical conditioning mechanisms). However, it may be equally likely that the open-label 
placebo could interact with treatment as usual and that this may enhance those 
pharmacological effects. For example, it may be possible that the open-label rationale (i.e. 
explaining the role of learning and expectations) interacts with expectations about or the 
pharmacological effects of treatment as usual, or that it impacts other components of 
treatment (e.g., patients’ belief in treatment efficacy) and influences symptomatology 
through those components. Therefore more research into the specific mechanisms of open-
label placebo effects is necessary. Likewise, the efficacy of open-label placebos for 
histamine-induced itch is unclear. Considering that placebo effects for itch appear to be 
substantial, it may be of interest to investigate them in an open-label (placebo) context as 
well. Finally, no study to date has investigated whether pharmacological conditioning of 
antihistamines for itch may be effective in an open-label context. 
In short, placebo and nocebo effects can be elicited through various pathways, among 
which pharmacological conditioning and verbal suggestions. Previous literature indicates 
that placebo and nocebo effects may be relevant for the field of dermatology and itch. 
However, little is known about whether pharmacological conditioning with antihistamines 
may impact itch specifically, and evidence for the influence of verbal suggestions 
(providing either positive or negative information) on itch is oftentimes mixed. In addition, 
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placebo and nocebo effects for itch have not yet been investigated in an open-label context, 
either in case of placebo effects elicited through pharmacological conditioning, or placebo 
and nocebo effects elicited through verbal suggestions. Doing so may be a first step towards 
therapeutic application of placebo and nocebo effects and may help in improving existing 
treatments for itch. 
 
The current dissertation 
In this dissertation, placebo and nocebo effect inductions for histaminergic itch are 
investigated using multiple approaches in various randomized controlled studies, i.e., 
pharmacological conditioning and positive and negative verbal suggestions in both an open-
label context as well as a closed-label context (i.e., concealed, with participants not 
knowing about the placebo or nocebo effect induction). Moreover, effects of these methods 
on other (psycho)physiological responses to histamine are addressed. An overview of the 
outline of this dissertation is provided in Figure 2. 
In Chapter 2, studies using experimental placebo and nocebo effect induction methods 
within the field of dermatology are systematically reviewed. Evidence for placebo and 
nocebo effects elicited in cutaneous conditions, in symptoms of the skin and mucous 
membranes associated with itch, and in relevant experimental animal and human models is 
summarized. The impact of different placebo and nocebo effect induction methods on three 
broad categories of outcomes (self-reported, physiological, and behavioral) is reviewed and 
differential aspects of studies (i.e., different designs) are compared. Potential implications 
for clinical practice are discussed.  
In Chapter 3, the design and results of a randomized controlled study are presented and 
discussed. In this study, the possibility of pharmacologically conditioning the antipruritic 
effects of antihistamines in healthy volunteers is assessed. Moreover, the potential of non-
concealed, or open-label, use of conditioning for influencing itch is explored for the first 
time. Effects of (open-label) conditioning on other (psycho)physiological parameters are 
assessed, and the role of individual characteristics (e.g., expectations, personality) in 
eliciting placebo effects for itch is explored.  
Chapter 4 describes the first in a series of three randomized controlled studies 
investigating the efficacy of open-label suggestions for itch. In this study, the effects of 
open-label positive verbal suggestions about the itch induction method are investigated for 
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itch and other responses to histamine in healthy volunteers and compared to neutral 
instructions.  
In Chapter 5, a study is presented that was conducted as a follow-up study to the one 
described in Chapter 4. In this follow-up study, we assessed whether verbal suggestions 
about an inert substance (i.e., a sham tonic) can influence itch and other responses to 
histamine in healthy volunteers. Effects of positive verbal suggestions and negative verbal 
suggestions are compared. Moreover, the efficacy of verbal suggestions in influencing itch 
is assessed for both an open-label context and a closed-label (i.e., concealed) context.  
The final of the three studies on the efficacy of open-label suggestions is described in 
Chapter 6. Here, it is investigated whether open-label and closed-label positive and 
negative suggestions can influence itch in healthy volunteers, when those suggestions are 
about side effects rather than treatment effects. As in the previous studies, the effects of the 
suggestions on itch and other responses to histamine are assessed.  
Chapter 7 is the summary and main discussion of this dissertation. Here, the results of the 
conducted studies are summarized and discussed in light of other work in this field and 
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Placebo and nocebo effects have a large influence on somatic symptoms such as pain. For 
itch and other dermatological symptoms these effects have been far less investigated. The 
current review systematically integrates for the first time evidence from both animal 
(mainly rodents, but also non-human primates) and human trials on the elicitation of 
placebo and nocebo responses in itch, itch-related symptoms and conditions of the skin and 
mucous membranes, and related immune outcomes (e.g., histamine). Thirty-one animal 
studies, twenty-one human studies with healthy participants, and thirty-four human studies 
with patients were included. Overall, studies consistently show that placebo and nocebo 
effects can be induced by various methods (e.g., suggestions, conditioning and social cues), 
despite a high level of heterogeneity across studies. Effects of verbal suggestions were 
found consistently across subjective (e.g., itch in humans) and behavioral (e.g., scratching 
in animals) parameters, whereas conditioning was likely to impact physiological parameters 
under certain conditions (e.g., more pronounced conditioning of histamine levels in stressed 
rodents). Brain areas responsible for processing of itch were associated with nocebo effects 
in itch. Future research should investigate how variations in methods may impact placebo 






Placebo and nocebo effects are known to influence symptom severity and treatment 
efficacy in various medical symptoms and conditions [1-4]. Placebo effects can be 
described as beneficial effects that are not due to a (pharmacologically) active treatment 
component, but are rather elicited by contextual cues, or by positive expectations regarding 
treatment outcomes [5,6]. Nocebo effects are adverse treatment outcomes (e.g., increased 
side effects, reduced treatment efficacy) elicited by non-active treatment components [5]. 
Studies show that placebo and nocebo effects can be experimentally induced by, among 
other things, conditioning (associative learning), expectancy manipulations through 
providing positive or negative information (verbal suggestions) about treatment outcomes 
(instructional learning), or by social cues (e.g., learning by observing others) [6-8]. In 
addition, some work suggests that placebo effects may still occur when it is known that a 
placebo is given (open-label placebo) [9-13].  
Placebo and nocebo effects have been found to impact various somatic symptoms such as 
pain and itch [3]. Itch is a key symptom of many dermatological conditions [14,15], has a 
high impact on patients’ quality of life and has high economic costs [16-18]. The estimated 
lifetime prevalence of itch in the general population is 7-22%, and in patients with a skin 
disease estimates are set on 100% [19]. Most often, itch is evoked in the skin by mediators 
(e.g., histamine) eliciting changes in the chemical environment that are detected by C 
nociceptive fibers (capable of transmitting noxious stimuli, including itch and pain) to 
regions in the brain stem, the thalamus, somatosensory cortex, as well as areas involving 
emotion and reward [20]. A meta-analysis shows that at least 30 percent of itch reduction in 
randomized controlled trials can be explained by placebo effects [21]. Research shows that 
such placebo effects may occur through top-down processes stemming from brain regions 
involved in planning, emotion regulation, as well as brain regions specific to the symptom 
or condition for which they occur, and that they can moreover be evoked by expectations 
regarding treatment outcomes [22,23].  
Most studies demonstrate that placebo and nocebo effects can be induced by verbal 
suggestions, for example, for self-reported symptoms of itch. There is some evidence, 
however, that these effects can also be elicited for physiological parameters related to itch, 
for instance, for wheal or flare responses to histamine [24]. Literature moreover shows that 
conditioning can influence immune parameters in animal models and human populations 
[25-27]. As such, conditioning may potentially be used to influence the immune pathways 
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underlying itch and cutaneous conditions as well. Although narrative reviews emphasize 
the impact of placebo and nocebo effects on itch [3,7,8], a systematic overview of studies 
investigating placebo and nocebo effects, which also encompasses the immunomodulatory 
aspects of these effects, has not been provided yet. Providing such an overview could 
provide new insights in the consistency of placebo and nocebo effects found across 
induction methods, clinical conditions, and symptoms. The current review therefore aims to 
summarize the available knowledge of placebo and nocebo effects that were experimentally 
elicited in controlled trials in cutaneous conditions, in symptoms of the skin or atopic 
symptoms of the mucous membranes that are associated with itch, as well as in related 
experimental human (i.e. healthy participants) or animal models. 
 
RESULTS 
Search results and study characteristics  
An overview of the literature search and number of articles in each step of the selection 
procedure can be found in Figure 1. In total, the literature search identified 16.440 unique 
studies, of which 79 were considered eligible for inclusion. An additional 7 studies were 
identified by screening the reference lists of the included studies, bringing the total to 86 
articles that were included in this review (k=31 animal and k=55 human studies). Articles 
that were identified through reference lists did not have keywords listed online, or provided 
no online abstract and were therefore not found in the systematic search. A semi-
quantitative overview of effects for each induction method and outcome type is provided in 
Table 1 (with a graphical representation and short summary being given in Supplementary 
Figure S1 and Supplementary Table S1, respectively). An extensive overview of the 
study characteristics and a short summary of results is presented for animal and human 
studies separately (with human studies further split into healthy volunteers and patient 










Risk of bias assessment 
An overview of the risk of bias assessment outcomes is provided separately for animal and 
human studies, in Supplementary Figures S2-S5. The quality of the 86 included studies 
varied. None of the included animal studies met all criteria for risk of bias, most often due 
to a lack of important information to decide risk of bias. For human studies, more 
information was provided, and risk of bias was lower. In general, no differences in risk of 
bias were detected between studies that reported null findings and studies that reported 
significant findings. Studies on verbal suggestions combined with hypnosis more often had 
a selection bias compared to the other studies – participants who were highly hypnotizable 
were often selected, which may have increased bias in the study findings. In addition, some 
studies on verbal suggestions had high risk of bias for blinding, mostly due to the personnel 



























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Of all thirty-one animal studies, most investigated effects in rodents (guinea pigs k=12; rats 
k=11; mice k=4; both rat and mice k=1) or non-human primates (k=3; exclusively included 
in studies on social induction of scratching behavior). The number of animals included in 
each experiment ranged from 5 to 96. Three studies did not report sample size. Most (k=18; 
58%) included male samples exclusively, followed by studies that included both sexes 
(k=5; 16%) or females exclusively (k=4; 13%). A minority (k=4; 13%) did not report the 
sex of the animals. Most animal studies were conducted before 1990 (k=19; 61%), and only 
a few took place within the last 10 years (2010-2019: k=3; 10%).  
 
1. Placebo effects 
1.1. Conditioned immunosuppression 
Eight studies investigated whether allergic responses could be suppressed by conditioning 
of a neutral stimulus (or conditioned stimulus, CS; e.g., a saccharin solution or an odor) 
with a pharmacological drug (unconditioned stimulus; UCS) in rodent models of delayed-
type hypersensitivity responses. Saccharin preference ratio (i.e. behavioral parameter – the 
amount of saccharin that was ingested by the animal in a subsequent testing phase 
following conditioning) was reduced in all studies (k=6) that assessed this parameter. 
Evidence of conditioned immunosuppression was found for most physiological parameters 
(i.e., for hemagglutination titers, ear or paw swelling, and leukocyte migration to the area of 
antigen injection). Conditioning did not affect paw swelling when dexamethasone was used 
as UCS [28]. One study found extinction of conditioned responses following the first of 
three re-exposures [29]. Moreover, one study indicated that conditioned effects are 
dependent on the induction of stress [30], suggesting that conditioned responses may be 
context-specific. 
 
2. Nocebo effects 
2.1. Conditioned allergic responses and anaphylactic shock 
Twelve studies investigated whether an allergic response could be learned through 
conditioning in rodent models by pairing a cue (the CS, for example, an odor) with an 
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allergen or substance for which animals were previously sensitized. Behavioral parameters 
were influenced in 5 of the 7 studies that assessed them: saccharin preference ratio 
decreased following conditioning in all studies (k=3), whereas behavior indicating 
anaphylactic shock or asthmatic attack increased in 2 of 4 studies. In the two studies that 
overall reported null effects, behavior indicating an asthmatic attack remained unchanged in 
one study [31], while another found conditional effects: exposure to the CS led towards 
asthmatic attacks – but only when animals were stressed [32]. It was demonstrated that 
freely-acting behavior (e.g., rearing, locomotion) did not change following conditioning 
[33]. Changes in physiological parameters were found following conditioning, which were 
indicative of an allergic response (i.e., increases in histamine serum levels, Rat Mast Cell 
Protease II, or lung tissue histamine levels; increased plethysmographic amplitude, and 
respiratory resistance, see also Table 1). Two studies failed to find effects on (secondary) 
physiological outcomes [34,35]. Others showed mixed evidence for conditioned histamine 
release in rodents: it was shown that effects depended on handling-induced stress [36,37], 
fasting stress [35], anesthetization [34], or receiving medication such as diazepam [38] or 
dexamethasone [39]. For example, conditioned histamine release occurred exclusively in 
stressed animals.  
2.2. (Operant) Conditioning of scratch responses 
Two studies described a series of experiments, in which it was investigated whether 
scratching behavior could be operationally conditioned by reinforcing bouts of scratching 
with food [40,41]. One study found scratching to be less readily conditioned compared to 
rearing or washing [40], while the other found that scratching could be increased through 
operant conditioning – with the behavior being more easily conditioned when an itchy 
stimulus (i.e. collar) was present [41]. 
2.3. Social induction  
Four studies investigated whether scratching behavior could be contagious in animals (k=1 
in rodents, k=3 in non-human primates). The most common designs consisted of either 
observing a live same-species animal, or of observing videos in which scratching behavior 
was displayed. Two studies found that scratching behavior in observers (i.e., animals that 
watched others scratching) increased [42,43], while two other studies found that scratching 





Of the 21 studies with healthy volunteers, most studies included both males and females 
(k=16; 77%). Two studies (9%) were stratified by sex (50:50 distribution in experimental 
groups) or investigated females exclusively (k=3; 14%). Sample sizes ranged between 10 to 
159 healthy volunteers. Most studies were conducted in the past 10 years (2010-2019: 
k=13, 64%). 
 
1. Placebo effects 
In total, fourteen studies were included that investigated placebo effects by verbal 
suggestions. A single study investigated the induction of placebo effects by conditioning 
combined with verbal suggestions (described in subsection ‘2.4.1.2. Conditioning’).  
1.1. Verbal suggestions 
Across studies, a further subdivision could be made for studies that induced placebo effects 
by: a combination of verbal suggestions and hypnosis (k=7), by verbal suggestions 
exclusively (k=6), or by open-label verbal suggestions (k=1). Three of the seven studies 
that provided positive verbal suggestions with hypnosis demonstrated improvement in self-
reported (i.e., pain induced by laser and histamine skin prick tests, [46]) and physiological 
parameters (i.e., skin responses to histamine and horse serum such as wheal and flare, 
titration gradient and endpoints, pain-related brain potentials) [46-48]. One study found that 
effects on wheal area were a function of the depth of the trance induced by hypnosis [47]. 
In addition, four studies compared suggestions of decreased responses to antigens or 
histamine for one arm with suggestions of increased responses for the other arm within 
subjects. All four studies included or divided participants on being highly hypnotizable [49-
52]. Only one study reported significant differences in skin thickness following suggestions 
at certain dilution strengths of the test substance [51]. The others reported no effects. Four 
studies investigated placebo effect induction by positive verbal suggestions exclusively. 
Expected itch, pain or skin responses were reduced following positive suggestions in all 
studies [53-56]. Three studies assessed histamine-induced itch [54-56], but only one of 
these found lower itch following suggestions [54]. Positive suggestions reduced pain during 
a cold-pressor task in one study [56], but not in another [55]. Wheal area was not affected 
by suggestions in any study. Two studies compared positive suggestions with negative 
suggestions [57,58]: overall, findings were mixed. In one study, suggestions of high and 
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low itch or pain were able to respectively enhance and decrease self-reported parameters of 
itch and pain after mechanical and electrical stimulation, but suggestions of low itch did not 
reduce histamine-induced itch [58]. In another study, physiological parameters (i.e. flare, 
wheal) differed between positive and negative suggestions groups, but no differences were 
found compared to a neutral control group [57]. Finally, a single study investigated whether 
open-label positive verbal suggestions could induce positive expectations and placebo 
effects for itch compared to a neutral control [59]. Suggestions decreased itch expectations, 
but not itch. No effects on physical skin response (histaminergic flare (area), skin 
temperature, wheal area) were found.  
1.2. Conditioning 
A single study investigated placebo effect induction by conditioning, verbal suggestions, 
and by combining suggestions and conditioning. While no significant reduction in 
electrically induced itch was found following conditioning exclusively or following verbal 
suggestions exclusively, a combination of the two did result in reduced itch levels [60]. 
 
2. Nocebo effects 
In total, seven studies investigated nocebo effects in healthy volunteers. Nocebo effects 
were induced by verbal suggestions (k=1), conditioning (k=1), a combination of verbal 
suggestions and conditioning (k=2; described in the subsection ‘2.4.2.2. conditioning’1), or 
by social cues (k=3; contagious itch).  
2.1. Verbal suggestions  
In the study that focused exclusively on suggestions-induced nocebo, participants received 
information (verbal suggestions) about the severity to which they would respond to 
histamine and saline skin prick tests [24]. Itch, unpleasantness of the test, and wheal 
diameter were higher in response to saline, and the histaminergic flare (measured by 




1 This includes the study of Bartels et al. (2014) that is also described under subsection ‘2.4.1. placebo effects’, as both placebo and 




Three studies investigated nocebo effect induction by conditioning. One study 
demonstrated successful nocebo effect induction by conditioning for itch. Moreover, the 
study showed that these learned responses could be reversed by positive suggestions, and 
demonstrated generalization of effects from electrical to histamine-induced itch [61]. Two 
studies found that conditioning and verbal suggestions could both increase itch [60,62]. In 
addition, one of these reported that a combination was most effective to induce nocebo 
effects [60]. Using functional magnetic resonance imaging (fMRI), increased activity was 
found in the contralateral Rolandic operculum, and increased functional coupling was 
found between the insula and the periaqueductal gray (PAG), all areas involved in the 
somatosensory processing of histaminergic itch [62].  
2.3. Social induction 
Three studies investigated whether itch could be induced by social or contextual factors in 
healthy participants, using a variety of methods to induce itch sensations: videos of people 
scratching [63], slideshows of itch-related pictures [64], or itch suggestions during music, 
which were presented either sub- or supra-liminally [65]. Itch and scratching behavior were 
increased in 2 of 3 studies [63,64]. In the remaining study, findings were mixed: itch and 
scratching were increased only when suggestions were presented supra-liminally during 
music, but not when presented super-liminally [65]. Watching itch-inducing videos 
moreover activated major areas of the itch matrix (thalamus, primary somatosensory cortex, 
premotor cortex (BA6), and insula) as demonstrated through fMRI [63]. 
 
Patients 
In the 34 studies on placebo and nocebo effects within patient samples, the investigated 
medical conditions were: allergic rhinitis (including, but not limited to, hay fever and dust 
mite allergy) (k=10; 29%), atopic dermatitis (k=9; 26%), allergic asthma (or other lung 
problems associated with irritation by allergens, e.g., bronchitis) (k=6; 18%), warts (k=3; 
9%), psoriasis (k=2; 6%), chronic urticaria (k=1; 3%), lichen simplex (k=1; 3%), multiple 
conditions combined (k=1; 3%), or unspecified skin diseases (k=1; 3%). Most studies 
included both male and female patients (k=23; 67%), but some did not describe sample sex 
(k=11; 33%). The majority of studies took place either within the last ten years (2010-2019: 
k=9, 27%) or before 1970 (k=8, 24%).  
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1. Placebo effects 
In total, nineteen studies investigated placebo effects in patient samples. Placebo effects 
were elicited by positive verbal suggestions and hypnosis (k=12), by open-label suggestions 
(k=2), by conditioning (k=4) or by social induction (k=1).  
1.1. Verbal suggestions 
Across studies investigating placebo effect induction by suggestions, medical conditions 
investigated were: allergy (k=4), warts (k=3), allergic asthma (k=2), atopic dermatitis 
(k=2), chronic urticaria (k=1), psoriasis (k=1), and multiple conditions combined (k=1). In 
the twelve studies on suggestions and hypnosis, eleven provided suggestions of non-
responding (e.g., to allergens) or symptom relief. Four studies investigated self-reported 
symptoms, with three demonstrating significant induction of placebo effects (in one of 
these studies, effects were found exclusively when symptoms were assessed 
retrospectively) [66-68]. Physiological parameters (e.g., clinical symptoms of skin 
conditions, such as wheals or warts) were assessed in 10 studies, and were generally 
reduced following suggestions and hypnosis in 3 studies [69-71]. In the other 7 studies, no 
or mixed evidence was found. One study gave suggestions of improvement for one side of 
the body and concluded that any observed improvement was on that side, however, no data 
or statistical tests were reported [72]. Some studies noted that symptoms improved only 
when deep hypnosis was achieved [73,74]. Finally, two studies investigated whether open-
label placebo effects could be induced for allergic rhinitis [75,76]. A briefing about the 
placebo effect was given together with inert pills (in addition to treatment as usual) in one 
study [75]. In the other, both separate and combined effects of the briefing and the inert 
pills were examined [76]. Open-label placebo effects were induced for allergic symptoms in 
both studies. Moreover, while the inert pills reduced allergic symptoms, no additional effect 
of the open-label briefing was found [76].  
1.2. Conditioning 
Medical conditions investigated were allergy (k=2), psoriasis (k=1), and atopic dermatitis 
(k=1). Studies on conditioning placebo effects in patient samples could be further 
subdivided into pharmacological conditioning (k=2), conditioned dose reduction (k=1), or 
suggestions and conditioning (k=1). In the two studies on placebo effects by 
pharmacological (antihistamine) conditioning for allergic rhinitis, no effects on subjective 
symptoms or wheal size were found [77,78]. Basophil activation after exposure to allergens 
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was reduced, however, which is indicative of conditioned immunosuppression [77]. In the 
single study that investigated conditioned dose reduction (i.e., using conditioning principles 
to partially replace medication by placebo), findings were mixed: although conditioned 
dose reduction prevented psoriasis relapse overall, significant improvement in symptoms 
was demonstrated only in one of two research sites [79]. Finally, a single study investigated 
whether verbal suggestions, conditioning, or a combination of both could influence 
electrically-induced pain in atopic dermatitis and healthy controls [80]. Verbal suggestions, 
but not conditioning, reduced pain in both atopic dermatitis and healthy controls. Moreover, 
a combination of suggestions and conditioning was most effective. 
1.3. Social induction 
A single study assessed whether advertising of antihistamine brands would influence drug 
efficacy (defined as % decrease in wheal) in allergic vs. non-allergic participants [81]. Two 
types of advertisements were shown, one where only brand A (the antihistamine used in the 
study) was promoted, and one where brand B was promoted as working faster than A. 
Decreased efficacy was found for allergic participants at 60 minutes following 
antihistamine use when brand A was promoted, compared to when brand B was promoted. 
For non-allergic participants, increased efficacy was found when brand A was promoted at 
120 minutes following antihistamine use.  
 
2. Nocebo effects 
In total, fifteen studies investigated nocebo effects in patient samples. Nocebo effects were 
elicited by negative verbal suggestions (k=5), by conditioning (k=5), or by social induction 
(k=5).  
2.1. Verbal suggestions 
Across studies investigating nocebo effect induction by suggestions, medical conditions 
examined were: atopic dermatitis (k=2), allergic asthma (k=2), and other lung problems 
related to irritants or allergens (k=1). One study investigated negative verbal suggestions 
with hypnosis, and four investigated negative verbal suggestions exclusively. Following 
suggestions and hypnosis, higher skin temperature was found in both atopic dermatitis and 
healthy controls [82]. Another study in atopic dermatitis investigated nocebo effects 
induction by suggestions exclusively, and found that this increased self-reported itch [83]. 
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Moreover, fMRI signal increased following suggestions in the dorsolateral prefrontal 
cortex, caudate, and intraparietal sulcus – all regions involved in motivational and cognitive 
processing, and all regions that respond when real allergens are presented [83]. Finally, 
three studies investigated effects of negative suggestions on physiological parameters 
representing airway reactivity [84-86]. One study failed to find effects of negative 
suggestions on physiological parameters (i.e., respiratory pattern, maximum expiratory 
flow) in bronchial asthma [84]. In the other two studies, suggestions did elicit significant 
changes in physiological parameters (i.e., airway resistance, thoratic gas volume, 
conductance-thoratic gas volume ratio) indicative of bronchoconstriction [85,86]. 
Moreover, positive suggestions (i.e., that a bronchodilator was given) reversed these effects 
[86]. 
2.2. Conditioning 
Five studies investigated whether nocebo effects could be induced by conditioning in 
allergic rhinitis (k=3), atopic dermatitis (k=1), and lichen simplex (k=1). No effects of 
conditioning on self-reported allergic symptoms were found [87,88]. Physiological 
parameters (i.e., peak nasal inspiratory flow, histamine level, nasal tryptase level) increased 
following conditioning in 2 studies [87,88], while another failed to find effects (i.e., for 
wheal response to sham allergens) [89]. Generally, conditioned effects were stronger when 
the number of acquisition trials increased, and effects were prone to extinction [87]. 
Finally, for patients with atopic dermatitis and lichen simplex, conditioning led to a higher 
number of scratch responses compared to healthy controls [90,91].  
2.3. Social induction 
Five studies investigated whether symptoms such as itch could be induced socially (e.g., 
contagious itch, induced by a lecture on itch, scratching videos, or pictures of allergens) in 
atopic dermatitis (k=3), non-specified skin diseases (k=1) or allergic asthma (k=1). Three 
studies compared patients with healthy controls. Self-reported parameters (i.e. itch, asthma 
symptoms composite score) and scratching behavior were increased following social 
induction in all studies that measured these outcomes. Both self-reported and behavioral 
parameters increased more for patients compared to healthy controls [92-95]. Moreover, 
fMRI data showed that activation of the supplementary motor area, the left ventral striatum 
and the right orbitofrontal cortex increased following an itch video compared to a control 
video – all regions that are particularly associated with the desire to scratch in itch [95]. 
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While breathing frequency increased in response to allergen pictures in allergic asthma, no 
changes were detected for other (physiological) respiratory parameters [96]. 
 
DISCUSSION 
This review summarizes the available knowledge on experimentally induced placebo and 
nocebo effects in cutaneous conditions, and symptoms of the skin or atopic symptoms of 
the mucous membranes associated with itch, in relevant animal or human models (i.e., 
healthy participants and patients). In general, considerable evidence is provided for placebo 
and nocebo effects in medical conditions and symptoms relevant to the field of 
dermatology. Placebo and nocebo effects were elicited in self-reported and behavioral 
parameters related to symptoms (e.g., itch, allergic symptoms or other self-reported 
symptoms, scratching behavior). Effects could also be induced for physiological 
parameters, most notably when (pharmacological) conditioning or a combination of 
suggestions and conditioning were used. Generally, findings were less consistent for 
physiological parameters than for self-reported or behavioral parameters. The findings 
illustrate that placebo and nocebo effects can be induced through similar mechanisms 
across animal studies, studies using healthy volunteers, and studies with patients, despite a 
high level of heterogeneity across studies. 
Animal studies show that both placebo and nocebo effects may be elicited through 
associative learning (conditioning). It was demonstrated that allergic reactions can be 
conditioned, which is indicative of a nocebo effect. Likewise, placebo effects were shown 
in rodent models of allergy (i.e. modelled hypersensitivity responses), as demonstrated by 
studies investigating conditioned immunosuppression. However, the methods used within 
these studies were very diverse. For example, the way in which hypersensitivity is modeled 
in rodents differed, as did the conditioning paradigms used: both CS and UCS were 
heterogeneous amongst studies, the number of acquisition and evocation sessions varied, 
and the specific control groups differed between studies (see Supplementary Table S2). 
There was consistency in behavioral outcomes, but physiological outcome parameters 
varied depending on the specific sensitization method and unconditioned stimulus that were 
used. Overall, the studies illustrate that learned placebo effects are moreover sensitive to the 
context (they may not be elicited when the context changes) and are prone to extinction 
[29,30,34-39]. In the future, research may consider systematically investigating which 
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conditioning paradigms are most effective. Moreover, replication and generalization of the 
conditioning paradigms used in previous studies may be considered.  
Of all human studies included in the review, the outcome parameters used were most 
consistent in studies with healthy participants – with self-reported measures of itch and 
physiological outcomes of wheal and flare responses to histamine being most often 
assessed [97,98]. Most models with healthy participants simulate cutaneous conditions by 
mechanical, electrical, and chemical (i.e., histamine) stimulation of the skin. Effects were 
found most consistently for self-reported outcomes such as itch, and behavioral outcomes 
such as scratching. Physiological outcomes, on the other hand, were less consistently 
influenced. In patient samples, similar trends in study outcomes were observed, with self-
reported and scratching behavior generally more likely to be affected than physiological 
parameters. Most studies investigated – and found placebo and nocebo effects for – atopic 
dermatitis and allergic rhinitis, with only a small body of research done on placebo and 
nocebo effects in other conditions (e.g., psoriasis, chronic urticaria, and other skin 
diseases). Future research may consider replicating these findings, as well as extending 
them to other dermatological conditions, in order to assess similarity of effect sizes for 
different symptom etiologies. It should be noted that the manner of placebo and nocebo 
effect induction varied a lot across human trials (both for healthy participants and patients). 
Overall, different mechanisms (i.e., verbal suggestions, conditioning, social induction) were 
used to elicit placebo and nocebo effects – furthermore, even in case of similar 
mechanisms, other variances in the study design (e.g., type of instructions, dissimilarities in 
conditioning paradigm) may complicate the comparability of placebo and nocebo effect 
sizes across studies. In trials with patients, an additional confounding factor is added by 
heterogeneity across medical conditions and condition-dependent outcome parameters.  
Finally, few studies have investigated neurological pathways and brain areas that are 
involved in placebo and nocebo effects for dermatological symptoms such as itch. Placebo 
and nocebo effects may modulate itch through top-down processing in brain areas related to 
the specific condition or symptom in which they emerge [23]. Indeed, work on itch shows 
that brain areas likely involved in nocebo responding are those that are responsible for 
somatosensory processing of itch or are otherwise related to the itch-scratch cycle as well 
[62,63,83,95]. Caution is needed in interpreting these findings, however, as only nocebo 
effects have been investigated. Moreover, of the four studies on brain processing of nocebo 
effects in itch, two were investigating contagious itch. Mirror neurons (i.e., activated when 
mirroring facial expressions for affective or empathetic purposes) have been proposed to 
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play a role in eliciting contagious itch [99]. It unclear whether or how this may relate to 
nocebo effects induced by other means. In addition, brain processing of placebo effects in 
itch have not yet been investigated. Future research may aim to further identify brain 
regions of interest for both placebo and nocebo effects processing.  
It has been proposed previously that verbal suggestions are more likely to elicit effects on 
self-reported outcomes in humans – either alone, or in combination with conditioning 
[3,8,98], whereas for physiological outcome parameters, (pharmacological) conditioning 
may be more likely to elicit effects. The studies included in the current review likewise 
underline this notion. Moreover, findings show that cues from the social environment may 
impact the experience of symptoms. Most evidence stems from the induction of contagious 
itch in experimental settings, for instance, while listening to a lecture or watching videos of 
people scratching. Research on the extent to which these concepts may translate towards 
clinical practice, or on how such cues may impact symptom experience in daily life, is 
lacking. Future research may consider further investigating the influence of social and 
contextual cues on treatment efficacy in clinical populations. In addition, future research 
may further investigate which (combination of) mechanisms would be most effective in 
inducing placebo and nocebo effects for a variety of symptoms across dermatological 
conditions. Clinical relevance and applicability may be considered here, and the 
mechanisms that are most promising to establish longer-term effects should have 
precedence over those that appear to elicit short-term changes. Conditioned dose reduction 
may be a promising approach, as this method is based on conditioning principles [100], 
could be considered most directly applicable in clinical practice [101], and has been found 
to be as effective as full medication doses – not just in psoriasis, but also in other conditions 
such as attention-deficit hyperactivity disorder [79,102]. Likewise, open-label placebo 
effect induction may be investigated further in the future. Even though this has been 
investigated only infrequently in relation to dermatological symptoms or conditions 
[59,75,76,103,104], research from various other fields further supports the notion that 
placebo effects can be elicited even when it is known that an inert substance is given [9-13]. 
Information derived from these studies may pave the way for new therapeutic possibilities, 
for example the development of psychoeducation regarding the role of expectations and 
learning in health and disease, or the development of a training specifically targeting the 
patients’ expectations of treatment, and in turn treatment effects. Open-label placebo effects 
may be a way to ethically apply placebo and nocebo effects in clinical practice [105]. The 
available body of evidence for open-label placebo effects within dermatology is currently 
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limited, however, and more research is necessary as a consequence, especially in patient 
populations.  
In addition to utilizing placebo effects in clinical practice, attention should be given to the 
occurrence of nocebo effects as well. The current review demonstrates that these can be 
evoked by a variety of methods, and attention should be given to ways to reduce their 
impact in clinical practice. Some work already shows that previously learned nocebo effects 
for itch can be reduced by a combination of suggestions and counterconditioning [61]. 
Studies in other research areas (e.g., in the field of pain) also show promising results for 
such methods [106]. Suggestions and counterconditioning may, for example, be used to 
reduce the occurrence of unwanted side effects, or to counter diminished treatment efficacy 
due to previously learned negative associations [106]. The efficacy of these methods in 
reducing nocebo effects for itch-related symptoms of the skin and mucous membranes 
should be researched more extensively in the future. 
Placebo and nocebo effects in symptoms and medical conditions are known to vary 
between individuals. For example, a study investigating pharmacological conditioning of 
anti-allergic effects demonstrated that symptoms in both conditioned and sham-conditioned 
groups were likely influenced by the participants’ own expectations and cognitions, as these 
differed from a natural history group [78]. Likewise, there is evidence that individual 
characteristics, such as personality characteristics and polymorphisms in genetic markers, 
may impact placebo and nocebo effects [7,107-110], although evidence for these specific 
predictors of placebo and nocebo effects within the field of dermatology is limited and 
mixed [8]. Of the studies included in the current review, few investigated predictive factors 
for placebo or nocebo responding. Some work illustrated that placebo and nocebo responses 
may have occurred in subgroups only, such as highly hypnotizable or suggestible 
individuals [73,74]. Likewise, the individual characteristics of the person who is providing 
information about a treatment (e.g., warmth and competence of a health care provider) may 
impact the size of effects [24]. Future research could aim to further investigate what factors 
may impact placebo and nocebo effects in order to provide a more complete and structured 
picture of under which circumstances these effects are likely to be most strong.  
Limitations of the current review were the heterogeneity of the included studies, which 
prevented a meta-analysis of study results. In addition, some studies have demonstrated 
high risk of bias, most notably in inclusion of participants (studies on hypnosis selected on 
high hypnotizability), or in blinding (experimenters providing verbal suggestions were not 
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blinded and often examined outcomes as well). Moreover, in most articles that described 
animal research, information needed to rate bias was lacking. As a result, most studies were 
rated as being unclear on bias. In addition, sample sizes reported in most studies included in 
this review are small. As such, effects that are small may not have been detected in these 
studies. Finally, some of the included studies describe experimentally elicited pain. These 
tests were incidentally included as they occurred alongside an itch induction test or in a 
relevant patient sample. However, the review did not systematically include pain-induction 
tests, so the number of studies finding placebo and nocebo effects for pain, as described 
here, might not reflect the actual incidence of placebo and nocebo effects studied within the 
field of pain. For a review on those studies see, for example, Peerdeman and colleagues [7].  
Overall, this review provides considerable evidence for placebo and nocebo effects within 
dermatological conditions, specifically for itch and other symptoms of the skin and mucous 
membranes associated with itch. Such effects can be elicited using various methods, most 
importantly, by using verbal suggestions, conditioning, or social induction. Some caution is 
needed in translating this work to clinical practice and more research is needed for a more 
robust foundation upon which clinical applications may be built. First and foremost, it is 
important to structurally investigate how variations in induction methods may impact 
placebo and nocebo effects, and whether all symptoms and medical conditions may be 
influenced similarly by placebo and nocebo effects elicited through these induction 
methods. Second, the impact of external factors (e.g., predictors such as suggestibility) on 
placebo and nocebo effects should be investigated more extensively. Finally, more research 
is needed to implement this knowledge about placebo and nocebo effects in clinical 
practice: clinical trials may further explore whether conditioning may be used to maximize 
placebo effects and minimize nocebo effects in clinical practice, to enhance treatment 
efficacy, reduce medication intake, and enhance patients’ quality of life.  
 
MATERIALS AND METHODS 
A complete overview of the methods for the systematic review is provided in the 
Supplementary Material. In short, this review was conducted in accordance with the 
PRISMA statement on systematic reviews [111] and pre-registered in Prospero 
(PROSPERO 2018: CRD42018096636). Articles were included in the review if they (1) 
were conducted in healthy volunteers, animals, or patients with chronic or acute itch 
associated with a dermatological condition, or associated with (atopic) symptoms of the 
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skin or the mucous membranes related to itch; (2) investigated experimentally-induced 
placebo or nocebo effects (e.g., elicitation of effects through conditioning, or social or 
verbal expectation induction methods such as suggestions); (3) were written in English, 
Dutch or German; (4) presented new data; and (5) assessed outcomes including – but not 
limited to – perceived itch, behavioral measures related to itch (e.g., scratching behavior), 
self-reported symptoms (e.g., allergic or atopic symptoms), extent of neurogenic 
inflammation, or itch-related inflammatory markers (e.g., histamine, substance P). Articles 
were excluded when data was presented on a case-by-case descriptive level or when total 
sample size was n<5.  
PubMed, PsycInfo, and Embase databases were searched for relevant articles on May 8, 
2018. Two independent raters (SM, CvL) screened titles for the inclusion criteria. Next, the 
two raters assessed abstracts and full-texts for eligibility, using a hierarchical approach. 
Discrepancies between the two raters were resolved by discussion with a third independent 
rater (HvM). The reference lists from the included articles were checked for additional 
relevant articles by both independent raters. Data from the included articles were extracted 
by one rater (SM) using a piloted form. Two independent raters (SM, KB) assessed risk of 
bias of each study using the Cochrane risk of bias tool [112]. The SYRCLE risk of bias tool 
was used for articles describing animal research [113], as were the guidelines described by 
O'Connor and Sargeant [114]. 
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Elaboration on the search strategy 
The inclusion criteria were transformed into a systematic search strategy consisting of 
Medical Subject Headings (MeSH) and title or abstract text words (tiab), that combined 
placebo or nocebo induction-related terms with (1) methods of experimental itch elicitation, 
(2) dermatological conditions associated with itch, or (3) eligible types of outcome 
parameters. The search was conducted in the PubMed, PsycInfo, and Embase databases on 
May 8th 2018, with search strategies for PsycInfo and Embase being derived from the 
PubMed strategy (see Supplementary Figure S6 for the search strategy).  
 
Parameters extracted from the articles 
The following categories of parameters were extracted from the articles: 1) self-reported 
parameters (when self-report measures were not directly related to the intended placebo or 
nocebo induction, the experimental model used or the medical condition assessed, they 
were not included); 2) behavioral parameters; and 3) physiological parameters. In addition, 
descriptives of the included articles were extracted by piloted forms.  
 
Risk of Bias assessment 
The SYRCLE risk of bias tool was used by two independent raters (SM, KB) for articles 
describing animal research [1] together with the guidelines provided by O'Connor and 
Sargeant [2]. Assessed criteria were: selection bias (clarity of the description in regard to a. 
random sequence generation, b., baseline characteristics of animals, and c. concealment of 
group allocation), performance bias (clarity of description for a. random housing of 
animals, and b. the blinding of personnel and participants), detection bias (clarity of the 
description of the blinding of outcome assessments), attrition bias (description of 
incomplete outcome data), reporting bias (whether selective reporting occurred), and other 
bias (not specified before). Risk of bias of each human study was assessed using the 
Cochrane risk of bias tool [3]. Ratings of both independent raters were compared, and 
discrepancies between ratings were resolved by discussion. The following criteria were 
assessed: selection bias (clarity of the description in regard to a. random sequence 
generation, and b. concealment of group allocation), performance bias (clarity of 
description for the blinding of personnel and participants), detection bias (clarity of the 
description of the blinding of outcome assessments), attrition bias (description of 
55 
 
incomplete outcome data), reporting bias (whether selective reporting occurred), and other 
bias (not specified before). For both human and animal studies, each category was scored as 
‘low RoB’ when the provided information was enough to suspect low bias, ‘high RoB’ 
when information was mentioned that would incur bias (e.g., insufficient blinding), or 
‘unclear RoB’ when information was not clearly provided. Risk of bias analyses were 
descriptive: no further steps were undertaken to conduct sensitivity analyses or to exclude 





Supplementary Table S1. Brief summary of the methods and results of the included studies.  











% confirmed  
Animals 8 Placebo  Conditioning Behavioral 6 / 6 100 
    Physiological 8 / 8 100 
 17 Nocebo Conditioning Behavioral 5 / 7 71 
    Physiological 10 / 11 91 
 2 Nocebo Operant conditioning Behavioral 1 / 2 50 
 4 Nocebo Social induction Behavioral 2 / 4 50 
       
Healthy 
participants 
7 Placebo Verbal suggestions + hypnosis Self-reported 1 / 1 100 
   Physiological 4 / 7 57 
 6 Placebo  Verbal suggestions Self-reported 2 / 5 40 
    Physiological 1 / 6 17 
 1 OL placebo Verbal suggestions Self-reported 0 / 1 0 
    Physiological 0 / 1 0 
 2 Placebo Conditioning (+ verbal 
suggestions)  
Self-reported 2 / 2 100 
 1 Nocebo Verbal suggestions Self-reported 1 / 1 100 
    Physiological 1 / 1 100 
 1 Nocebo Conditioning (+ verbal 
suggestions)  
Self-reported 3 / 3 100 
    Physiological 1 / 1 100 
 3 Nocebo Social induction (e.g., contagious 
itch by video of people scratching) 
Self-reported 3 / 3 100 
    Behavioral 3 / 3 100 
Patients 12 Placebo Verbal suggestions + hypnosis Self-reported 3 / 4 75 
    Physiological 3 / 10 30 
 2 OL placebo Verbal suggestions (+ inert pill)  Self-reported 2 / 2 100 
 3 Placebo Pharmacological conditioning / 
conditioned dose reduction  
Self-reported 1 / 3 33 
    Physiological 2 / 3 67 
 1 Placebo  Conditioning (+ verbal 
suggestions) 
Self-reported 1 / 1 100 
 1 Placebo Social induction (advertising) Physiological 1 / 1 100 
 1 Nocebo Verbal suggestions + hypnosis Physiological 1 / 1 100 
 4 Nocebo Verbal suggestions Self-reported 1 / 1 100 
    Physiological 3 / 4 75 
 5 Nocebo Conditioning a Self-reported 0 / 2 0 
    Physiological 2 / 3 67 
 5 Nocebo Social induction (e.g., contagious 
itch by video of people scratching) 
Self-reported 5 / 5 100 
    Behavioral 4 / 4 100 
    Physiological 0 / 1 0 
       
General summary of the proportion of positive results for the studies above (summarized across type of induction and learning mechanisms 
involved) 









studies per outcome 
% con-firmed  
Animals 31 All types All mechanisms Behavioral 14 / 19 74 
    Physiological 18 / 19 95 
Healthy 
participants 
21 All types All mechanisms Self-reported 10 / 14 71 
   Behavioral 3 / 3 100 
    Physiological 7 / 16 44 
Patients 34 All types All mechanisms Self-reported 13 / 18 72 
    Behavioral 4 / 4 100 
    Physiological 12 / 23 52 




Note. Total no. of studies is the number of studies on the same type of induction (e.g., placebo). The ‘k studies per outcome’ in the 
column of proportion of hypotheses confirmed refers to the number of studies measuring that specific category of outcomes. Some 
studies report multiple experiments (e.g., follow-up experiments) or multiple outcomes of the same type (e.g., more than 1 self-
report measure). For these studies, a hypothesis was considered confirmed when the average across experiments or outcomes 
indicated effective placebo or nocebo induction.  
 
OL = open-label (non-concealed placebo effect induction). a Two out of five studies (Jordan, 1972, and Robertson, 1975) 
compared the efficacy of conditioning scratch responses for patients and healthy controls. While it was concluded that scratch 
responses were more easily conditioned in patients, no remarks regarding the efficacy of conditioning itself were made (i.e. no 
comparisons with control groups / a non-conditioned state). As such, these were not counted amongst the proportional positive 





































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure S1. Proportion of hypotheses confirmed by different placebo and nocebo effect induction methods for (A) 
animals studies, (B) studies with healthy volunteers, and (C) studies with patients, with a summary of results presented in (D). 



















Supplementary Figure S3. Overview of the Risk of 


















Supplementary Figure S6. Search strategies for PubMed, Embase, and PsycInfo databases  
PubMed search 
(„nocebo“ [tiab] OR „inert“ [tiab] OR “sham” [tiab] OR “dummy” [tiab] OR “aversive 
conditioning” [tiab] OR “configural learning” [tiab] OR “associative learning” [tiab] 
OR “mediated learning” [tiab] OR “animal learning” [tiab] OR “verbal 
reinforcement” [tiab] OR “attribution” [tiab] OR “conditioning” [tiab] OR “pavlov*” 
[tiab] OR “expecta*” [tiab] OR “expectation*” [tiab] OR “social learning” [tiab] OR 
“suggestibility” [tiab] OR “placebo response*” [tiab] OR “placebo effect*” [tiab] OR 
“placebo induced” [tiab] OR “suggestion*” [tiab] OR “placebo effect” [mesh] OR 
“nocebo effect” [mesh] OR “conditioning (psychology)” [mesh] OR “association 
learning” [mesh] OR “anticipatory learning” [tiab] OR “contagious” [tiab]) AND 
(“quantitative sensory testing” [tiab] OR “QST” [tiab] OR “histamin*” [tiab] OR 
“capsaicin” [tiab] OR “cowhage” [tiab] OR “cowage” [tiab] OR “scratch*” [tiab] OR 
“rash” [tiab] OR “pruri*” [tiab] OR “Pruritus” [tiab] OR “Pruritic” [tiab] OR “Prurigo” 
[tiab] OR “itch*” [tiab] OR “wheal*” [tiab] OR “weal*” [tiab] OR “extravasation” 
[tiab] OR “flare” [tiab] OR “neurogenic inflammation” [tiab] OR “skin” [tiab] OR 
“cutaneous” [tiab] OR “inflamm*” [tiab] OR “allerg*” [tiab] OR “hypersens*” [tiab] 
OR “anaphyla*” [tiab] OR “antigenic” [tiab] OR “pruritus” [mesh] OR “psoriasis” 
[tiab] OR “dermatitis” [tiab] OR “eczema” [tiab] OR “lichen planus” [tiab] OR 
“prurigo nodularis” [tiab] OR “neurodermatitis” [tiab] OR “lichen simplex 
chronicus” [tiab] OR “neurofibroma*” [tiab]) 
Embase search 
((nocebo OR inert OR sham OR dummy OR aversive conditioning OR configural 
learning OR associative learning OR mediated learning OR animal learning OR 
verbal reinforcement OR attribution OR conditioning OR pavlov* OR expecta* OR 
expectation* OR social learning OR suggestibility OR placebo response* OR 
placebo effect* OR placebo-induced OR suggestion* OR anticipatory learning 
OR contagious).ti,ab. OR (placebo effect OR nocebo effect OR conditioning 
psychology OR association learning).sh.) AND ((quantitative sensory testing OR 
QST OR histamin* OR capsaicin OR cowhage OR cowage).ti,ab. OR (Scratch* 
OR Rash OR Pruri* OR pruritus OR prurigo OR pruritic OR Itch* OR Wheal* OR 
Weal* OR Extravasation OR Flare OR neurogenic inflammation OR Skin OR 
Cutaneous Inflamm* OR Allerg* OR Hypersens* OR Anaphyla* OR Antigenic OR 
psoriasis OR dermatitis OR eczema OR lichen planus OR prurigo nodularis OR 






((TI nocebo) OR (TI inert) OR (TI sham) OR (TI dummy) OR (TI “aversive 
conditioning”) OR (TI “configural learning”) OR (TI “associative learning”) OR (TI 
“mediated learning”) OR (TI “animal learning”) OR (TI “verbal reinforcement”) OR 
(TI attribution) OR (TI conditioning) OR (TI pavlov*) OR (TI expecta*) OR (TI 
expectation*) OR (TI “social learning”) OR (TI suggestibility) OR (TI “placebo 
response*) OR (TI “placebo effect*) OR (TI “placebo-induced”) OR (TI 
suggestion*) OR (MA “placebo effect”) OR (MA “nocebo effect” OR (MA 
“conditioning (psychology)” OR (MA “association learning”)) OR ((AB nocebo) OR 
(AB inert) OR (AB sham) OR (AB dummy) OR (AB “aversive conditioning”) OR 
(AB “configural learning”) OR (AB “associative learning”) OR (AB “mediated 
learning”) OR AB “animal learning”) OR (AB “verbal reinforcement”) OR (AB 
attribution) OR (AB conditioning) OR (AB pavlov*) OR (AB expecta*) OR (AB 
expectation*) OR (AB “social learning”) OR (AB suggestibility) OR (AB “placebo 
response*) OR (AB “placebo effect*) OR (AB “placebo-induced”) OR (AB 
suggestion*) OR (TI anticipatory learning) OR (TI contagious) OR (AB anticipatory 
learning) OR (AB contagious)) 
AND  
((TI “quantitative sensory testing”) OR (TI QST) OR (TI histamin*) OR (TI 
“capsaicin”) OR (TI “cowhage”) OR (TI “cowage”)) OR ((AB “quantitative sensory 
testing”) OR (AB QST) OR (AB histamin*) OR (AB “capsaicin”) OR (AB 
“cowhage”) OR (AB “cowage”)) OR ((TI Scratch*) OR (TI Rash) OR (TI Pruri*) OR 
(TI Pruritus) OR (TI pruritic) OR (TI prurigo) OR (TI Itch*) OR (TI Wheal*) OR (TI 
Weal*) OR (TI Extravasation) OR (TI Flare) OR (TI “neurogenic inflammation”) OR 
(TI Skin) OR (TI “Cutaneous Inflamm*”) OR (TI Allerg*) OR (TI Hypersens*) OR 
(TI Anaphyla*) OR (MA “Antigenic Pruritus”)) OR ((AB Scratch*) OR (AB Rash) 
OR (AB Pruri*) OR (AB Pruritus) OR (AB pruritic) OR (AB prurigo) OR (AB Itch*) 
OR (AB Wheal*) OR (AB Weal*) OR (AB Extravasation) OR (AB Flare) OR (AB 
“neurogenic inflammation”) OR (AB Skin) OR (AB “Cutaneous Inflamm*”) OR (AB 
Allerg*) OR (AB Hypersens*) OR (AB Anaphyla*) OR (TI psoriasis) OR (TI 
dermatitis) OR (TI eczema) OR (TI lichen planus) OR (TI prurigo nodularis) OR (TI 
neurodermatitis) OR (TI lichen simplex chronicus) OR (TI neurofibroma*) OR (AB 
psoriasis) OR (AB dermatitis) OR (AB eczema) OR (AB lichen planus) OR (AB 
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Objective. Allergic rhinitis symptoms can be reduced by behaviorally conditioning 
antihistamine. It is unclear whether these findings extend to histamine-induced itch or work 
when participants are informed about the conditioning procedure (open-label conditioning). 
The current study aims to investigate the efficacy of (open-label) antipruritic behavioral 
conditioning for histamine-induced itch.  
Methods. Healthy participants (n = 92; 84% female) were randomized to I) an open-label 
conditioned, II) closed-label conditioned, III) conditioned-not-evoked control, or IV) 
nonconditioned control group. A two-phase conditioning paradigm was used. During 
acquisition, a conditioned stimulus (CS; distinctively tasting beverage) was repeatedly 
paired with the H1-antihistamine levocetirizine (groups I–III). During evocation, the CS 
was paired with placebo (I, II), or instead of the CS, water was paired with placebo (III). 
The nonconditioned control group (IV) received CS with placebo in both phases. Itch after 
histamine iontophoresis and physiological data (i.e., spirometry, heart rate, skin 
conductance) were assessed. Combined conditioned and combined control groups were first 
compared, and analyses were repeated for separate groups. 
Results. Marginally lower itch was reported in the combined conditioned compared with 
the control groups (F(1,88) = 2.10, p = .076, η2partial = 0.02); no differences between 
separate groups were found. No effects on physiological data were found, except for heart 
rate, which reduced significantly and consistently for control groups, and less consistently 
for conditioned groups (group by time interaction: F(7,80) = 2.35, p = .031, η2partial = 0.17).  
Conclusion. Limited support was found for the efficacy of antipruritic behavioral 
conditioning, regardless of whether participants were informed about the conditioning 
procedure. The application of open-label conditioning in patient populations should be 






Placebo effects are beneficial effects that cannot be attributed to active treatment 
ingredients [1,2]. Instead, these effects are ascribed to expectancy mechanisms, with 
expectations of benefit resulting in improvement of somatic symptoms (e.g., itch and pain; 
[3-6]). The opposite has also been demonstrated, with expectations of deterioration 
resulting in exacerbation of symptoms or increased adverse effects (i.e., nocebo effects; 
[3,7]). Current evidence shows that placebo and nocebo effects can be induced through 
multiple pathways, for example, by providing positive or negative information regarding 
treatments, or through associative learning processes such as conditioning [8-10]. In 
behavioral conditioning, repeated pairing of an initially neutral stimulus (to-be conditioned 
stimulus [CS]) with an unconditioned stimulus (UCS), which elicits a certain innate 
response, may lead to the CS eliciting a similar response (conditioned response), even when 
the UCS is not presented [9,10].  
There is evidence that conditioning of allergens to a CS can exacerbate allergic symptoms, 
upregulate histamine release in animal models of allergy (which has been linked to 
exacerbation of allergic responses), and adversely influence itch [11-20]. Moreover, studies 
indicate that conditioning can also potentially alleviate allergic symptoms by repeatedly 
pairing a CS (e.g., a novel-tasting beverage) with an H1-antihistamine (e.g., desloratadine) 
as UCS [21,22]. This has previously resulted in a conditioned basophil response to dust 
mite allergens [21]. However, findings for subjective symptoms were less clear, as these 
also tended to decrease in the control groups [21,22]. Moreover, no study to date has 
investigated whether conditioning of H1-antihistamine may influence histamine-induced 
itch specifically. Because histamine is a modulator of itch not only in allergic conditions 
but also in other inflammatory conditions such as atopic dermatitis [23,24], demonstrating 
these effects may provide a basis for new therapeutic approaches aimed at enhancement of 
placebo responses, reduction of medication use, and minimization of adverse effects 
[25,26].  
Traditionally, a blinded study protocol is used for behavioral conditioning, in which 
participants do not know whether they receive medication or inert pills [27]. This makes 
direct translation of these effects to clinical practice difficult, as it insinuates that deception 
is needed to elicit placebo effects, and patients in clinical practice need to be fully informed 
about treatment [27]. However, there is accumulating evidence that placebo effects may 
also occur when it is known that an inert substance is given (i.e., open-label). Symptoms of 
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allergic rhinitis, irritable bowel syndrome, and chronic low back pain can be reduced when 
placebo pills are given together with a rationale explaining the placebo effect [28-34]. The 
efficacy of open-label conditioning (i.e., explaining the learning procedure from the 
beginning) for reduction of symptoms such as itch has not yet been demonstrated.  
The current study investigated whether behavioral conditioning of the antihistaminergic 
properties of levocetirizine could reduce itch in response to a short-term histamine 
challenge. Effects of behavioral conditioning on other clinical, physiological, and 
psychological responses were explored. Moreover, the study aimed to explore the effects of 
open- versus closed-label conditioning. 
 
MATERIAL AND METHODS 
Study design 
Detailed methodology is described in the Methods section in the Supplementary Material. 
This study was a block-randomized (1:1:1:1), placebo-controlled crossover study (Dutch 
Trial Registry ID: NTR5544, registration on October 6, 2015) that was approved by the 
Medical Ethical Committee at the Leiden University Medical Center, the Netherlands (ID 
NL52687.058.15) and conducted in concordance with the Declaration of Helsinki [35]. All 
participants provided written informed consent. Data for the study were collected between 
October 2015 and October 2017. 
 
Conditioning paradigm and blinding 
In line with previous studies [21,22,36-39], a two-phase conditioning paradigm was applied 
that consisted of an acquisition phase, in which a distinctively tasting beverage (to-be CS) 
was combined with a UCS (a capsule containing 5 mg levocetirizine diHCl, an H1-
antihistamine) or an identically looking placebo capsule, and an evocation phase, in which 
the CS was combined with a placebo capsule. Both phases had three sessions on three 
consecutive days, and were separated by a 4-day drug washout period. Participants were 
allocated to I) an open-label conditioned group (acquisition: CS + UCS with an explanation 
of conditioning and its expected effects; evocation: CS + placebo); II) a closed-label 





not-evoked control group (acquisition: CS + UCS; evocation: water + placebo), which was 
added to control for carry-over effects of the conditioning procedure; or IV) a 
nonconditioned control group (acquisition: CS + placebo; evocation: CS + placebo), which 
was added to control for the effects of CS only. Block randomization was used to generate a 
randomization sequence and was managed by an independent party (the Leiden University 
Medical Center pharmacy that distributed the UCS and placebo capsules). The study was 
conducted double blinded for the closed-label conditioned group and nonconditioned 
control group, single blinded for the conditioned-not-evoked group, and nonblinded for the 
open-label conditioned group. In the conditioned-not-evoked group, the CS was not 
administered during evocation, and the acquisition phase was conducted by a different 
experimenter in a different laboratory setting (e.g., location and lighting), to prevent 
conditioning to the environment. In the open-label conditioned group, the experimenter 
provided participants with information regarding the conditioning procedure at the start of 
acquisition (see the Supplementary Material for further details). Notification of allocation 
to these two groups by the pharmacy was given to the experimenter after inclusion. 
 
Participants 
Healthy male and female volunteers aged between 18 and 35 years were recruited for this 
study. Inclusion criteria consisted of a good understanding of written and spoken Dutch, 
and absence of allergic rhinitis or allergic conjunctivitis within 3 months before enrolment 
in the study. Potential participants were excluded in case of somatic or psychological 
morbidities that may interfere with the study protocol or participants’ safety; allergic 
rhinitis or conjunctivitis within 3 months before participation; any allergic condition 
presenting symptoms other than rhinitis or conjunctivitis; recent use of analgesics, 
antibiotics, antihistamines, or anti-inflammatory medication; recent vaccinations; (intended) 
pregnancy; or intolerance for any substances used in the study. 
 
Procedure and study outcomes 
An overview of the study protocol is provided in Figure 1. The study took place at Leiden 
University and was advertised as a study on the influence of psychological factors on anti-
allergic medication. Participants were invited for a screening session, and upon inclusion, 
psychological factors and expected itch were assessed. Well-being was measured through 
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questionnaires (measurement set A; i.e., Positive and Negative Affect Schedule [40], State 
Trait Anxiety Index-State Anxiety [41], and Numeric Rating Scales (NRS) for general 
wellbeing items). Next, spirometry (forced vital capacity, FVC%predicted; forced expiratory 
volume in 1 second, FEV1%predicted) was assessed, and 5-minute measures of heart rate (HR) 
and skin conductance level (SCL) were taken (measurement set B). Itch was induced 
experimentally through 2.5 minutes of transdermal iontophoresis with a 0.6% diphosphate 
histamine solution on the volar side of the nondominant forearm. Itch was assessed verbally 
every 30 seconds during iontophoresis, and the self-rated and clinical skin response to 
histamine was measured (measurement set C). Finally, participants indicated how much 
itch they expected to experience during the final evocation session, and blood samples were 
taken to assess eosinophil profile and immunoglobulin E response to aeroallergens. In the 
next week, participants were invited for the acquisition sessions. For each of the three 
acquisition sessions, measurement set A was assessed before the CS was administered with 
the UCS or placebo pill. After a 4-day drug washout, participants were invited for the 
evocation sessions. During evocation, measurement sets A + B were assessed pre-CS, and 
+30 and +60 minutes post-CS administration, with an additional +90-minute post-CS 
assessment for the final session. Measurement set C (histamine iontophoresis) was 
reassessed in the final session between +60 and +90 minutes post-CS. At the start of the 
final session, expected itch, remembered itch, and expected medication efficacy were 
assessed. Finally, participants filled in a closing questionnaire in which they indicated 
whether they suspected to have received placebo or active medication, and compared the 
itch experienced during both tests. Participants rated the pleasantness of the CS taste in 
each session on an NRS. Participation was reimbursed by €150. An overview of the 
measurement schedule is provided in Figure 2. 
 
Power calculation and statistical analysis 
A detailed description of the statistical analyses can be found in the Methods section in the 
Supplementary Material. An a priori power calculation using 1000 simulated datasets at a 
power level of β=0.85, an alpha level of α=.05, and an assumed effect size of Δ/σ = 1/1, 
indicated that 92 participants were needed to find differences between the four groups. All 
analyses were performed using SPSS 23.0 for Windows (IBM SPSS Inc., Chicago, Illinois, 
US). As described in the a priori plan for the statistical analyses, differences in mean itch 





conditioned groups and the combined control groups were assessed using a one-sided 
general linear model (GLM) analysis of covariance (ANCOVA), including baseline itch as 
covariate. Secondarily, a GLM ANCOVA was conducted two-sided to explore effects 
between the separate groups. In case of significant group effects, Bonferroni post hoc tests 
were conducted. These analyses were repeated for the secondary parameters itch 
expectation and other iontophoresis-related outcomes (measurement set C). For well-being 
and physiological outcomes (measurement sets A + B), mixed between-within-subject 
repeated-measures analysis of variance (RMAs) were conducted. In case of significant 
effects, within-subjects RMAs were conducted post-hoc to assess changes from baseline for 
individual groups. The groups were compared on the closing questionnaire items by χ2 
tests. Relations between suspected medication intake and the primary outcome of itch were 
assessed by GLM ANCOVAs. Because the open-label group received information on 
medication administration, analyses for the closing questionnaire items were repeated 
without this group. Assumptions were checked before analyses, and all analyses were 
conducted with α = .05. As an effect size, η2partial was calculated for each analysis. All 


















Figure 1. Overview of the study protocol. A conditioned stimulus (CS; distinctively tasting drink) was combined with an 
unconditioned stimulus (UCS; levocetrizine) or placebo capsule (PLAC) during acquisition. During evocation, the CS was 
combined with PLAC, and for the conditioned-not-evoked group, PLAC was provided with water (H2O). Histamine iontophoresis 









































































































































































































































Ninety-nine participants were included in the study, of whom 7 dropped out of the study 
after inclusion for various reasons. For a complete overview of participants’ flow see 
Supplementary Figure S1. The final sample consisted of 92 participants (Mage [SD], 22.1 
[2.5] years, 84% female) randomized to the open-label conditioned group (n=23), the 
closed-label conditioned group (n=24), the conditioned-not-evoked control group (n=23) or 
the non-conditioned control group (n=22). Participants did not differ significantly between 
groups on demographic factors (see Table 1, combined groups; and Supplementary Table 
S1, separate groups). 
 
Group differences at baseline and during the acquisition phase 
Participants randomized to the combined open- and closed-label conditioned groups 
showed a larger wheal area after baseline histamine iontophoresis (M [SD], 12.3 [3.1]) 
compared with the combined control groups (M [SD], 10.6 [3.6]; F(1,88) = 6.14, p = .015, 
η2partial = .07). A marginal overall difference between the separate groups was found for 
positive affect on the second acquisition day (F(3,88) = 2.61, p = .057, η2partial = 0.08; 
Bonferroni post hoc tests: p > .31). No other differences were found between groups at 
baseline, or at the pre-CS measurements during the acquisition and evocation sessions (all, 
p > .09). Groups did not differ in their rating of the pleasantness of the taste of the CS (all, 
p > .20), which was generally rated as unpleasant (Mrating [SD], 3.8 [1.5]). 
 
Expected itch 
No differences in expected itch, remembered itch, or expected medication efficacy were 
found between the combined conditioned groups and the control groups (all, p > .11). 
When effects of separate groups were explored, a medium-sized effect on expected itch was 
demonstrated (F(3,86) = 2.96, p = .037, η2partial = 0.09), with post hoc Bonferroni tests 
illustrating that the open-label conditioned group expected borderline significantly less itch 
(M [SD], 3.2 [2.2]) compared with the conditioned-not-evoked group (M [SD], 4.6 [1.6]; p 





Mean self-reported itch 
As illustrated in Figure 4, a marginal small-sized conditioned effect was demonstrated for 
mean itch (F(1,88)=2.10, p=.076, η2partial=.02), with the combined conditioned groups 
reporting lower itch compared to the combined control groups in response to iontophoresis 
during evocation (Mdifference=-0.34, SE=0.24). A non-significant difference in itch was found 
when analyses were repeated for the separate groups; F(3,86)=1.47, p=.23, η2partial=.05.  
 
Self-rated and clinical skin response to histamine iontophoresis 
No effects on self-rated skin response to iontophoresis were demonstrated for both the 
combined (F(1,88) = 0.47, p = .25, η2partial = 0.01) and separate group analyses (F(3,86) = 
0.53, p = .66, η2partial = 0.02). Moreover, no effects were detected for the clinical skin 
response parameters (all, p > .21, see also Table 1 [combined groups] and Supplementary 
Table S1 [separate groups]).  
 
Spirometry 
No significant group by time interactions were found for FVC%predicted or FEV1%predicted 
during the course of the evocation sessions for both the combined and separate group 
analyses (all, p > .32), indicating that conditioning did not evoke changes in spirometry 
over time. In addition, no main effect of group on spirometry parameters was found (all, p 




Table 1. Analyses of (co)variance results, means, and standard deviations for the combined conditioned groups vs the combined 
control groups 









effects of group on 
outcome parameter 
   p-value η2partial 
     
Demographic factors     
 Age A 22.59 ± 3.00 21.44 ± 1.80 .15  
 Body Mass Index B 23.53 ± 3.29 22.90 ± 3.35 .37  
 Sex [male]: n(%) 9 (19.6) 6 (13.3) .42  
 Ethnicity [Caucasian]: n(%) C 41 (93.2) 41 (95.3) .51  
 Allergy – anamnesis [yes]: n(%) 14 (30.4) 14 (31.1) .94  
 Allergy – IgE response [positive]: n(%) D 16 (65.2) 18 (41.9) .49  
 Eosinophilic profile [within normal range]: n(%) 42 (93.3) 45 (97.8) .39  
 History of antihistamine use E 12 (26.1) 8 (17.8) .34  
     
Pre-conditioning histamine iontophoresis 
(baseline) 
    
     
 Process measure     
  Expected itch pre-iontophoresis 4.27 ± 2.06 4.17 ± 2.04 .83 < .01 
  Expected itch post-iontophoresis 3.79 ± 1.87 3.92 ± 1.93 .75 < .01 
       
 Primary outcome measure     
  Mean self-reported itch 3.66 ± 1.94 3.39 ± 1.66 .48 < .01 
       
 Secondary outcome measures     
  Subjective skin response 24.19 ± 14.22 24.62 ± 11.79 .88 < .01 
  Wheal area (cm2) F 12.33 ± 3.05 10.63 ± 3.55 .02 .07 
  Flare area (cm2) F 47.98 ± 12.46 46.90 ± 10.63 .66 < .01 
  Skin temperature change (°C) G 1.66 ± 1.57 1.64 ± 1.83 .96 < .01 
       
Post-conditioning histamine iontophoresis 
(evocation) 
    
     
 Process measure     
  Expected itch H 3.79 ± 2.25 4.25 ± 1.71 .15 .02 
  Remembered itch from baseline 3.96 ± 2.12 3.90 ± 1.99 .90 < .01 
  Expected medication efficacy 4.60 ± 2.33 3.81 ± 2.40 .11 .03 
       
 Primary outcome measure     
  Mean self-reported itch H 2.88 ± 1.96 3.02 ± 1.54 .08 .02 
       
 Secondary outcome measures     
  Subjective skin response H 23.81 ± 14.28 25.39 ± 11.37 .50 < .01 
  Wheal area (cm2) I 11.03 ± 3.09 10.00 ± 3.41 .66 < .01 
  Flare area (cm2) I 45.29 ± 12.82 45.31 ± 12.18 .45 < .01 
  Skin temperature change (°C) G 1.33 ± 1.71 1.06 ± 1.47 .42 < .01 
        
Note (Table 1). A As tested by non-parametric Mann Whitney test (ANOVA assumptions were violated). B n=1 missing. C n=4 
missing. D n=2 missing. E Not within past 2 months and an extensive history of levocetirizine use was considered ground for 
exclusion F Analysis corrected for the amount of time passed between histamine iontophoresis and measurement of the variable. G 
Calculated as post-histamine iontophoresis skin temperature – control. H Analysis corrected for pre-conditioning (baseline) 
variable. I Analysis corrected for pre-conditioning (baseline) variable, as well as for the amount of time passed between histamine 










Figure 3. Means and standard errors of expected itch, with (A) the effects of the combined conditioned groups and the 
combined control groups on expected itch, controlled for baseline expected itch as measured post-iontophoresis during the 









Figure 4. Means and standard errors of the mean for itch during iontophoresis in the final evocation session, with (A) mean 






HR and SCL 
A medium-sized significant group by time interaction was demonstrated in the combined 
groups for HR (Wilk λ = 0.83, F(7,80) = 2.35, p = .031, η2partial = 0.17). Separate-group 
RMAs demonstrated an overall reduction in HR compared with baseline for both 
conditioned and control groups (both, Wilk λ > 0.25; both, p < .001). Post hoc comparisons 
over time demonstrated that in the combined conditioned groups, HR was significantly 
reduced compared with baseline for only three of seven post-CS measures (p ≤ .001). In the 
combined control groups, HR was significantly reduced compared with baseline for six of 
seven post-CS measures (p ≤ .001) and marginally reduced for the other (1/7) post-CS 
measure (p = .075). When analyses were repeated for the four (noncombined) groups, a 
similar medium-sized group by time interaction was found (Wilk λ = 0.64, F(21,225) = 
1.79, p = .021, η2partial = 0.14). Post hoc separate-group RMAs and pairwise comparisons 
demonstrated significant HR reduction in line with the patterns for the combined groups. 
No group by time interactions (both, p > .44) or main effects of group (both, p > .43) were 
found for SCL in analyses with combined or separate groups. An overview is provided in 
Supplementary Tables S2 and S3.  
 
Wellbeing 
No group by time interactions (all, p > .23) or main effects of group (all, p > .11) were 
demonstrated for the Positive and Negative Affect Schedule positive affect, State Trait 
Anxiety Index–State Anxiety, or NRS general well-being measures for both the combined 
and separate group analyses (see Supplementary Table S2 and S3). 
 
Closing questionnaire: suspected medication intake and its association with mean itch 
and other iontophoresis-related outcomes 
No differences between groups were found when participants compared baseline and 
evocation itch in the closing questionnaire (all, p > .15). The groups differed marginally to 
significantly in suspected medication intake for all sessions (all, p < .066), except for the 
first evocation session. When the open-label conditioned group was excluded from the 
analysis, no differences were found (all, p > .11). Participants who suspected taking active 
medication during the final evocation session had reported less itch during iontophoresis as 
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compared with those who suspected taking placebo (open-label conditioned group 
included: F(1,88) = 3.82, p = .054, η2partial = 0.04; open-label conditioned group excluded: 
F(1,65) = 6.09, p = .016, η2partial = 0.09) and also reported lower subjective skin response 
(open-label conditioned group included: F(1,88) = 5.95, p = .017, η2partial = 0.06; open-label 
conditioned group excluded: F(1,65) = 4.92, p = .030, η2partial = 0.07; Supplementary 
Table S4 and S5). 
 
DISCUSSION 
The current study investigated whether behavioral conditioning of the antihistaminergic 
properties of levocetirizine could reduce itch and other clinical, physiological, and 
psychological responses to histamine, under both open-label (i.e., with participants 
knowing about the conditioning procedure) and closed-label conditions. Conditioning was 
found to be marginally effective in reducing itch when the combined conditioned groups 
were compared with the combined control groups. However, no effects of conditioning 
were found for self-rated or clinical skin responses to histamine. Marginal antipruritic 
effects occurred regardless of whether participants were informed about the procedure, 
implying that, if further optimized, open-label behavioral conditioning might be suitable for 
future applications in clinical practice. 
These findings show that conditioning, albeit only marginally, influenced self-reported itch, 
which is in line with previous findings that show that associative learning mechanisms can 
influence itch and allergic symptoms [11,14,21,22]. Most studies have investigated 
conditioned exacerbation of allergic responses, whereas evidence for alleviation of itch 
through associative learning mechanisms is more limited and has only so far been examined 
in allergic patients [21,22]. In patients, it may be especially difficult to ascribe findings 
exclusively to behavioral conditioning because external influences on learning may also be 
relevant. For example, natural fluctuations in symptom severity during acquisition of the 
conditioned response may affect conscious expectancy, due to these fluctuations being 
interpreted as medication effects. This in turn could influence symptom reporting within 
both the conditioned and control groups. Resultantly, to reduce the influence of such 
external factors on conditioning, the current study sought to investigate whether antipruritic 





Goebel and colleagues [21] had previously found a unique conditioned response for 
basophil activation in allergic patients, but symptoms reduced regardless of group 
allocation. Vits and colleagues [22] confirmed these findings and demonstrated symptom 
reduction for the conditioned and sham-conditioned (placebo) patient groups, compared 
with a natural history group. This led them to conclude that other cognitive processes, for 
example, patients’ expectations of benefit, may be relevant. Likewise, the current study 
provides only limited evidence for the role of conditioning in reducing histamine-induced 
itch. Some differences between the current study and previous studies can be noted. In the 
studies of Goebel and colleagues [21] and Vits and colleagues [22] patients reported 
symptoms at the time of enrolment in the study. In the current study, the sample consisted 
of nonallergic participants, or allergic participants who had not experienced symptoms for 
some time before enrollment. Potentially, this may have elicited smaller conditioned 
responses, as the pharmacological effects of levocetirizine during acquisition may not have 
been clearly perceived as much as they would be when allergic symptoms were present. 
Moreover, itch was induced in the final evocation session, to prevent that histamine 
iontophoresis—which entails the introduction of a foreign chemical substance to the skin 
[42]—interfered with measurements of conditioned responses for other study outcomes. 
Although literature indicates that conditioned immunological responses can persist for 
multiple—potentially even up to fourteen—evocation moments [39,43,44], it may be 
possible that some extinction in the conditioned response was already present in the second 
and third evocation sessions. Future research could investigate whether conditioned effects 
for itch are stronger at earlier evocation moments, for example, when participants are for 
the first time reexposed to the CS after the acquisition phase. Alternatively, it may be 
possible that the antipruritic effects of levocetirizine were too small for experimental 
histamine-induced itch to be effectively conditioned. Indeed, in the current study, itch 
reduced from baseline in general, with only marginal differences between the conditioned 
and control groups (21.3% reduction of itch from baseline in the conditioned groups versus 
10.9% reduction in the control groups). Previous evidence dispels the notion that this small 
difference between groups may be due to failure of the UCS to suppress itch though, 
because it is demonstrated that levocetirizine has a suppression rate for itch that lies 
between 62% and 94% [45-47]. A similar suppression rate would be expected for 
levocetirizine in the current study. Future research, however, may want to include a drug 




Speculatively, the marginal antipruritic conditioned effect in the current study could have 
emerged through peripheral neurobiological mechanisms, for example, immune-mediated 
inhibition of pruriceptor neurons [48-50]. Such mechanisms have been proposed to underlie 
systemic behaviorally conditioned immunosuppression [8,51]. Alternatively, effects may 
have emerged through top-down central nervous system antipruritic mechanisms, for 
example, in case of itch with a neuropathic and psychogenic origin [23,52,53]. As an 
example of central nervous system–mediated itch, itch has been found to be socially 
contagious in both patients and healthy volunteers [54-56]. Future research may aim to 
clarify through which pathways antipruritic conditioned effects are established. 
 No conditioning effects were found for spirometry parameters. Literature indicates that 
pulmonary conditions such as asthma are sensitive to placebo responding [57,58], and 
antihistamines have been found to have bronchodilatory properties, as shown by their 
impact on spirometry parameters such as FEV1 [59-62]. As such, we explored whether 
conditioning of antihistamines could affect these parameters as well. The missing data rate 
in the current study likely affected the findings, however, and the study may have been 
underpowered for small effects. Moreover, as the sample consisted of healthy volunteers, 
conditioned responses may be very small because lung function may have already been 
optimal for a large number of participants. It may be interesting for future research to test 
the effects of conditioning with antihistamines by experimentally inducing 
bronchoconstriction, for example, through embedding a histamine bronchial provocation 
test. No conditioned responses were found for the secondary parameter SCL. HR reduced 
significantly during evocation for the combined control groups. The time that participants 
spent sitting in the laboratory was relatively inactive, which likely explains the decrease in 
HR. For the conditioned groups, HR did not decrease as much in the second and final 
evocation sessions. Levocetirizine is considered safe for use, and studies show no effects on 
cardiac safety parameters [63], however, subclinical cardiac effects are often not reported. 
Moreover, H1-antihistamines—including cetirizine, from which levocetirizine is derived—
have been associated with tachycardia and other cardiac adverse effects [64-66]. As such, 
the difference in HR change over time between the conditioned and control groups might 
speculatively be the result of a conditioned response, although this should be further 
investigated. In addition, future research may aim to investigate how to enhance the 
learning process exclusively for the itch-suppressive effects of antihistamines, while 





Following the open-label rationale, significantly lower itch was expected during evocation 
in the open-label group compared with the conditioned-not-evoked group. However, 
although findings were in the expected direction, itch expectations in the open-label group 
did not significantly differ from those in the closed-label conditioned and nonconditioned 
groups. That an open-label rationale may potentially influence expectancy is in line with 
studies that found that inert pills combined with an open-label rationale can reliably induce 
placebo effects [28-34]. It has also been shown that an open-label rationale regarding the 
role of expectations in eliciting placebo effects for itch can, in an experimental setting, 
result in lower expected itch even without providing inert pills [67]. The current study 
extends these findings by preliminary showing an effect of an open-label rationale for a 
conditioning framework. Potentially, these expectations may help strengthen placebo 
effects induced by conditioning, although this needs to be investigated more extensively. 
Demonstrating the efficacy of open-label conditioning could lead toward new therapeutic 
possibilities and help facilitate utilization of placebo effect mechanisms in clinical practice. 
It should be noted, though, that the open-label rationale in the current study consisted of 
multiple components (e.g., an explanation of the conditioning procedure, a suggestion that 
effects may be as large as the effects of the medication, and a suggestion of reduced itch). 
Future research may clarify which of these components are essential for inducing 
expectations of reduced itch, and investigate what other factors help optimize these effects. 
For example, higher likability and competence of a health care provider have been shown to 
enhance placebo effects for allergic responses [68]. It may be worthwhile to investigate to 
which extent factors such as likability and competence may influence the efficacy of an 
open-label rationale as well. 
Some limitations of the current study should be considered. Because participants were 
mostly women, a sex bias cannot be excluded. The experimenter was blinded to group 
allocation only for the closed-label conditioned and the nonconditioned groups, but not for 
the open-label conditioned and conditioned-not-evoked groups, because of the differences 
in the protocol for these latter two groups. Future research may consider having a second, 
blinded experimenter performing measurements, to prevent that the experimenters’ own 
expectations influence measurement of the outcome parameters. Second, participants 
underwent histamine iontophoresis only twice, to prevent interference of histamine 
application on the conditioned response. As a result, it was not possible to assess 
conditioned effects for itch on the first and second evocation days, or to assess whether 
extinction may have taken place. In addition, no drug control group was included in the 
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current study. Moreover, effects of antihistamine administration were not assessed in the 
acquisition phase because this could influence participants’ conscious expectancy and thus 
the conditioning procedure. Because the efficacy of levocetirizine for inhibiting the 
response to histamine has been described in previous literature [45-47,63], we did not 
directly compare the magnitude of conditioned effects with those of levocetirizine. Future 
research may consider measuring the response to histamine on multiple testing days and 
including a drug control group. Finally, all groups received some form of intervention 
(either conditioning or placebo throughout the study). This may complicate an estimation of 
a true placebo response, as the idea of receiving an intervention may already influence 
study outcomes. Moreover, itch was induced twice. Although unlikely to have largely 
affected study findings—given that the itch stimulus was of short duration and inductions 
were spaced over 2 weeks apart—habituation cannot be ruled out. Future research may also 
consider adding a natural history group to control for this. 
In conclusion, the current study provides preliminary support for behavioral conditioning of 
antipruritic effects. In addition, the findings suggest that conditioning may be effective 
when it is known that a learning paradigm is used. Future research may aim to clarify under 
which circumstances and on which evocation moments conditioning can be successful in 
reducing itch. Demonstrating the efficacy of (open-label) conditioning of antipruritic effects 
may lead toward new therapeutic possibilities. Moreover, further investigation of the 
content of the open-label rationale may help facilitate utilization of placebo effect 
mechanisms in clinical practice. 
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Elaboration on the participant group 
Healthy male and female volunteers, aged between 18 and 35 years, were recruited for this 
study through advertisements at locations of Leiden University, the Leiden University 
Medical Center (LUMC), the University of Amsterdam, and the University of Delft, and 
through social media (e.g., Facebook). Inclusion criteria consisted of a good understanding 
of written and spoken Dutch, and absence of allergic rhinitis or allergic conjunctivitis 
within the three months prior to enrolment in the study. Participants were excluded in case 
of any (severe) allergic condition that presented symptoms other than rhinitis or 
conjunctivitis (e.g., food allergy); sensitivity to levocetirizine diHCl or other substances 
used in the study; lactose intolerance; somatic morbidity that could interfere with the 
participant’s safety or with the study protocol (e.g., histamine intolerance, asthma); current 
Diagnostic and Statistical Manual of Mental Disorders-IV (DSM-IV) psychiatric diagnoses; 
recent (within past 2 months) use of antihistamines, antibiotics, or anti-inflammatory 
medication; recent vaccinations; and pregnancy. Participants were asked to refrain from 
consuming heavy meals, caffeine, or smoking 2 hours, exercise 12 hours, and alcohol and 
drugs 24 hours prior to the sessions. Adherence to these lifestyle guidelines, as well as any 
significant changes in health status during the course of the study (e.g., illness or other 
changes in physical health, or occurrences of highly stressful events) were monitored at the 
start of each session.  
 
Elaboration on the conditioning paradigm  
The CS was a distinctively-tasting green beverage that has been used as a CS in previous 
conditioning studies [1-6]. The beverage consisted of 150 mL of commercially available 
strawberry milk, which was coloured green by adding the coloring powders Quinoline 
Yellow (E104, 80 mg/L) and Patent Blue V (E131, 20 mg/L) and flavoured with lavender 
oil (0.6 mL/L)1. As unconditioned stimulus (UCS), 5 mg of levocetirizine diHCl was 
capsuled by the LUMC pharmacy. Identically-looking placebo capsules were also prepared 
by the pharmacy. Presentation of the CS and UCS or placebo in both the acquisition and 
 
1 Three participants (1 in the open-label conditioned group, 2 in the conditioned-not-evoked group) received a beverage containing 
160 mg/L of Quinoline Yellow and 40 mg/L of Patent Blue due to administrative error. Sub-analyses of the total sample without 




evocation sessions was accompanied by a brief instruction that emphasized: 1) that it was 
important that the beverage and capsule were taken simultaneously, and 2) that the 
experimenter did not know whether the capsule contained active medication or an inert 
substance (for the open-label conditioned group, a different instruction was used, see 
‘Open-label instructions’). 
 
Elaboration on materials and measures 
1. Open-label instructions 
At the start of the acquisition phase, participants in the open-label conditioned group were 
provided with scripted instructions regarding five points: 1) that part of the effects of anti-
allergic medication can be learned through the principle of conditioning, 2) that an example 
of conditioning is the experiment of Pavlov, in which a dog was taught to respond to the 
ringing of a bell with salivating, by pairing this sound with food, 3) that this learning 
paradigm can be utilized for medication use by, for example, pairing medication with a 
beverage, 4) that these effects may be large, and potentially just as large as the effects of the 
medication itself, and 5) that effects may be noticed in the evocation phase, for example, as 
improved performance on the spirometry tests and reduced itch during iontophoresis in the 
final session. During each session, administration of the beverage and capsule was 
accompanied by instructions that consisted of a brief repetition of points 1 and 4. In 
addition, point 5 was briefly repeated at the start of the final session.  
 
2. Histamine iontophoresis 
Itch was evoked experimentally by transdermal histamine iontophoresis (Chattanooga 
Group, Hixson, TN, USA) at baseline and during the final evocation session. Histamine 
iontophoresis has been previously used as a reliable method to induce itch in healthy 
participants [7-10]. An electrode with an active surface of 11.7 cm2 (Iogel, Iomed, DJO 
Global, Hannover, Germany) was treated with 2.5 ml of a 0.6% diphosphate histamine  
solution (prepared in distilled water with propylene glycol and Hypromellose 4000 mPa; 
equivalent to 1% histamine dihydrochloride). The prepared electrode was placed on the 
volar side of the non-dominant forearm. A reference electrode was placed on the volar 
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surface of the upper arm. Histamine iontophoresis was conducted for 2.5 minutes with the 
current level set at 0.4 mA.  
 
3. Primary outcome measure: self-reported itch 
During iontophoresis, itch was assessed verbally every 30 seconds on a Numeric Rating 
Scale (NRS) ranging from 0 (‘no itch’) to 10 (‘worst itch ever experienced’). Directly 
following iontophoresis, mean self-reported itch during the test was assessed using the 
same NRS. Between 1 and 4 minutes after iontophoresis, itch was again assessed every 30 
seconds as a follow-up period to the test. Mean self-reported itch during iontophoresis 
assessed directly following iontophoresis was used as the primary outcome measure, and 
correlations with other itch measures taken during iontophoresis were calculated in order to 
validate the reliability of the main outcome measure.  
 
4. Secondary outcome measures 
4.1. Expectations regarding histamine iontophoresis 
Participants rated the amount of itch they expected to experience during iontophoresis on 
the same NRS as used for the itch assessments. Measures of expectations were taken at the 
start of both the screening session and the final evocation session. Moreover, participants 
rated the amount of itch they expected to experience during the final evocation session at 
the end of the screening session (following the first iontophoresis test). Finally, using the 
same NRS, participants rated, prior to histamine iontophoresis in the final evocation 
session, how much itch they remembered experiencing at baseline (screening session), as 
well as the expected efficacy of the administered capsules (0 ‘not effective’, 10 ‘very 
effective’). 
 
4.2. Self-rated skin response 
Self-rated skin response was measured using an adjusted version of the Sensitive Scale-10 
(SS-10; [11]). This questionnaire assesses a variety of skin symptoms that are either 
subjectively experienced (e.g., itch, tingling, burning, pain), or visibly rateable (e.g., 




intensity’) scale. Total scores are calculated by summing across items. For the purpose of 
the current study, the timeframe for which the symptoms were rated was tailored to 
histamine iontophoresis (i.e., ‘during the histamine test’, rather than the original ‘during the 
past three days’). As a baseline measurement, participants also filled in the original 
questionnaire. Cronbach’s alpha was .58 for the original questionnaire in the current study. 
For the adjusted SS-10 following histamine iontophoresis at baseline and during evocation, 
Cronbach’s alpha was .88 and .89, respectively.   
 
4.3. Clinical skin response 
A 1 cm2 gridded, transparent sheet was used to trace the wheal and flare area in response to 
histamine iontophoresis. The outer edges of the drawn areas were retraced in ImageJ [12], 
after which the areas of the wheal and flare response were calculated in cm2. Skin 
temperature following iontophoresis was measured using a handheld infrared thermometer 
(accuracy ±2.0 °C, resolution 0.1 °C, BaseTech, Conrad Electronic Benelux B.V., 
Hirschau, Germany). Measurements were taken with the thermometer held approximately 1 
cm above the centre of the wheal. A similar measurement was taken on the same area of 
skin on the opposite arm, to control for individual differences in skin temperature. Increase 
in skin temperature as a result of iontophoresis was calculated by subtracting temperature of 
the control area from temperature of the wheal area, with positive values indicating a higher 
skin temperature increase following iontophoresis.  
 
4.4. Spirometry  
Spirometry was performed in accordance with the American Thoracic Society/European 
Respiratory Society (ATS/ERS) Task Force guidelines on the Standardisation of Lung 
Function Testing [13]. The experimenters were trained in spirometry by certified 
technicians at the LUMC. Tests were performed using a mounted, non-heated Lilly type 
pneumotachograph and SentrySuite software package Version 2.7 (Carefusion, Hoechberg, 
Germany). For FVC and FEV1, percentages of the predicted scores were calculated using 
the standard DE#GLI 2012 reference values [14]. Tests that did not meet the acceptability 




4.5. Heart rate and skin conductance level 
Heart rate (HR; in beats per minute, BPM) and skin conductance level (SCL) were 
measured during the screening session and during the sessions of the evocation phase. 
Measurements were taken using an MP150 system and Acqknowledge software, version 
4.4 (BIOPAC Systems Inc., Goleta, CA, USA). As has been done previously by our 
research group [15], the skin was abraded with Nuprep scrub (Weaver and Company, 
Aurora, CO, USA) in preparation of the HR measurements, after which two disposable 
electrodes were placed (Ø 38 mm; Kendall 200 Foam Electrode, Covidien, Mansfield, MA, 
USA) on the sternum and on the participant’s left side below the ribs. An ECG100C 
amplifier at 100 Hz with a gain of 100, a 0.5-Hz high pass and a 35-Hz low pass filter, and 
a 50-Hz notch filter measured the electrocardiography signals. The skin was cleaned with 
water in preparation of the SCL measurements, after which two disposable Ag/AgCl 
electrodes (Ø 32 mm; DBF3D77, Multi Bio Sensors Inc., El Paso, TX, USA) were placed 
on the medial phalanges of the index and middle finger of the non-dominant hand. A 
GSR100C amplifier at 1000 Hz with a gain of 10 μmho/V and a 1.0-Hz low pass filter 
recorded SCL. Five-minute HR and SCL resting state measurements were taken, once in 
the screening session, and at various time points during evocation (i.e., prior to, and every 
30 minutes post-CS administration). Visual inspection of the data and calculation of mean 
HR and SCL were done using the Physio Data Toolbox Version 0.1 [16], a standalone 
MATLAB-based application (MATLAB Release 2016a, The MathWorks, Inc., Natick, 
MA, USA) that was written at the Faculty of Social and Behavioural Sciences at Leiden 
University. 
 
4.6. Self-rated wellbeing 
Self-rated wellbeing was measured throughout the study by means of questionnaires. To 
measure positive affect (PA) and negative affect (NA), the 20-item Positive and Negative 
Affect Schedule (PANAS; [17]) was administered. Cronbach’s alpha ranged from .88 to .93 
for PA in the current study. As the scores for NA were only within the lower range of the 
scale for all participants, NA data were not analysed. A short 6-item version of the State 
Trait Anxiety Index – State Anxiety (STAI-S-s; [18]) was administered to assess state 
anxiety. Cronbach’s alpha ranged from .66 to .81. In addition, participants were asked to 
rate seven psychological states (relaxed, nervous, calm, well, tense, concerned, stressed) on 




negative items were recoded and all NRS were summed and divided by seven to calculate a 
general wellbeing score, for which Cronbach’s alpha ranged from .81 to .91.  
 
4.7. Taste of the Conditioned Stimulus (CS) 
Following each administration of the CS in the acquisition and evocation phase, 
participants rated the taste of the beverage on a 9-point Likert scale (1 ‘very unpleasant’ to 
9 ‘very pleasant’). For the conditioned-not-evoked group, the CS was not administered 
during the evocation phase. Instead, the capsule was administered with water and, to 
standardise procedures over all groups, participants were asked to rate the taste of the 
water. The ratings of water during the evocation phase for the conditioned-not-evoked 
group were not analysed.  
 
5. Additional measures: potential predictors of conditioned effects 
5.1. Atopic constitution and allergy 
To assess whether participants were allergic or had a tendency towards allergic or overly 
sensitive responses (atopic constitution), participants were asked during the screening to 
indicate whether they had ever experienced any allergic responses to food, animals or 
pollen. In case of severe allergic responses, e.g., throat swelling, or in case of recent allergic 
responses, participants were excluded. In addition, blood samples were taken at the LUMC, 
to assess eosinophil profile and to conduct an allergy test using the blood Immunoglobulin-
E (IgE) response to inhalant allergens. Blood samples were treated with a mixture of 
various aeroallergens (i.e., dust mite, grass pollen, animals, birch, mugwort) and the IgE 
response was measured and divided into semiquantitative classes to determine sensitization 
level [19]. Data were collected in order to assess – in the event of significant effects of 
conditioning on the outcome parameters – whether these effects may potentially 
differentiate between subgroups of participants. Of all participants, 27 (31%) indicated 
being allergic to either food products or aeroallergens, and 34 (37%) responded positively 





5.2. Individual characteristics 
Individual characteristics and personality factors were assessed during the screening 
session. Participants filled in the following questionnaires: a multidimensional measure of 
general health status, the RAND SF-36 Health Status Inventory (RAND-36 [20]), the 
Behavioural Inhibition System / Behavioural Approach System scales (BIS/BAS scales 
[21]), the Eysenck Personality Questionnaire short version – subscales extraversion and 
neuroticism (EPQ-RSS-EN [22]), the Hospital Anxiety and Depression Scale (HADS [23]), 
the Life Orientation Test – revised (LOT-R [24]), the Perceived Stress Scale (PSS [25]), 
and the Penn State Worry Questionnaire (PSWQ [26]). Potential moderating effects of 
individual characteristics were tested and are described in the supplementary material (see 
section 7.5.).  
 
Elaboration on the general procedure 
1. Pre-enrolment procedures and additional details on the screening session 
Prior to the study, potential participants were briefly screened for the in- and exclusion 
criteria by telephone, and subsequently, potentially eligible participants were invited to the 
laboratory for a first (screening) session. An interview was used to further assess whether 
participants met the inclusion criteria (e.g., presence of any psychological diagnoses 
according to the DSM-IV criteria). Afterwards, questionnaires assessing individual 
characteristics and personality factors were filled in, and measurement sets A, B and C 
were assessed. At the end of the screening session, blood samples were collected at the 
LUMC to assess eosinophil profile and immunoglobulin-E (IgE) response to aeroallergens 
for potential subgroup analyses, as well as potential analyses of baseline cytokine levels. 
 
2. Acquisition and evocation phase 
The acquisition and evocation phases were scheduled within the same 30-minutes time 
frame in the next two weeks. Within each phase, all sessions started at the same time on 
three consecutive days. At the start of each session, participants were given an overview of 
the procedures of that day, and a brief interview was conducted (e.g., to verify adherence to 
lifestyle guidelines). Within the evocation phase, participants completed several neutral 




puzzles) for the purpose of standardising the time that participants had to spend waiting 
between measurements. At the end of the final evocation session, participants filled out a 
closing questionnaire, in which they were asked, for example, whether they believed to 
have received active medication, and were debriefed about the study purpose. Finally, 
participants were asked to provide a saliva sample in order to test associations between 
genotype and the conditioned response (the results of which will be described elsewhere), 
and a second blood sample was taken at the LUMC to potentially assess blood cytokine 
levels. 
 
Elaboration on statistical analysis 
1. Pre-analyses checks of data and assumptions 
Prior to analyses, variables were checked for normal distribution and outliers, and 
underlying assumptions for each analysis were checked. To detect differences in 
demographics and baseline measures of the study outcome parameters, χ2 tests and general 
linear model (GLM) analyses of variance (ANOVAs) were used. For wellbeing during the 
acquisition phase, and taste ratings for the CS throughout the study, GLM ANOVAs were 
also performed. 
 
2. Reliability of primary outcome measure 
The primary outcome measure of mean self-reported itch at evocation correlated highly 
with the calculated average of the itch measures taken during histamine iontophoresis at 
evocation (r = .96, p < .001), supporting the reliability of the primary outcome measure 
used for itch.  
 
3. Covariates included in the analyses of the primary and secondary outcomes 
All GLM analyses of covariance (ANCOVAs) conducted for expected itch, self-reported 
mean itch, and the self-rated and clinical skin response were controlled for baseline values 
(screening session). Expected itch was assessed twice during the screening session: once 
prior to baseline histamine iontophoresis, and once following baseline iontophoresis (as a 
measure assessing the amount of itch participants expected to experience during the final 
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evocation session). The latter was included as a covariate in the ANCOVA. For 
remembered itch and expected efficacy of the capsules, no covariates were included. For 
the clinical skin response measures of wheal and flare area an additional covariate was 
included, which consisted of the amount of time between the end of iontophoresis and the 
drawing of the affected skin areas onto the transparent sheet, in order to control for changes 
in skin response over time.  
 
4. Missing data 
Due to technical issues with the equipment for histamine iontophoresis, data of one 
participant was excluded for the analyses of outcome parameters related to histamine 
iontophoresis (i.e., expected itch, measurement set C). Due to technical issues and the 
occurrence of artefacts (e.g., a significant number of extra systoles in HR data), HR and 
SCL data were not reliable for 4 participants. Subsequently, these participants were 
excluded from the analyses. For spirometry, only data of participants who performed well 
on all MEFV curves assessed during evocation (i.e., all 10 tests taken during evocation 
meeting the ATS/ERS criteria for acceptability and repeatability, to prevent that the group 
composition changed for each time point in the study) were included in subsequent 
analyses, resulting in loss of data of 45 participants. Since conditioning only marginally 
influenced the primary outcome of itch, no further subgroup analyses based on allergic 
constitution were conducted, nor were the blood samples analysed for cytokine levels.  
 
5. Testing the moderating role of individual characteristics and personality in conditioning 
the effects of antihistamines for itch 
To assess whether individual characteristics would influence conditioning effects on the 
main outcome of self-reported itch during iontophoresis, controlled for baseline, 
moderation analyses were conducted according to the Preacher and Hayes moderation 
regression method PROCESS 3.3. [27]. For each individual characteristic (predictor of the 
conditioned response), a separate moderation model was tested two-sided with an alpha 
level of .05. Analyses were first conducted for the combined conditioned versus the 
combined control groups, and then repeated to assess effects for the separate four groups. 
Bootstrap was set at 5000 samples in PROCESS, and conditional effects were probed at -




were assessed by one-way ANOVA, and the assumptions of regression were checked. In 
addition, the predictors were centered, and the group variables were dummy coded prior to 
moderation analyses (with the non-conditioned control group serving as the reference 
group). For some predictors (i.e., the RAND-36, the EPQ-RSS-EN, and the HADS 
subscales), there was very low variance in scores between individuals, and scores were non-
normally distributed. For these factors, moderation analyses were not conducted.  
 
SUPPLEMENTARY RESULTS 
Group differences on individual characteristics and personality 
No significant differences between the combined conditioned groups and the combined 
control groups were found for individual characteristics (all p>.13), with the exception of 
optimism (LOT-R; F(1,89)=6.07, p=.016). Participants in the conditioned groups scored 
higher on optimism (M=18.33±2.72) compared to the control groups (M=16.93±2.67). 
Repetition of these analyses for the separate groups showed that factors did not 
significantly differ between groups (p≥.072). An overview of individual characteristics of 
the study sample is provided in Supplementary Table S6.  
 
Moderating role of individual characteristics and personality in conditioning the 
effects of antihistamine for itch: the combined conditioned and combined control 
groups.  
No significant moderation of the effect of the combined conditioned and the combined 
control groups on mean itch in response to iontophoresis during evocation was found for 
optimism, perceived stress, worrying, behavioural activation scales (BAS) drive, fun 
seeking, and reward responsiveness, or behavioural inhibition scale (BIS) (all group x 
factor interactions: p≥.053; see Supplementary Table S7). 
 
Moderating role of individual characteristics and personality in conditioning the 
effects of antihistamines for itch: separate groups 
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Optimism was found to moderate the effects of closed-label conditioning on mean itch in 
response to iontophoresis during evocation, compared to the other groups (closed-label 
conditioning dummy variable x optimism interaction: p=.021; see Supplementary Table 
S8). Higher levels of optimism were related to lower levels of mean itch in the closed-label 
conditioned group, compared to the other groups (see Supplementary Figure S2). 
However, post-hoc conditional effects of group at various levels of optimism were not 
significant (p≥.12). For the other dummy group factors, no effects were found (all pinteraction≥ 
.29).  
BAS reward responsiveness was found to significantly moderate the effect of the 
conditioned-not-evoked group on mean itch in response to iontophoresis during evocation, 
compared to the other groups (conditioned-not-evoked dummy variable x BAS reward 
responsiveness: p=.020). Higher levels of reward responsiveness were significantly 
associated with higher levels of mean itch in the conditioned-not-evoked group, compared 
to other groups (conditional effect at +1 SD of BAS reward responsiveness: t=2.18, p=.032; 
see Supplementary Figure S3). For the other dummy group factors, no effects were found 
(all pinteraction≥ .087). Finally, group effects were not significantly moderated by worrying, 
perceived stress, behavioural activation scales (BAS) drive and fun seeking, or behavioural 
inhibition scale (BIS) (all group x factor interactions: p≥.077; see Supplementary Table 
S8). 
 
Concluding note on the moderating role of individual characteristics and personality 
in conditioning the effects of antihistamine for itch 
Some evidence was found for a moderating role for optimism in the closed-label 
conditioned group compared to others, however, post-hoc conditional effects at various 
levels of optimism were not significant, illustrating that such an effect may be limited. 
These results need to be interpreted very cautiously, especially given that the groups 
differed in optimism at baseline. Finally, a potential moderating effect of BAS reward 
responsiveness within one of the control groups was shown, with higher reward 
responsiveness being related to higher itch compared to other groups. This moderation is 
likely not related to the conditioning procedure, as this moderation also encompassed 





405 potential participants 
(expressed interest in study) 
286  excluded by telephone 
137  Reasons not related to exclusion criteria (e.g.,  
no response, scheduling conflicts) 
46  Participation in similar conditioning trials  
performed at Leiden University 
30  DSM-IV diagnosis and/or somatic morbidity 
16  Recent rhinitis/conjunctivitis, or other allergies 
14  Medication use (e.g., antihistamines, antibiotics) 
or vaccinations 
2  Lactose intolerance 
119 potential participants 
(scheduled first appointment) 
20  excluded during screening session 
11  Reasons not related to exclusion criteria (e.g.,  
no show) 
3  DSM-IV diagnosis and/or somatic morbidity 
3  Recent rhinitis/conjunctivitis, or other allergies 
2  Medication use (e.g., antihistamines, antibiotics) 
or vaccinations 
1  Participation in similar conditioning trial  
performed at Leiden University 
99 participants included 
 
N = 92 
  
7  drop-out 
5 No show, or reasons unknown 
2  Nausea 
 


















Supplementary Figure S2. Conditional effect of the closed-label conditioned group versus other groups on mean itch during 
iontophoresis in the evocation phase, controlled for itch during baseline, moderated by optimism.  
 
 
Supplementary Figure S3. Conditional effect of the conditioned-not-evoked control group versus other groups on mean itch 
during iontophoresis in the evocation phase, controlled for itch during baseline, moderated by behavioural activation scale (BAS) 





















































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table S7. Moderation by individual characteristics for the effects of the combined conditioned groups on self-
reported itch during iontophoresis in the evocation phase, controlled for baseline, using the PROCESS moderation method. 
 
Note. A Model controlled for mean itch during baseline histamine iontophoresis. In all models, itch during baseline iontophoresis 
was strongly related to itch during evocation (all p < .001). This association causes the high explained variance in the model. B 
Assessed by the Life Orientation Test – revised (LOT-R [24], C Assessed by the Perceived Stress Scale (PSS [25], D Assessed by 
the Penn State Worry Questionnaire (PSWQ [26], E Assessed by the Behavioural Inhibition System / Behavioural Approach 
System scales (BIS/BAS scales [21]. † p<.10. LLCI = lower limit confidence interval. ULCI = upper limit confidence interval.   
    Bootstrap  
Variable Coefficient t p LLCI ULCI R-square 
model 
       
Model 1: moderation by optimism A       
Conditioning (group) -0.39 -1.67 .11 -0.88 0.09 
.62 Optimism B 0.07 1.14 .26 -0.05 0.20 
Conditioning x optimism -0.09 -1.01 .31 -0.27 0.09 
       
Model 2: moderation by perceived stress  A       
Conditioning (group) -0.34 -1.41 .16 -0.81 0.14 
.61 Perceived stress C 0.03 0.79 .43 -0.05 0.11 
Conditioning x perceived stress -0.05 -0.90 .37 -0.16 0.06 
       
Model 3: moderation by worrying  A       
Conditioning (group) -0.33 -1.40 .16 -0.80 0.14 
.61 Worrying D -0.02 -1.16 .25 -0.05 0.01 
Conditioning x worrying 0.03 1.15 .25 -0.02 0.07 
       
Model 4: moderation by BAS drive  A       
Conditioning (group) -0.38 -1.59 .12 -0.85 0.10 
.61 BAS drive E 0.07 0.85 .40 -0.10 0.25 
Conditioning x BAS drive -0.15 -1.38 .17 -0.37 0.07 
       
Model 5: moderation by BAS fun seeking  A       
Conditioning (group) -0.36 -1.51 .13 -0.84 0.11 
.61 BAS fun seeking  E -0.06 -0.70 .49 -0.25 0.12 
Conditioning x BAS fun seeking 0.04 0.27 .78 -0.23 0.30 
       
Model 6: moderation by BAS reward 
responsiveness  A 
      
Conditioning (group) -0.36 -1.52 .13 -0.82 0.11 
.63 BAS reward responsiveness  E 0.12 1.21 .23 -0.08 0.31 
Conditioning x BAS  reward responsiveness -0.27 -1.96 .053 † -0.54 0.003 
       
Model 7: moderation by behavioral inhibition 
(BIS)  A 
      
Conditioning (group) -0.34 -1.44 .15 -0.81 0.13 
.61 BIS  E 0.01 0.24 .81 -0.07 0.09 
Conditioning x BIS 0.03 0.50 .62 -0.09 0.15 
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Supplementary Table S8. Moderation by individual characteristics for the effects of the separate groups on self-reported itch 
during iontophoresis in the evocation phase, controlled for baseline, using the PROCESS moderation method. 
    Bootstrap  
Variable Coefficient t p LLCI ULCI R-square 
model 
       
Model 1: moderation by optimism:        
Open-label conditioned group dummy A       
Open-label conditioning -0.46 -1.36 .18 -1.13 0.21 
.62 Optimism B  > -0.01 -0.01 .99 -0.10 0.10 
Conditioning x optimism 0.11 1.06 .29 -0.10 0.31 
Closed-label conditioned group dummy A       
Closed-label conditioning 0.05 0.15 .88 -0.62 0.72 
.64 Optimism B 0.09 1.75 .084 † -0.01 0.19 
Conditioning x optimism -0.23 -2.35 .021 * -0.42 -0.04 
Conditioned-not-evoked control group dummy A       
Conditioned-not-evoked 0.35 1.00 .32 -0.35 1.04 
.62 Optimism B < 0.01 0.09 .93 -0.10 0.11 
Conditioned-not-evoked x optimism 0.07 0.73 .47 -0.12 0.26 
       
Model 2: moderation by perceived stress       
Open-label conditioned group dummy A        
Open-label conditioning -0.47 -1.41 .16 -1.14 0.94 
.63 Perceived stress C 0.03 1.01 .32 -0.03 0.09 
Conditioning x perceived stress -0.12 -1.79 .077 † -0.25 0.01 
Closed-label conditioned group dummy A       
Closed-label conditioning 0.02 0.05 .96 -0.66 0.70 
.62 Perceived stress C < 0.01 -0.13 .90 -0.07 0.06 
Conditioning x perceived stress 0.04 0.54 .59 -0.09 0.16 
Conditioned-not-evoked control group dummy A       
Conditioned-not-evoked 0.27 0.80 .43 -0.40 0.94 
.62 Perceived stress C < 0.01 0.10 .92 -0.06 0.07 
Conditioned-not-evoked x  perceived stress 0.01 0.16 .87 -0.12 0.14 
       
Model 3: moderation by worrying       
Open-label conditioned group dummy A       
Open-label conditioning -0.42 -1.24 .22 -1.09 0.25 
.62 Worrying D -0.01 -0.45 .65 -0.03 0.02 
Conditioning x worrying 0.01 0.18 .86 -0.05 0.06 
Closed-label conditioned group dummy A       
Closed-label conditioning 0.02 0.07 .94 -0.65 0.70 
.62 Worrying D -0.01 -0.94 .35 -0.04 0.01 
Conditioning x worrying 0.03 1.13 .26 -0.02 0.08 
Conditioned-not-evoked control group dummy A       
Conditioned-not-evoked 0.25 0.75 .45 -0.42 0.92 
.62 Worrying D  > -0.01 -0.04 .97 -0.03 0.03 
Conditioned-not-evoked x worrying -0.02 -0.61 .54 -0.07 0.04 
       
Model 4: moderation by BAS drive       
Open-label conditioned group dummy A       
Open-label conditioning -0.46 -1.33 .19 -1.14 0.23 
.62 BAS drive E 0.01 0.08 .94 -0.13 0.14 
Conditioning x BAS drive -0.06 -0.57 .57 -0.28 0.16 
Closed-label conditioned group dummy A       
Closed-label conditioning -0.03 -0.09 .93 -0.71 0.65 
.62 BAS drive E 0.01 0.22 .83 -0.11 0.14 
Conditioning x BAS drive -0.15 -1.12 .26 -0.40 0.11 
Conditioned-not-evoked control group dummy A       
Conditioned-not-evoked 0.27 0.79 .43 -0.40 0.94 
.62 BAS drive E -0.04 -0.67 .50 -0.16 0.08 
Conditioned-not-evoked x BAS drive 0.11 0.80 .43 -0.17 0.39 





Supplementary Table S8. Continued (2/2) 
    Bootstrap  
Variable Coefficient t p LLCI ULCI R-square 
model 
       
Model 5: moderation by BAS fun seeking       
Open-label conditioned group dummy A       
Open-label conditioning -0.43 -1.28 .20 -1.11 0.24 
.62 BAS fun seeking E -0.05 -0.72 .47 -0.20 0.10 
Conditioning x BAS fun seeking 0.03 0.20 .84 -0.28 0.34 
Closed-label conditioned group dummy A       
Closed-label conditioning -0.01 -0.02 .98 -0.68 0.67 
.62 BAS fun seeking E -0.05 -0.59 .55 -0.20 0.11 
Conditioning x BAS fun seeking > -0.01 -0.01 .99 -0.33 0.33 
Conditioned-not-evoked control group dummy A       
Conditioned-not-evoked 0.26 0.78 .44 -0.41 0.93 
.62 BAS fun seeking E -0.05 -0.59 .56 -0.21 0.11 
Conditioned-not-evoked x BAS fun seeking < 0.01 0.02 .97 -0.27 0.28 
       
Model 6: moderation by BAS reward responsiveness       
Open-label conditioned group dummy A       
Open-label conditioning -0.37 -1.08 .28 -1.05 0.31 
.63 BAS reward responsiveness E 0.04 0.52 .61 -0.12 0.20 
Conditioning x BAS  reward responsiveness -0.28 -1.73 .087 † -0.60 0.04 
Closed-label conditioned group dummy A       
Closed-label conditioning 0.03 0.09 .93 -0.66 0.72 
.62 BAS reward responsiveness E -0.02 -0.21 .83 -0.18 0.15 
Conditioning x BAS  reward responsiveness -0.03 -0.22 .83 -0.34 0.27 
Conditioned-not-evoked control group dummy A       
Conditioned-not-evoked 0.34 1.00 .32 -0.33 1.01 
.64 BAS reward responsiveness 
E -0.13 -1.58 .12 -0.29 0.03 
Conditioned-not-evoked x BAS  reward 
responsiveness 
0.37 2.37 .020 * 0.06 0.67 
       
Model 7: moderation by behavioral inhibition (BIS)       
Open-label conditioned group dummy A       
Open-label conditioning -0.41 -1.22 .23 -1.08 0.26 
.62 BIS E 0.04 1.28 .21 -0.02 0.11 
Conditioning x BIS -0.05 -0.72 .47 -0.18 0.08 
Closed-label conditioned group dummy A       
Closed-label conditioning 0.12 0.36 .72 -0.55 0.79 
.63 BIS E 0.01 0.19 .85 -0.06 0.07 
Conditioning x BIS 0.12 1.64 .10 -0.02 0.25 
Conditioned-not-evoked control group dummy A       
Conditioned-not-evoked 0.29 0.83 .41 -0.39 0.95 
.62 BIS E 0.03 0.95 .35 -0.04 0.10 
Conditioned-not-evoked x BIS > -0.01 -0.06 .95 -0.14 0.13 
       
 
Note. Dummy variables were computed with the non-conditioned control group as reference category. A Models controlled for 
mean itch during baseline histamine iontophoresis, and other dummy variables. In all models, itch during baseline iontophoresis 
was strongly related to itch during evocation (all p < .001). This association causes the high explained variance in the model. B 
Assessed by the Life Orientation Test – revised (LOT-R [24], C Assessed by the Perceived Stress Scale (PSS [25], D Assessed by 
the Penn State Worry Questionnaire (PSWQ [26], E Assessed by the Behavioural Inhibition System / Behavioural Approach 
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Placebo effects are positive outcomes that are not due to active treatment components, 
which may be elicited even when patients are aware of receiving an inert substance (open-
label). This proof-of-principle study investigated for the first time whether open-label 
placebo effects on itch can be induced by verbal suggestions alone. Ninety-two healthy 
volunteers were randomized to experimental (open-label suggestions) or control (no 
suggestions) groups. Self-reported itch evoked by histamine iontophoresis was the primary 
study outcome. In addition, itch expectations, skin condition and affect were assessed. The 
experimental group expected lower itch than the control group, which was, in turn, related 
to less experienced itch in this group only, although no significantly different itch levels 
were reported between groups. The results illustrate a potential role for open-label placebo 
effects in itch, and suggest that further study of verbal suggestions through an extensive 






Itch is the most common somatosensory symptom in skin conditions such as psoriasis and 
atopic dermatitis, and can cause significant impairment in patients [1]. For example, itch 
has previously been associated with impaired quality of life, a reduction in social activities, 
reduced quality of sleep, concentration problems, and depression [2]. Current treatments are 
often aimed at reducing the severity of the skin condition through pharmacological 
interventions with, for example, (topical) antihistamines or corticosteroids. However, these 
interventions have usually shown limited effects and are often accompanied by side-effects 
[3,4]. Over recent years, researchers have aimed to identify other factors involved in the 
experience of itch that might be used to improve treatment effectiveness [5]. A promising 
factor influencing the experience of itch without requiring medication is the placebo effect 
[6–8]. 
Placebo effects are beneficial effects of pharmacologically inert treatment components 
[6,8]. A recent meta-analysis indicated that itch may be especially prone to such effects, 
and that up to 30% of improvement in itch may be attributed to the occurrence of placebo 
effects rather than pharmacological intervention [9]. Experimental studies further 
demonstrate that placebo effects can be induced in itch by providing suggestions that a 
treatment is able to alleviate itch, or by suggesting that a test that generally provokes itch 
will elicit no itch [10,11]. In addition, there is evidence that the opposite instructions (e.g. 
suggesting that a treatment will sensitize a person to itch) can increase itch, a phenomenon 
known as the nocebo effect [10,12–14]. In addition to studies investigating the effects of 
verbal suggestions on self-report measures such as itch, a few studies have investigated 
whether verbal suggestions can influence physical skin conditions, for example wheal and 
flare size in response to histamine [11,12,14,15]. It has been demonstrated recently that 
negative outcome expectations, or nocebo, can result in a greater physical skin response, as 
demonstrated by larger flare size in response to histamine and wheal size in response to 
natrium chloride following negative verbal suggestions [14]. Placebo (and nocebo) effects 
can be established by a patient’s belief in treatment effectiveness and outcomes [6,8,16–
18]. The main working mechanisms of placebo effects include associative learning 
processes, such as conditioning, and expectations, such as positive information regarding 




Most studies on placebo effects have used an experimental approach eliciting placebo 
effects by providing uncertainty or deception about the specific treatment provided (e.g., 
actual medicine or placebo). It is assumed that the benefits that patients experience from 
inert substances stem from the covert belief that a pharmacologically effective treatment is 
being given [19]. This uncertainty or deceptive component complicates the potential 
utilization of placebo effects in clinical practice, considering that omission of treatment 
information and provision of deceptive information are unethical [18,20]. Studies have, 
however, indicated that a placebo treatment can still be effective when patients are aware of 
receiving an inert treatment [21–28]. Most of these studies on open-label placebo treatment 
have reported medium-to-large effect sizes [21,22,25], comparable to the effect sizes found 
by studies in which patients were not informed about receiving an inert substance (closed-
label placebo [29]). A recent pilot study furthermore demonstrated that such an open-label 
placebo treatment may also be effective for symptoms of allergic rhinitis, including itch 
[28]. Within this pilot study, symptom improvement by open-label placebo treatment was 
furthermore associated with higher subjective well-being [28]. 
It is not yet clear by which mechanisms open-label placebo effects may be elicited. 
Previous open-label studies have combined different components, namely the 
administration of an inert pill and a rationale concerning placebo effectiveness and its 
mechanisms [21–28]. This complicates the understanding of which of these components 
contribute to open-label placebo effects, or the extent to which they contribute. It is not yet 
known whether providing a positive rationale (e.g. verbal suggestions) exclusively might be 
sufficient to induce open-label placebo effects by changing expectations regarding itch and 
affecting the response to an itch stimulus. If proven possible, this would facilitate clinical 
applications; for example, by optimizing existing treatment methods for chronic itch by 
improving doctor–patient communication. 
The aim of the current proof-of-principle study was to investigate for the first time in an 
open-label design whether positive verbal suggestions about itch in response to an itch-
provoking test without combining it with an inert treatment can induce positive outcome 
expectancies and reduce self-reported itch in response to a short-term itch-provoking 
histamine test. Physical and self-reported skin condition and positive and negative affect 
were secondary outcomes. In addition, the specific role of expectations in the effects of 
open-label verbal suggestions on itch was examined. It was expected that open-label 
positive verbal suggestions about itch would reduce the level of itch that participants 




experienced during the test, compared with a control condition that received no verbal 
suggestions. In addition, it was expected that open-label positive verbal suggestions 
compared with the control group would reduce the severity of the participants’ skin 
condition, and that verbal suggestions would diminish changes in positive and negative 
affect as a consequence of itch induction by histamine iontophoresis. 
 
METHODS 
The study was approved by the Medical Ethical Committee at the Leiden University 
Medical Center, The Netherlands (protocol number NL54570.058.15) and performed in 




Healthy male and female volunteers were recruited primarily through advertisements and 
flyers at various sites of Leiden University, The Netherlands, and through online media. 
Participants were included if they were between 18 and 35 years old and had a sufficient 
understanding of written and spoken Dutch. Exclusion criteria consisted of severe somatic 
or psychological morbidity (e.g. heart and lung diseases, histamine intolerance, or the 
Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision 
(DSM-IV-TR) psychiatric diagnoses) that might interfere with the study protocol, current 
chronic itch or pain complaints, current medication use (analgesics, anti-inflammatory 
drugs, antihistamines, or antibiotics), or pregnancy. In order to prevent potential influences 
on the response to the itch stimulus, participants were asked to refrain from the 
consumption of food, caffeine, and smoking 2 h prior to the laboratory session. In addition, 
they were asked to avoid heavy exercise 12 h, and alcohol and drugs 24 h prior to the 
session. This was verified at the beginning of the laboratory session, including a brief check 







A between-subjects experimental randomized controlled trial design was used. Subjects 
considered eligible to participate in the study were invited to a 1-h laboratory session and 
randomized to either the experimental (i.e. open-label positive verbal suggestions) group or 
the control (no verbal suggestions) group. The randomization sequence was acquired 
through the use of an online random number generator (www.random.org, Dublin, Ireland). 
The laboratory session was conducted by 2 experimenters; only one of whom was aware of 
group allocation and provided the verbal suggestions. Participants and the experimenter 
who conducted the outcome assessments were unaware of group allocation during the 
laboratory session. 
 
Materials and measures 
1. Histamine iontophoresis.  
Histamine was applied to the skin through transdermal iontophoresis (Chattanooga Group, 
Hixson, TN, USA). This method has been used previously to experimentally induce itch in 
healthy volunteers [10,30,31]. A 0.6% diphosphate histamine solution was prepared in 
distilled water with propylene glycol and hypromellose 4000 mPa. An electrode (Iogel, 
Iomed, DJO Global, Hannover, Germany) was prepared that contained 2.5 ml of the 
histamine solution. The electrode had an active area of 11.7 cm2 and was placed on the 
volar side of the non-dominant forearm, and the reference electrode was placed on the volar 
surface of the upper arm. Current level was set at 0.4 mA. Histamine iontophoresis was 
applied for 2.5 min, after which the electrodes were removed and a follow-up period of 4 
min was started. 
 
2. Verbal suggestions.  
Participants were informed prior to the session that the study aimed to investigate 
individual differences in the experience of itch. Upon arrival at the laboratory session, the 
following general instructions were given to all participants: “During the test, histamine 
will be applied on your skin by means of a small electrical current. This elicits a response 
that is similar to a mosquito bite. Your skin may become red and may swell up.” In the 




followed by an open-label instruction: “Previous research indicates that the test elicits 
little or no itch in most healthy people, meaning in 95% of cases. We would also like to give 
you some extra information. From research we know that expectations play a large role in 
how itch is experienced, for example through giving information about what to expect from 
a test such as this one. I just told you that the test that you are about to do elicits little or no 
itch in most healthy people. From research we know that this suggestion will really cause 
people to experience little itch, even when they are aware of receiving this suggestion. 
Thus, the suggestion alone that the test causes little or no itch will already cause you to 
experience little itch.” 
 
3. Process measure: expectations about itch.  
Participants were asked to indicate on the computer the level of itch they expected to 
experience, using a numerical rating scale (NRS) ranging from 0 (“no itch at all”) to 10 
(“worst itch ever experienced”). Expected itch was assessed at 2 time-points during the 
laboratory session: once during baseline assessments and once after the verbal suggestions 
but before the histamine iontophoresis. 
 
4. Primary outcome measure: self-reported itch.  
The level of experienced itch during histamine iontophoresis was assessed verbally every 
30 s during iontophoresis and during a 4-min follow-up period, using the same NRS as 
described in the previous paragraph. Directly following histamine iontophoresis, the mean 
experienced itch during iontophoresis was assessed verbally using the same NRS. As part 
of a series of online questionnaires that assessed baseline measures (see Procedure), the 
level of itch experienced prior to iontophoresis was measured graphically by dragging a 
slider over a bar slide using the same NRS, with a 2-decimal score depicted next to the bar 
slide. 
 
5. Secondary outcome measure: physical skin condition.  
Wheal size and flare size in response to histamine iontophoresis were traced on a 1 cm2 
gridded, transparent sheet following histamine application using a 0.4-mm black permanent 
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marker (Staedtler, Germany). Scans of the sheets were then uploaded and analysed using 
ImageJ [32]. Images were calibrated to the 1 cm2 grid in ImageJ, after which wheal and 
flare area were estimated in cm2 through tracking the outer edges of the drawn wheal and 
flare areas. In addition, skin temperature was assessed following histamine iontophoresis on 
the application site on the arm using a hand-held infrared digital thermometer (accuracy 
±2.0°C, resolution 0.1°C, BaseTech, Conrad Electronic Benelux B.V., Hirschau, Germany). 
The thermometer was held vertically approximately 1 cm above the area. To control for 
individual differences in skin temperature, a second measurement was taken of a similar 
skin area of the contralateral arm and used as a covariate in the analysis. 
 
6. Secondary outcome measure: self-reported skin condition.  
The Sensitive Scale-10 (SS-10) was used to assess self-reported skin condition [33]. This 
scale assesses the severity of skin sensitivity over the past 3 days through evaluation of 9 
skin condition items (e.g. burning, tautness, itch, and redness of the skin) on a 0 (“zero 
intensity”) to 10 (“intolerable intensity”) scale. In addition, the scale assesses skin irritation 
on a visual analogue scale (VAS), ranging from 0 to 10 [33]. The SS-10 total score was 
calculated by summing all items, with a higher score indicating more intense skin 
sensations (range 0–100). Upon arrival in the laboratory, participants completed the SS-10 
for a baseline measurement. A slightly adjusted version of the SS-10 was used to assess 
self-reported skin condition following histamine iontophoresis, with participants having to 
indicate the symptoms experienced during histamine iontophoresis rather than symptoms 
experienced during the past 3 days. In the current study, Cronbach’s alpha was 0.83 for 
baseline SS-10 and 0.89 for the adjusted post-test SS-10. 
 
7. Secondary outcome measure: positive and negative affect.  
The Positive and Negative Affect Schedule (PANAS) was used to assess positive (PA) and 
negative affect (NA; [34]). In this 20-item questionnaire, participants indicated the extent to 
which they experience specific emotions (e.g. interested, excited, or nervous) at that 
moment on a 1 (“very slightly or not at all”) to 5 (“extremely”) scale. PA total score was 
calculated by summing the 10 positive items of the scale and NA total score by summing 
the 10 negative items (total score range 10–50, with higher scores indicating higher PA or 




and following histamine iontophoresis (post-test PA and NA). Cronbach’s alpha was 0.83 
for baseline PA and 0.79 for post-test PA. For NA, Cronbach’s alpha was 0.82 and 0.91, 
respectively. To examine group differences in the changes over time in positive and 
negative affect in response to the histamine iontophoresis, PA and NA change scores were 
calculated for each scale by subtracting baseline scores from post-test scores. For both 




Prior to being invited to a laboratory session, participants were provided with written 
information about the study. Participants subsequently completed a series of online 
questionnaires assessing the screening criteria and several personality characteristics, which 
are not described here since they are unrelated to the aim of the current study. Prior to this, 
participants provided written informed consent for the online questionnaires. At the start of 
the laboratory session, the study procedures were explained to all participants and written 
informed consent for the entire study was provided, following which participants were 
given instructions regarding the histamine test by the first experimenter. Next, baseline 
measurements were taken of itch, self-reported skin condition, positive and negative affect, 
and itch expectations before verbal suggestions. Positive expectations were then induced 
through open-label verbal suggestions in the experimental group. Participants then again 
indicated the level of itch they expected to experience. In the meantime, the first 
experimenter left the room and was replaced with the second experimenter. Histamine 
iontophoresis was then conducted by this second experimenter. During histamine 
iontophoresis as well as during the 4-min follow-up period, the level of itch participants 
experienced was assessed verbally on the NRS every 30 s. Directly following 
iontophoresis, mean experienced itch during iontophoresis was assessed, again using the 
same NRS. Subsequently, measurements of physical skin condition (e.g. wheal, flare) were 
taken and post-test questionnaires SS-10 and PANAS were administered. The second 
experimenter was then replaced by the first experimenter and participants were debriefed 






A power calculation for an analysis of covariance (ANCOVA) using G*Power 3.1 [35] 
indicated that a total of 92 participants was needed to achieve a power of β=0.80 at a 2-
sided significance level of α=0.05 to detect a Cohen’s d effect size of at least 0.30 on the 
primary outcome measure of mean itch. Analyses were performed using SPSS 21.0 for 
Windows (IBM SPSS Inc., Chicago, Illinois, US). Variables were checked for normal 
distribution. In order to achieve normal distributions, square root transformations were 
applied for baseline itch and self-reported skin condition, as well as the physical skin 
condition parameters wheal size and flare response, and a log10 transformation was applied 
to baseline skin temperature. For PANAS negative affect change scores, transformations 
failed to achieve a normal distribution; therefore, a non-parametric Kruskal–Wallis test was 
used to examine group differences on this outcome measure. χ2 tests and general linear 
model (GLM) ANOVAs were used to detect differences between groups on demographic 
factors and baseline measurements of itch, self-reported skin condition (SS-10), and 
positive and negative affect. The primary outcome measure of mean experienced itch, as 
rated by participants following histamine iontophoresis (mean ± standard deviation (SD) 
3.3 ± 1.6) was correlated very highly with the mean score of itch ratings during the 
histamine iontophoresis (mean ± SD 2.9 ± 1.4; r = 0.93, p < 0.001), supporting the reliability 
of the itch measure used. To examine whether the groups differed on the process measure 
of itch expectation (post-verbal suggestions) and on the primary outcome of mean itch 
experienced during the histamine test, 2 GLM ANCOVAs were conducted, with baseline 
expectations and baseline itch level included as covariates in the analyses, respectively. 
Similar ANCOVAs were conducted for the secondary outcome measures of the SS-10 and 
skin temperature. For wheal and flare size in response to histamine iontophoresis, as well as 
for PANAS positive affect change scores, GLM ANOVAs were performed. As an effect 
size measure, Cohen’s d was calculated for analyses on the primary and secondary outcome 
parameters, with d = 0.2, 0.5 and 0.8 being interpreted as a small, medium and large effects, 
respectively [36]. In order to explore whether itch expectation after the verbal suggestions 
was related to the level of mean experienced itch during histamine iontophoresis, and 
whether this relationship differed between groups, separate effects, as well as an interaction 
effect of post-verbal suggestions itch expectation and group, were examined in a multiple 
regression analysis, with baseline itch and pre-verbal suggestions itch expectation as 
covariates. Post-verbal suggestions itch expectation was centred prior to the analysis. All 






A total of 139 potential participants expressed interest in the study, of whom 24 were 
excluded due to medical morbidity (e.g. migraine, asthma, presence of a skin disorder) and 
9 due to psychological morbidity (e.g. depression, anxiety). In addition, 14 persons 
refrained from participation for other reasons (e.g. no response after first postal contact). In 
total, the sample consisted of 92 healthy male (n = 17) and female (n = 75) participants 
between 18 and 26 years of age (mean ± SD 21.3 ± 1.9 years). Participants were of Dutch 
(98%), Dutch–Turkish (1%), or German (1%) nationality. Of all participants, 41% had a 
partner, of whom 7% were living with a partner or were married. Of the female 
participants, 69% used oral contraceptives. Randomization resulted in a total of 46 
participants in the experimental group and 46 participants in the control group. Data for one 
participant in the experimental group were excluded from analysis, due to technical issues 
during histamine iontophoresis. χ2 tests and ANCOVAs revealed no differences between 
groups with regard to age, sex, education, or nationality (all p-values ≥ 0.19). Table I 
displays the means ± SD for the baseline measurements, and the primary and secondary 
study outcomes for the 2 groups. 
 
Effects of verbal suggestions on the process measure of post-suggestion expected itch 
As shown in Fig. 1, in the experimental group significantly lower itch expectations were 
reported following verbal suggestions (mean ± SD 2.66 ± 2.04) than in the control group 
(mean ± SD 5.73 ± 1.51). A statistically significant large-sized effect of verbal suggestions 
on post-verbal suggestions itch expectation, controlled for pre-verbal suggestions itch 
expectation, was demonstrated in the ANCOVA; F(1, 89)=59.57, p < 0.001, Cohen’s 
d = 1.62. 
 
Effects of open-label verbal suggestions on the mean level of itch during histamine 
iontophoresis  
No statistically significant difference between groups in mean self-reported itch in response 
to histamine iontophoresis, controlled for baseline itch, was found in the ANCOVA; F(1, 
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90)=1.40, p = 0.24, Cohen’s d = 0.21. Multiple regression analysis to test for interaction 
effects between post-verbal suggestions itch expectation and group on self-reported mean 
itch during histamine iontophoresis did not show significant main effects for group 
(β = 0.06, p = 0.69) or post-verbal suggestions expected itch (β = 0.36, p = 0.10). As 
expected, baseline itch and pre-verbal suggestions expected itch were not predictive of self-
reported mean itch during histamine iontophoresis (p ≥ 0.36). However, a statistically 
significant interaction effect for group × post-verbal suggestions itch expectation was found 
(p = 0.04), indicating that in the experimental group only, lower expected itch was 
associated with lower self-reported mean itch during the histamine iontophoresis, whereas 
no association between expected and experienced itch was found in the control group (full 
model: R2=0.11, F(5,89)=2.04, p = 0.08; see also Fig. 2). 
 
 
Effects of open-label verbal suggestions on skin condition  
Self-reported skin condition (SS10) scores following histamine iontophoresis were 
marginally significantly lower, indicating better self-reported skin condition, in the 
experimental group (25.88 ± 13.55) than in the control group (29.88 ± 14.48; F(1, 90)=3.67, 
p = 0.059, Cohen’s d = 0.29). No statistically significant group differences were found for 








Table 1. Means ± standard deviations for baseline and outcome measures of study parameters per group.  
 Experimental group  
(n = 45) 
Control group  
(n = 46) 
p value  
    
Process measure    
  Pre-VS itch expectation a 4.84 ± 1.61 5.19 ± 1.83 .28 
  Post-VS itch expectation a 2.66 ± 2.04 5.73 ± 1.72 < .001 
    
Primary outcome measure    
  Baseline itch 0.47 ± 0.84 0.39 ± 0.89 .27 
  Self-reported average itch 3.14 ± 1.61 3.46 ± 1.51 .24 
    
Secondary outcome measures    
 Subjective skin response    
  Baseline self-reported skin condition 6.94 ± 9.12 5.02 ± 5.50 .16 
  Self-reported skin condition b 25.88 ± 13.55 29.88 ± 14.48 .059 
      
 Physical skin response    
  Wheal size (cm2) 10.40 ± 2.67 11.23 ± 2.67 .16 
  Flare response (cm2) 33.81 ± 7.85 35.54 ±10.19 .44 
  Skin temperature (°C) 33.35 ± 1.21 33.54 ± 1.38 .26 
      
 Change in Positive and Negative Affect    
  Baseline positive affect  24.74 ± 6.34 25.54 ± 6.21 .54 
  Post-histamine positive affect 24.09 ± 6.58 22.61 ± 4.69 .22 
  Baseline negative affect d 12.00 ± 4.00 12.00 ± 4.00 .67 
  Post-histamine negative affect d 11.00 ± 3.00 11.00 ± 2.00 .53 
      
  Change in positive affect c -0.64 ± 3.22 -2.93 ± 3.69 .002 
  Change in negative affect c d 0.00 ± 2.00 0.00 ± 3.00 .98  
     
 
Note. a VS = open-label verbal suggestions; b As measured by an adjusted version of the Sensitive Scale-10 [33]; c Change in 
mood parameters measured by the Positive and Negative Affect scales [34] over time, as calculated by subtracting the baseline 
scores from the post-histamine scores. More positive scores indicate an increase over time, whereas zero indicates no change 
and more negative scores indicate a decrease over time; d Median ± interquartile range is presented, with p value calculated by 





Figure 1. Mean Numeric Rating Scale (NRS) scores for the experimental (open-label positive verbal suggestions; n=45) and 
control (no suggestions; n=46) group for the process measure and primary study outcome measure: expected itch from 
before to after instructions on the histamine iontophoresis test (A), average itch in response to histamine iontophoresis (B). Error 
bars represent standard error of the mean. *** p < .001; n.s. non-significant 
 
 
Figure 2. Scatter plot of the interaction effect between expected itch following verbal suggestions, controlled for pre-verbal 
suggestions expected itch, and group (experimental, n = 45 and control, n = 46) on self-reported mean itch during histamine 




Effects of open-label verbal suggestions on change in positive and negative affect  
A statistically significant and medium-sized effect of verbal suggestions on PA change 
scores was demonstrated compared with the control group; F(1, 90)=9.93, p = 0.002, 
Cohen’s d = 0.66. Participants in the control group showed a stronger decline in positive 
affect from before to after the histamine iontophoresis (mean ± SD PA change score –
2.93 ± 3.69, range –15 to 5), whereas participants in the experimental group remained more 
stable over time (mean ± SD PA change score –0.64 ± 3.22, range –8 to 8). The Kruskal–
Wallis test revealed no statistically significant difference in NA change scores between the 
experimental and control groups (p = 0.98). 
 
DISCUSSION 
This proof-of principle study investigated for the first time whether open-label positive 
verbal suggestions alone can induce outcome expectations and reduce the level of itch 
experienced during histamine iontophoresis. It was demonstrated that the open-label 
positive verbal suggestions were successful in reducing the level of itch participants 
expected to experience during histamine iontophoresis, but not in reducing itch experienced 
in response to the histamine test. The relevance of expectations was demonstrated further 
by showing that a decrease in expected itch in response to verbal suggestions was 
significantly associated with lower experienced itch in response to the histamine test in the 
experimental group, but not in the control group. Moreover, a tendency was found for 
patients to rate the severity of the self-reported skin condition as lower following open-label 
suggestions, compared with the control group, but no effects on physical skin condition 
were found. Furthermore, a significantly smaller decrease in positive, but not negative, 
affect was found in response to the histamine test in the verbal suggestions group, 
compared with the control group.  
These findings, that open-label positive verbal suggestions did not affect actual experienced 
level of itch, are not in line with the findings of previous studies on open-label placebo in, 
for example, allergic rhinitis, low-back pain and irritable bowel syndrome [21–26,28]. This 
may be due to the current study using verbal suggestions exclusively without an inert 
treatment. In previous studies, open-label placebo effects have been induced by asking 
participants to ingest pharmacologically inert pills combined with providing a suggestive 
positive rationale to participants, in which it was explained how placebo effects induce 
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symptom improvement and in which the effectiveness of placebo treatment was 
emphasized [21,22,28]. It is possible that the mere act of taking medicine could have 
elicited stronger placebo effects. Influential conditioning theories of placebo effects state 
that the placebo effect is a conditioned response that is a result of previously learned 
associations [16]. As pointed out previously by Carvalho et al. [21], the rituals surrounding 
administration of medication may have activated previously learned associations between 
symptom alleviation and capsule or pill ingestion. Considering that all previous open-label 
studies have been conducted in patient populations in which medication administration is 
common, it seems likely that these effects were further strengthened by associative learning 
pathways and heightened relevance of symptom improvement for patients in these studies. 
The current study, on the contrary, sought to examine the ability to elicit placebo effects by 
provision of positive verbal suggestions without coupling with an inert substance in healthy 
participants. Investigating these effects not only provides information regarding the 
mechanisms of open-label placebo, but if proven possible would also allow for easier 
implementation in clinical practice, for example by optimizing the information provided to 
patients in existing treatment in order to maximize placebo effects. The placebo effects 
induced in the current study may have had some impact, as evidenced by the successful 
expectation induction, which was in turn related to lower itch level, but speculatively may 
not have been strong enough to significantly alter the way in which itch was actually 
perceived in response to the itch stimulus.  
Next to effects on itch expectancy, there was also a tendency for participants in the 
experimental group to indicate better self-reported skin condition following the histamine 
test than controls. That positive affect in the open-label suggestions group also decreased 
significantly less than in the control group upon itch induction also indicates that some 
effects may have occurred. This may be compared with the previous finding that 
improvement in allergic rhinitis by open-label placebo treatment is related to higher 
wellbeing [28]. However, no effects of open-label positive verbal suggestions on physical 
skin condition (i.e., wheal and flare size, skin temperature) were found, which is in line 
with previous findings for closed-label placebo effects on physical skin responses [11,15], 
but not with findings for closed-label nocebo effects on physical skin response [14]. 
Although indications were found that the verbal suggestions may have mostly influenced 
subjective measures, they were potentially not strong enough to significantly alter the 




In this study, a potential predictive role of a change in itch expectations due to open-label 
verbal suggestions was observed for the resultant itch level that was reported in response to 
the histamine test, showing that a larger decrease in itch expectations was associated with 
lower experienced itch. This is in accordance with the idea that placebo effects can impact 
symptoms by means of changing people’s expectations and is in line with the provided 
rationale explaining that expectations can alter the way in which itch can be perceived. 
Whereas in closed-label placebo studies the expectation that a certain treatment or medicine 
results in symptom improvement is attributed to the provision of uncertainty or deceptive 
information by the doctor or experimenter [27,37], in open-label studies this might be 
attributed to the provision of a rationale on how placebo effects could instead lead to 
beneficial treatment outcomes. For both, the actual expectation of symptom improvement 
of the patient is suggested to be present and to have an impact. Previous studies, however, 
have always combined open-label placebo pill administration with the rationale that 
explained that “the placebo effect can be powerful” and that “the body may respond 
automatically to placebo treatment” [21,22,28]. Furthermore, as in most of these trials, 
open-label placebo treatment was given along with treatment as usual [21,22,28] and the 
effects that patients might experience were not specified, placebo effects may have been 
enlarged by simultaneously occurring pharmacologically-induced reduction in symptoms. 
As such, it is difficult to determine the exact underlying cause of placebo effects in these 
studies. Demonstrating that placebo effects could be exclusively due to a positive rationale, 
on the other hand, would facilitate easier implementation in clinical practice, as no 
additional inert pills would need to be given. Instead, a positive framework for patients in 
which placebo mechanisms are illustrated could then potentially suffice to strengthen 
existing treatment methods for itch. 
Some strengths and limitations of this study need to be taken into account. This is the first 
study to examine the ability of positive verbal suggestions to induce placebo effects in itch 
in an experimental, open-label design without combining it with an inert treatment. The 
relatively large sample size and use of a homogenous participant group allowed for a robust 
indication of effect sizes. Assessment of outcome variables was conducted by an 
experimenter who was blinded to group allocation in order to minimalize reporting bias. 
However, as in all research in which placebo effects are induced by verbal suggestions, 
reporting bias cannot be ruled out, as participants may still have adjusted their answers due 
to the explicit instructions on expectations. Fourthly, participants underwent histamine 
iontophoresis only once and most were unfamiliar with histamine iontophoresis. Prior to the 
168 
 
test, participants were told that the response to histamine iontophoresis could feel like a 
mosquito bite. However, since the participants did not know exactly what to expect during 
the test, this lack of a reference frame for itch may have complicated changing these 
expectations and, consequently, the induction of placebo effects. Future studies could 
examine whether providing a more familiar stimulus, for example by providing a baseline 
test prior to placebo induction, would lead to clearer expectation effects [13]. Finally, while 
in the open-label verbal suggestions a distinction was made between the suggestion (i.e., 
“research indicates that the tests elicits little to no itch in most healthy people, meaning in 
95% of cases”) and the open-label rationale, both were given to one group only. As such, 
we cannot distinguish between effects of the suggestion itself and the open-label rationale 
that followed. For future research, it may also be useful to compare open-label with closed-
label placebo induction, in order to better distinguish between open- and closed-label 
placebo effects in itch. 
In conclusion, this proof-of-principle study indicates for the first time that open-label 
positive verbal suggestions were able to reduce itch expectations prior to a histamine test. 
Also, open-label suggestions were associated with a smaller impact on positive affect and 
indications were found for a more positive self-perceived, but not physical, skin condition 
in response to the validated histamine test. However, the suggestions did not significantly 
impact actual itch levels between groups, although within the experimental group an 
association was found between expected and experienced itch after verbal suggestions. 
Future research should aim to strengthen the open-label verbal suggestions, for example by 
providing a more explicit explanation of placebo mechanisms and effectiveness, in order to 
investigate whether open-label placebo effects can be induced in itch without the need to 
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Placebo and nocebo effects have been shown to influence subjective symptoms such as 
itch. These effects can be induced by influencing outcome expectations through, for 
example, combining the application of an inert substance (e.g., a cream) with verbal 
suggestions on the anticipated effects of this substance. Interestingly, placebo effects also 
occur when it is known that a treatment is inert (i.e., open-label placebo). However, no 
study to date has examined the efficacy of negative and positive verbal suggestions under 
similar open-label and closed-label (i.e., concealed placebo/nocebo) conditions in itch. A 
randomized controlled between-subjects study design was applied in which healthy 
volunteers (n = 92) were randomized to 1) an open-label positive verbal suggestion group, 
2) a closed-label positive verbal suggestion group, 3) an open-label negative verbal 
suggestion group, or 4) a closed-label negative verbal suggestion group. Verbal suggestions 
were made regarding the topical application of an inert substance. Itch was evoked 
experimentally by histamine iontophoresis at baseline and again following suggestions. Itch 
expectations, self-reported itch during and following iontophoresis, and skin response 
parameters were measured. Positive suggestions were found to result in significantly lower 
expected itch than were negative suggestions in both open- and closed-label conditions. No 
effects of the suggestions on itch during iontophoresis were found, but significantly lower 
itch was reported in the 4 min following iontophoresis in the (combined open- and closed-
label) positive compared with negative verbal suggestion groups. In addition, a smaller 
increase in skin temperature was found in the positive compared with negative suggestion 
groups. The findings illustrate a potential role of (open- and closed-label) placebo for 
optimizing expectations and treatment effects for itch in clinical practice. 





Itch is the most common somatosensory symptom in dermatological conditions. It is a 
hallmark symptom of atopic eczema [1], and its prevalence in psoriasis is high [2]. 
Moreover, itch is a common symptom of various other disorders, including kidney failure, 
liver disease, cancer, allergy, and diabetes mellitus [3-5]. Due to its high prevalence—
approximately 8% of the general population and over 50% of dermatological patients—the 
burden of itch and its impact on society are high [6,7]. Often, patients report significantly 
lowered quality of life, increased depressive and anxious symptoms, and sleep disturbances 
due to chronic itch [8]. While current treatments aim to suppress itch through 
pharmacological interventions, oftentimes, limited effects and significant side effects are 
reported [3,9]. As such, it is important to identify factors that contribute to treatment 
efficacy. 
One of the factors that may be especially relevant for treatment outcomes is the placebo 
effect. Placebo effects are defined as beneficial effects of otherwise pharmacologically inert 
substances [10,11] and have been studied in a variety of medical conditions and symptoms, 
including itch and pain [12-14]. Multiple pathways through which these effects can be 
elicited have been identified, including associative learning processes, social learning, or 
instructional learning [12,15-17]. Within these pathways, expectancy is a key component. 
To illustrate, a positive expectation may be elicited through past experiences with the 
beneficial effects of a certain type of medication (associative learning), through observation 
of treatment efficacy in others (social learning), or through receiving positive (verbal) 
information about a treatment (instructional learning) [17]. In turn, this positive expectation 
can then result in psychoneurobiological changes and symptom reduction [18,19]. On the 
other hand, when expectations regarding a treatment outcome are low or negative outcomes 
are expected, symptoms may worsen or the occurrence of treatment side effects may 
increase, known as the nocebo effect [12,20]. 
The current literature indicates that at least 30% of itch reduction in clinical practice might 
be attributable to placebo effects [21]. Placebo and nocebo effects can be experimentally 
induced for itch by changing expectations through verbal suggestions regarding inert 
treatments or through the use of associative learning mechanisms [22-28]. However, not all 
studies confirm these findings [28,29]. In addition, there is some evidence that it may be 
necessary to combine multiple placebo induction methods (e.g., associative learning and 
positive suggestions) and that a single induction method may not be sufficient to elicit 
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significant placebo effects [22]. Hence, further study of the circumstances under which 
placebo effects may be elicited for itch is relevant. 
Most studies on placebo effects take on a traditional approach, in which patients or healthy 
individuals are told that a pharmacologically effective substance (e.g., a pill or cream) is 
given, whereas in reality, the substance is pharmacologically inert [30,31]. While this 
concealing or deceptive approach is useful for studying the underlying mechanisms of 
placebo effects in general, it may become problematic when it comes to utilizing these 
effects in clinical practice, where concealment or deception regarding the treatment 
provided brings along ethical issues. For a long time, it was believed that this would 
prevent strategic use of the placebo effect in clinical practice [30]. In the past years, 
however, studies have demonstrated that placebo effects can also occur when it is explicitly 
told that, although a given substance is inert, placebo effects may still help in alleviating 
symptoms. These so-called open-label placebo effects have been found to significantly 
reduce symptoms of irritable bowel syndrome, depression, attention deficit hyperactivity 
disorder, chronic low back pain, and allergic rhinitis [31-39]. Most of these studies induce 
open-label placebo effects through a combination of an attribute (e.g., an inert pill) that may 
trigger previously learned associations between medicine and symptom reduction in 
general, and a scripted briefing in which the positive effects of placebo pills are emphasized 
(a suggestive framework) [31-34,36-28]. Findings on whether these effects can be 
attributed to the provided pill or the provided explanation alone are contradictory 
[35,39,40]. 
In view of the previous findings, further research is needed to demonstrate the efficacy of 
both open-label and closed-label (i.e., concealed) placebo effects for itch. It is not yet 
known whether effect sizes of open-label and closed-label placebo effects are comparable. 
Moreover, no study to date has investigated whether nocebo effects can be induced under 
both closed-label and open-label conditions for itch. To this end, we investigated in the 
current study whether negative or positive outcome expectations, induced by a suggestive 
framework (negative and positive verbal suggestions, provided in an open-label and closed-
label context) combined with an attribute (an inert tonic), can influence self-reported itch 
during an experimental itch induction by histamine in healthy volunteers. We primarily 
tested the effects of the positive and negative suggestions on itch by combining open- and 
closed-label groups. Secondarily, we tested these effects for open-label and closed-label 
contexts separately to see whether these effects were comparable, and we investigated the 




physical skin response to histamine. We expected a decrease in itch following positive 
verbal suggestions compared with an increase in itch following negative verbal suggestions 
for both the open-label and closed-label conditions. 
 
MATERIALS AND METHODS 
The study was approved by the Medical Ethical Committee at the Leiden University 
Medical Center, the Netherlands (NL58792.058.16), and registered in the Dutch Trial 
Register (NTR6530). The study was performed in accordance with the Declaration of 
Helsinki [41]. All participants provided written informed consent. 
 
Participants 
Healthy male and female participants were recruited through advertisements at Leiden 
University and through social media (e.g., Facebook). Inclusion criteria consisted of an age 
between 18 and 35 years and a good understanding of the Dutch written and spoken 
language. Interested volunteers were excluded in case of self-reported severe somatic or 
psychological morbidity that could interfere with the participant’s safety or study protocol 
[e.g., heart or lung diseases, histamine intolerance, or Diagnostic and Statistical Manual of 
Mental Disorders - Fourth Edition Text Revised (DSM-IV-TR) psychiatric diagnoses]; 
current chronic itch or pain complaints; current use of analgesics, anti-inflammatory 
medication, antihistamines, or antibiotics; and (suspected) pregnancy. Participants were 
asked to refrain from the consumption of heavy meals, caffeine, and smoking 2 h, exercise 
12 h, and alcohol as well as drugs 24 h prior to the sessions to prevent potential influences 
on study outcomes. Adherence to these lifestyle guidelines, as well as the exclusion criteria, 
was verified at the start of each session by means of interviewing. 
 
Study design 
A between-subjects, single-blinded, randomized controlled experimental trial design was 
applied. Eligible participants were randomized to (I) an open-label positive verbal 
suggestion (VS) group, (II) a closed-label positive VS group, (III) an open-label negative 
VS group, or (IV) a closed-label negative VS group. Randomization sequence was acquired 
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using an online random number generator (www.random.org, Dublin, Ireland). Allocation 
was not concealed for experimenters. Participants were invited for a baseline and an 
experimental session, which were timed 1 week apart. An overview of the study design and 













Measures and Materials 
1. Verbal suggestions.    
Before the study, participants were informed that the study aimed to investigate individual 
differences in the sensitivity to itch and the role of psychological factors in explaining these 
differences. They were informed that the itch induction method would elicit a response 
similar to a mosquito bite (e.g., that their skin may become red and swollen). During the 
experimental session, participants were told that, prior to itch induction, a tonic would be 
applied that influences sensitivity to itch. In reality, this tonic was a pink-colored skin 
disinfectant (Orphi Pharma B.V., Dordrecht, the Netherlands). The itch induction during 
the baseline session was used as a reference point for the suggestions. In the positive VS 
groups (I and II), the following suggestion was given: “This tonic has an itch-reducing 
effect and will make the skin less sensitive to itch. From previous research we know that the 
application of this tonic will reduce itch for most people, meaning around 95 percent of the 
studied people. As such, we expect that you will experience less itch, compared to the 
previous test.” Participants in the negative VS groups (III and IV) were given the same 
information, but negative words were used instead of positive words (e.g., “itch-increasing” 
rather than “itch-reducing”).  
When participants were allocated to one of the two open-label groups, additional 
instructions were given. For the positive VS group, these were: “I just told you that the 
tonic reduces itch. In fact, the tonic is a placebo. From research we know that the 
expectation that a remedy reduces itch will really cause people to experience less itch. This 
is caused by different processes, for example itch-reducing substances that are released in 
the brain. These substances are also released when people know that they receive a 
placebo. So, even though I told you this, you will likely experience less itch during the test.” 
For the open-label negative VS groups, negative words were again used in the instructions 
instead of positive words. During application of the tonic, the provided suggestions and, if 
applicable, open-label instructions were briefly repeated in a single sentence. 
 
2. Expected itch.    
Expected itch in response to histamine iontophoresis was assessed on a Numeric Rating 
Scale (NRS) ranging from 0 (“no itch”) to 10 (“worst itch imaginable”). Participants rated 
the amount of itch they expected to experience during iontophoresis twice: once at the start 
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of the baseline session and once during the experimental session, following the verbal 
suggestions but prior to histamine iontophoresis. 
 
3. Histamine iontophoresis.   
Histamine was applied to the skin by transdermal iontophoresis (Chattanooga Group, 
Hixson, Tennessee, US). This method has been previously validated and reliably induces 
itch in healthy populations [22,28,29,35]. A 0.6% diphosphate (equivalent to 1% histamine 
dihydrochloride) histamine solution was prepared in distilled water with propylene glycol 
and hypromellose 4,000 mPa by the local pharmacy. In preparation of iontophoresis, the 
skin was cleaned with either a transparent disinfectant (alcohol 70%; baseline session) or a 
pink-colored disinfectant (0.5% chlorhexidine in alcohol 70%, with rhodamine; 
experimental session) suggested to be itch-reducing or itch-increasing, depending on 
placebo or nocebo condition. A 2.5-cc electrode (Iogel, Iomed, DJO Global, Hannover, 
Germany; active surface: 11.7 cm2) was treated with the histamine solution and applied to 
the volar side of the non-dominant forearm. A reference electrode was placed on the volar 
side of the upper arm. The electrode nodes were spaced approximately 10 cm apart. 
Histamine was applied to the skin by iontophoresis with a current level set at 0.4 mA for 
2.5 min, following which the electrodes and any residual histamine were removed from the 
skin. 
 
4. Self-reported itch.    
Self-reported itch in response to histamine iontophoresis was assessed using the same 0–10 
NRS as described under ‘Expected itch’. During iontophoresis, participants continuously 
rated itch using a vertical bar slide depicting the NRS. Scores were sampled at a 10-Hz rate 
using E-Prime 2.0 [42]. Directly following iontophoresis, mean itch was verbally assessed 
by asking participants how much itch (on a 0–10 scale) they experienced in general during 
the test. From 1 to 4 min after iontophoresis, participants were asked to rate self-reported 
itch every 30 s on the bar slide as a follow-up period. The primary study outcome was the 
area under the curve (AUC) of itch during the 2.5 min of iontophoresis. Secondary 
outcomes were maximum itch reported during the 2.5 min of iontophoresis, verbally 




itch during iontophoresis were computed using MATLAB Release 2012b (The MathWorks, 
Inc., Natick, Massachusetts, US). 
 
5. Subjective skin response.    
Participants filled in the Sensitive Scale-10 (SS-10 [43]) to measure their subjective skin 
response. The SS-10 contains 10 items, of which 9 items assessed specific skin symptoms 
(e.g., itch, pain, general discomfort, and heat sensations). Participants were asked to rate in 
what intensity they had experienced these symptoms over the past 3 days as a baseline 
measurement, as well as during histamine iontophoresis. Symptoms were rated on NRS 
ranging from 0 (“zero intensity”) to 10 (“intolerable intensity”). An additional symptom 
(“redness of the skin”) was assessed on a 0–10 NRS [43]. Total scores were calculated by 
summing all items and ranged from 0 to 100. Cronbach’s alpha ranged from .83 to .87 in 
the current study for baseline and post-iontophoresis assessments of the SS-10. 
 
6. Physical skin response.    
Wheal size and flare areas following histamine application were measured after the 4-min 
follow-up period after the iontophoresis test. The size of the skin response was measured by 
drawing the outline of the redness and thickening of the skin onto a 1-cm2 gridded 
transparent sheet with a 0.4-mm black permanent marker (Staedtler, Germany). The sheets 
were scanned and then retraced using ImageJ software [44], after which the wheal and flare 
area (in cm2) were calculated. In addition, skin temperature was measured following 
iontophoresis, using a handheld infrared digital thermometer (accuracy ± 2.0 °C, resolution 
0.1 °C; BaseTech, Conrad Electronic Benelux B.V.). Measurements were taken with the 
thermometer held vertically and approximately 1 cm above the center of the histamine 
application area. To control for individual differences in skin temperature, a baseline 
measurement was taken prior to iontophoresis, with change from baseline temperature 







Prior to participation, written information regarding the study was provided, and volunteers 
were asked to fill in an online questionnaire assessing the study’s inclusion and exclusion 
criteria. When volunteers were considered eligible for participation, they were invited to the 
lab for a 30-min baseline session and a 45-min experimental session, which were timed 1 
week apart. At the start of the baseline session, the study procedures were explained, and 
written informed consent was provided. Next, personality questionnaires were 
administered, which are not further described here as they are unrelated to the aim of the 
current study. Baseline measurements of itch expectation and subjective skin responses in 
the past 3 days were taken. Next, the skin of the non-dominant forearm was disinfected, and 
electrodes were placed on the arm, after which the histamine test was conducted. 
Measurements of itch and physical skin responses were taken, followed by an assessment 
of subjective skin responses. After 1 week, the experimental session took place. First, the 
general procedure of the second session was explained, and verbal suggestions were given 
(the content of which depended on group allocation). Measurements of post-VS expected 
itch and of subjective skin responses in the past 3 days were taken. Next, the skin was 
cleaned using the pink disinfectant, during which the verbal suggestions were briefly 
repeated. Histamine iontophoresis was conducted; and measurements of itch, physical skin 
response, and subjective skin response were taken. At the end of the session, participants 
were asked to fill in a final questionnaire assessing the general amount of itch experienced 
during both baseline and post-VS iontophoresis and, for the open-label groups only, how 
believable and convincing participants thought the open-label rationale was (on a 0–10 
NRS). Upon completion, they were debriefed on the true purpose of the study. For each 
session, participants received a compensation of €7.50. 
 
Statistical Analyses 
As input for the power calculation, we used the effect size of Cohen’s d = 1.10, that was 
found by Napadow et al. [25], who investigated nocebo effects induced by an inert 
substance (i.e., a sham allergen solution) on itch. As the current study investigated not only 
nocebo effects following application of an inert substance but also placebo effects, and both 
were investigated under closed-label and open-label conditions, a more conservative effect 
size of d = 0.90 was used for computation of sample sizes for the separate open-label and 




G*Power 3.1 [45] indicated that 21 participants per group would be needed at a power of β 
= .80 and a significance level of α = .05 for the primary outcome of AUC itch during 
iontophoresis in the experimental session between the (separate closed-label or open-label) 
positive verbal suggestion group and the negative verbal suggestion group while controlling 
for AUC itch at baseline. A missing data rate of 10% was taken into account, resulting in a 
sample size of 23 participants in each group. 
Analyses were performed using SPSS 21.0 for Windows (IBM SPSS Inc., Chicago, Illinois, 
US). Normal distribution of the variables and the assumptions of each analysis were 
checked prior to analysis. To test for group differences in demographics and baseline 
variables, chi-square tests and one-way analyses of variance (ANOVAs) were conducted. 
As a priori determined primary analysis, differences between the combined negative VS 
groups and positive VS groups in AUC itch during iontophoresis were assessed by a 
general linear model (GLM) ANCOVA, controlled for AUC itch during baseline 
iontophoresis. Similar analyses were conducted for the secondary outcome parameters, 
maximum itch during iontophoresis, mean itch (assessed verbally following iontophoresis), 
AUC itch during the 4-min follow-up, subjective skin response, and the physical skin 
response parameters. 
Due to technical difficulties with the NRS bar slide and E-Prime, data of some participants 
(n = 6) were missing for the analyses of AUC itch and maximum itch during iontophoresis. 
Data of one participant were missing for the skin temperature measurements. For those 
variables that were non-normally distributed (i.e., AUC itch during follow-up), a change 
score was calculated by subtracting baseline scores from those measured post-VS (with 
zero indicating no change, negative scores indicating a decrease, and positive scores 
indicating an increase from baseline to post-VS). A GLM ANOVA was then performed to 
detect differences in change scores between groups. For expected itch following 
suggestions, an ANOVA was also conducted. For each AN(C)OVA, Cohen’s d was 
calculated, and the following interpretations were used: small effect size 0.20, medium 
effect size 0.50, and large effect size 0.80 [46]. When appropriate, covariate-adjusted means 
were used for calculation of Cohen’s d. In addition, paired sample t-tests were conducted 
within each group to assess changes in each outcome parameter from the baseline to post-
VS measurements. In order to examine whether the effects of verbal suggestions were 
similar regardless of participants knowing about the expectation induction, all analyses 
were repeated for the separate open-label and closed-label conditions. As the effects of 
suggestions were expected to be similar under open-label and closed-label contexts, 
182 
 
differences between open- and closed-label groups were not tested statistically. Rather, 
effect sizes generated by the separate open-label and closed-label analyses were used for 
indirect comparisons. 
To explore potential group differences in the strength of associations between the process 
measure of post-VS itch expectation and the outcome measures of itch and skin response, 
Pearson’s r correlations were calculated within each group, and Cohen’s q was computed as 
an effect size for the difference in strength of association, with the following categories of 
interpretation: no effect < 0.10, small effect size 0.10 < 0.30, medium effect size 0.30 < 
0.50, and large effect size ≥ 0.50 [46]. For AUC itch during follow-up, Spearman’s rho was 
calculated. The open-label groups were compared on how believable and convincing 
participants thought the open-label rationale was by independent-samples t-tests. All 
analyses were conducted two sided with α = .05. For the secondary analyses (i.e., 
AN(C)OVAs and paired-sample t-tests for separate open-label and closed-label analyses), 
Bonferroni’s correction for multiple comparisons was used, thus resulting in a significance 
level of α/2 = .025. To correct for alpha inflation due to multiple itch outcomes, an 
additional Bonferroni’s correction was applied for the secondary itch outcomes, resulting in 
a significance level of α/3 = .017 for the combined-group analyses and (α/3)/2 = .008 for 
the separate-group analyses of the secondary itch outcomes. All values described in the 




A total of 138 potential participants expressed interest in the study, of whom 44 were not 
included (18 had somatic or psychological morbidity, 4 were non-proficient in the Dutch 
language, and 22 gave no response following screening). Two participants dropped out 
after the baseline session and were replaced. This resulted in the intended sample size of 92 
participants (16 males, 17.4%; 76 females, 82.6%), whose age ranged from 18 to 30 (M = 
21.8 ± 2.7). Participants were randomized into 1) the open-label positive VS group (n = 22), 
2) the closed-label positive VS group (n = 23), 3) the open-label negative VS group (n = 
23), or 4) the closed-label negative VS group (n = 24). The groups did not differ in 
demographic factors (all p ≥ .42), baseline itch expectation prior to iontophoresis (p= .13), 




skin condition (all p ≥ .12). An overview of the means and standard deviations of the 
baseline and outcome measures is presented in Table 1 (combined open-label and closed-




A large-sized effect of verbal suggestions on expected itch was found; F(1,90) = 20.94, p < 
.001, Cohen’s d = 0.96. As illustrated in Figure 2, expected itch following suggestions was 
significantly lower in the combined positive VS groups (M = 2.62 ± 1.82) compared with 
the combined negative VS groups (M = 4.41 ± 1.93). A secondary analysis showed a large-
sized effect of suggestions in the open-label groups [F(1,43) = 15.84, p < .001, Cohen’s d = 
1.21] and a medium-sized effect in the closed-label groups [F(1,45) = 6.15, p = .017, 
Cohen’s d = 0.74], both indicating significantly lower expected itch in the positive VS 
group (open label: M = 2.35 ± 1.88; closed label: M = 2.88 ± 1.77) than in the negative VS 
group (open label: M = 4.59 ± 1.91; closed label: M = 4.24 ± 1.99). 
 
Primary itch measure: area under the curve (AUC) of itch during histamine 
iontophoresis 
For the primary outcome AUC itch, a small-sized non-significant difference between the 
combined positive VS groups and the combined negative VS groups was found; F(1,83) = 
1.75, p = .19, Cohen’s d = 0.29. Secondary analyses for the separate open- and closed-label 
groups revealed similar findings (both p ≥ .31; see Figure 3). Within-group analyses of 
baseline to post-VS changes indicated that AUC itch decreased marginally in the combined 
positive VS groups [t(39) = 1.98, p = .055] but did not change in the combined negative VS 
groups [t(45) = −0.19, p = .85]. No within-group changes in AUC itch from baseline to 
post-VS were detected for the separate open- and closed-label groups (all p ≥ .12). An 
overview of within-group comparisons for AUC itch and other outcome measures is 
presented in Table 2 (combined open-label and closed-label groups) and Supplementary 




Table 1. Means ± standard deviations for the combined open- and closed-label positive and the combined open- and closed-label 
negative verbal suggestion groups. 
 
Note. A VS = verbal suggestions. B AUC = Area under the Curve. C Assessed verbally on a Numeric Rating Scale ranging from 0-
10. D Group differences assessed by ANCOVA, controlled for baseline. Cohen’s d was calculated with the estimated marginal 
means (controlled for baseline). E Calculated as post-VS measure – baseline measure (session 2 – session 1) and corrected for 
significant outliers. F As measured by an adjusted version of the Sensitive Scale 10 (Misery et al., 2014). G Calculated as post-




 Combined open- and closed-label 
  AN(C)OVA 
 n Positive VS (n=45) Negative VS (n=47) p-value Cohen’s d 
      
Process measure       
Pre-iontophoresis itch expectation 92 5.15 ± 1.95 4.82 ± 1.75 .40  
Post-VS itch expectation A 92 2.62 ± 1.82 4.41 ± 1.93 <.001 0.96 
      
Baseline histamine iontophoresis      
AUC itch B 88 369.79 ± 241.69 361.35 ± 230.24 .87  
Maximum itch 88 3.95 ± 2.44 3.78 ± 2.26 .73  
Mean itch C 92 3.10 ± 1.90 2.93 ± 1.75 .66  
      
Post-VS histamine iontophoresis      
AUC itch B,D 86 314.61 ± 237.34 367.54 ± 266.63  .19 0.29 
Maximum itch D 86 3.44 ± 2.54 3.81 ± 2.45 .24 0.26 
Mean itch C,D 92 2.83 ± 1.93 3.19 ± 2.09 .076 0.38 
      
Change from baseline to post-VS scores      
AUC itch during follow-up B,E 90 -3.38 ± 6.37 0.02 ± 6.88 .017 0.52 
      
Baseline skin response to iontophoresis      
Subjective skin response F 92 24.37 ± 11.77 22.78 ± 12.25 .53  
Wheal area [cm2] 92 10.52 ± 3.47 11.09 ± 3.00 .40  
Flare area [cm2] 92 47.74 ± 11.05 48.16 ± 12.45 .86  
Change in skin temperature [°C] G 91 1.70 ± 1.01 1.58 ± 1.22 .61  
      
Post-VS skin response to iontophoresis      
Subjective skin response D,F 91 21.08 ± 12.31 20.79 ± 12.21 .58 0.12 
Wheal area [cm2] D 92 10.12 ± 3.80 10.68 ± 3.69 .78 0.06 
Flare area [cm2] D 92 45.54 ± 13.11 47.17 ± 11.75 .54 0.13 
Change in skin temperature [°C] D,G 90 1.83 ± 1.15 2.34 ± 1.62 .018 0.52 













































































































































































































































































































































































































































































Table 2. Within-group mean changes from baseline and separate paired sample t-test results for the combined open- and closed-
label positive verbal suggestion groups and combined negative verbal suggestion groups.  
    
 Combined open- and closed- label 
positive VS groups (n=45) 
 Combined open- and closed-label 
negative VS groups (n=47) 
 n Mean change t p  n Mean change t p 
          
Histamine iontophoresis          
AUC itch A 40 -46.91 1.98  .055  46 6.19 -0.19  .85 
Maximum itch 40 -0.44 2.00  .053  46 0.02 -0.07  .94 
Mean itch B 45 -0.26 1.34  .19  47 0.26 -1.30  .20 
          
Post-iontophoresis follow-up          
AUC itch A 43 -3.73 3.24 .002  47 0.02 -0.02 .98 
          
Skin response to iontophoresis          
Subjective skin response C 44 -3.30 2.59 .013  47 -2.00 1.61 .12 
Wheal area [cm2] 45 -0.40 0.79 .43  47 -0.41 0.87 .39 
Flare area [cm2] 45 -2.20 1.31 .20  47 -0.99 0.50 .62 
Change in skin temperature [°C] D 44 0.14 -0.88 .38  46 0.76 -3.88 <.001 
          
Note. Mean change was calculated as post-verbal suggestions score – baseline score, with negative values indicating a decrease 
from baseline, and positive scores indicating an increase from baseline. A AUC = Area under the Curve. B Assessed verbally on a 
Numeric Rating Scale ranging from 0-10. C As measured by an adjusted version of the Sensitive Scale 10 (Misery et al., 2014). D 
Calculated as post-iontophoresis temperature – pre-iontophoresis temperature. 
 
Secondary itch measures during and following histamine iontophoresis 
1. Maximum itch and mean itch during iontophoresis.    
Findings for maximum itch during iontophoresis were similar to those of AUC itch, with no 
effects of suggestions for the combined as well as separate groups (all p ≥ .24) and a 
marginal decrease from baseline to post-VS exclusively for the combined positive VS 
groups [t(39) = 2.00, p = .053]. The combined positive VS groups showed a small-sized 
tendency to report lower (post-iontophoresis-assessed) mean itch (M = 2.83 ± 1.93) than did 
the combined negative VS groups (M = 3.19 ± 2.09); F(1,89) = 3.22, p = .076, Cohen’s d = 
0.38. No effects of verbal suggestions were found when open- and closed-label groups were 
separated, nor were changes from baseline to post-VS scores detected for any of the groups 






2. AUC of itch during follow-up after iontophoresis 
A significant and medium-sized difference in the change scores of AUC for itch during the 
4-min follow-up was found when open- and closed-label groups were combined [F(1,88) = 
6.09, p = .016, Cohen’s d = 0.52], with AUC itch during follow-up decreasing significantly 
in the combined positive VS groups (M = −3.73 ± 7.55) compared with the combined 
negative VS groups (M = 0.02 ± 6.88). A small-sized non-significant effect of verbal 
suggestions was found in the open-label groups; F(1,43) = 2.11, p = .15, Cohen’s d = 0.43, 
and a marginal and medium-sized effect in the closed-label groups, in the same direction as 
for the combined groups; F(1,43) = 4.94, p = .032, Cohen’s d = 0.67. A significant change 
from baseline to post-VS in AUC itch during follow-up was demonstrated for the combined 
positive VS groups [t(42) = 3.24, p = .002]. In the combined negative VS groups, however, 
no change was detected [t(46) = −0.02, p = .98]. Separating open- and closed-label groups 
revealed a non-significant change within the open-label positive VS group [t(21) = 1.87, p 




1. Subjective skin response (SS-10) 
For subjective skin response following the histamine test, no significant difference was 
found between the combined positive and negative VS groups, nor between the separate 
open- and closed-label positive and negative VS groups (all p ≥ .12). A significant decrease 
in subjective skin response from baseline to post-VS was demonstrated in the combined 
positive VS groups [t(43) = 2.59, p = .013], but not in the negative VS groups [t(46) = 1.61, 
p = .12]. When analyses were conducted for separate open- and closed-label groups, a 
significant decrease was demonstrated only for the closed-label positive VS group; t(22) = 
3.75, p < .001. 
 
2. Physical skin response 
No effects of verbal suggestions on wheal or flare areas were found for either the combined 
or separate open- and closed-label groups (all p ≥ .23). Regarding skin temperature, the 
combined positive VS groups showed a medium-sized lower increase in skin temperature 
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from before to after iontophoresis (M = 1.83 ± 1.15) than did the combined negative VS 
groups (M = 2.34 ± 1.62); F(1,87) = 5.84, p = .018, Cohen’s d = 0.52. In the same direction, 
marginally significant medium-sized effects of verbal suggestions on skin temperature 
increase were found in the open-label [F(1,41) = 3.01, p = .090, Cohen’s d = 0.54] and 
closed-label groups [F(1,43) = 2.93, p = .094, Cohen’s d = 0.52], respectively. Within-
group comparisons for both combined and separate open- and closed-label positive and 
negative VS groups showed that skin temperature increased significantly from baseline to 
post-VS for the negative VS groups (all p ≤ .048), but not for the positive VS groups (all p 
≥ .12). 
 
Associations between expected itch and the outcome measures of itch 
In the combined open- and closed-label groups, expected itch following suggestions was 
significantly and positively associated with all itch measures during and following 
iontophoresis (all r ≥ .43, all p ≤ .01). Comparisons of the strength of the association 
between expected itch and the itch outcome measures showed small-sized to no differences 
in associative strength between the combined positive and combined negative VS groups 
(all Cohen’s q ≤ 0.15). In the separate open-label and closed-label groups, findings were 
similar, with one exception: in the open-label positive VS group exclusively, itch 
expectations were not associated with mean itch and AUC of itch during follow-up (both p 
≥ .11). An overview of Pearson’s r and Spearman’s ρ correlation coefficients can be found 
in Table 3 (combined open- and closed-label groups) and Supplementary Table S3 
(separate open- and closed-label groups). 
 
Open-label instruction believability 
Overall, participants in the open-label conditions rated the instructions as very clear (M = 
7.90 ± 2.32). Ratings on how convincing the instructions had been were more ambiguous 
(M = 5.37 ± 2.46). In general, participants in the open-label groups believed that 
expectations are able to influence itch (M = 6.49 ± 1.97) but rated the extent in which their 
own itch experience was influenced by the application of the tonic as low (M = 3.81 ± 





Table 3 Within-group Pearson’s r and Spearman’s rho correlations for the process measure of post-VS itch expectation and 
outcome measures of self-reported itch and skin response for the combined open- and closed-label group comparisons, with 
Cohen’s q as estimate of the difference in effect size between groups. 
Note. A AUC = Area under the Curve. B Assessed verbally on a Numeric Rating Scale ranging from 0-10. C Calculated using the 
non-parametric Spearman’s rho. D As measured by an adjusted version of the Sensitive Scale 10 (Misery et al., 2014). E Calculated 
as post-iontophoresis temperature – pre-iontophoresis temperature. † p<.10; * p<.05; ** p<.01; *** p<.001 
 
DISCUSSION 
The current study investigated whether positive and negative outcome expectations, 
induced by open-label and closed-label positive and negative verbal suggestions regarding 
an inert tonic, could influence self-reported itch in response to a histamine test. For the first 
time, open- and closed-label placebo effects for itch were investigated within a single study, 
including a comparison with open- and closed-label nocebo effects. It was demonstrated 
that both open-label and closed-label verbal suggestions were able to influence itch 
expectations. For the primary outcome of area under the curve for itch during histamine 
iontophoresis, a small-sized but non-significant effect of verbal suggestions was found. 
Participants in the combined open- and closed-label positive VS groups reported lower itch 
during an immediate follow-up period after iontophoresis compared to the negative VS 
groups. Post hoc tests indicated that this was mostly due to differences between positive 
and negative VS groups under closed-label conditions. In addition, a significantly smaller 
increase in skin temperature was observed in the combined positive VS groups compared 
with the negative VS groups, but no effects on other markers of the physical skin response 
to histamine were found. Overall, the current study shows that verbal suggestions regarding 
   
 Combined open- and closed-label groups  
 Positive VS (n=45) Negative VS (n=47) Cohen’s q  
    
Post-VS histamine iontophoresis    
AUC itch A .67 *** .58 *** 0.15 
Maximum itch .63 *** .59 *** 0.06 
Mean itch B .52 *** .60 *** 0.12 
    
Post-VS follow-up on iontophoresis    
AUC itch during follow-up A, C .43 ** .49 *** 0.08 
    
Post-VS skin response to iontophoresis    
Subjective skin response D .50 *** .59 *** 0.13 
Wheal area [cm2] -.09 -.01 0.08 
Flare area [cm2] .03 -.23 0.26 
Change in skin temperature [°C] E .04 -.19 0.23 
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a topical application of a substance can influence expectations for itch, regardless of 
whether or not participants know about receiving suggestions, and provides limited 
evidence that these suggestions may influence itch and skin response in response to 
histamine. 
The findings that verbal suggestions were able to influence itch in the follow-up period 
after histamine iontophoresis are in line with a previous study that found medium-to-large-
sized effects of positive suggestions on histamine-induced itch [24]. While that particular 
study made use of a cream to help induce placebo effects, the current study used a pink-
colored tonic. Potentially, the use of this particular attribute may have led towards smaller 
effects in the current study, since a cream could be perceived as a common treatment for 
itch by some participants, could trigger previously learned associations, and could thus 
potentially elicit stronger effects overall [47]. Moreover, negative verbal suggestions did 
not elicit negative expectations for itch in the current study and did not increase itch either 
during or following the histamine test, which is not in line with previous evidence for 
verbal suggestion-induced nocebo effects in itch [25,26,28]. It should be noted though that 
these previous studies have induced nocebo effects through negative suggestions regarding 
the experimental itch induction method that was used, whereas the current study provided 
suggestions regarding the topical application of an attribute prior to itch induction. While 
this did allow for a direct comparison of positive and negative expectation induction, 
potentially, it may have influenced the credibility of the negative verbal suggestions as 
well. Topical application of, for example, a cream or tonic in a laboratory setting might be 
associated more easily with symptom reduction rather than worsening of symptoms. In 
comparison, information regarding an experimental itch induction method, though less 
clinically relevant, may provide a more neutral basis for induction of nocebo effects 
through suggestions. Alternatively, although the baseline histamine application was 
valuable for participants as a comparison point for the second application, nocebo effects 
induced through negative verbal suggestions could have been influenced by participants 
being less anxious about the second histamine test, in comparison with the first test (since 
participants were generally unfamiliar with histamine iontophoresis prior to participating in 
the study). Future research may utilize a counterbalanced design to examine this more in 
detail. Likewise, more research is needed to investigate under which circumstances and 
through which attributes placebo and nocebo effects may be elicited for itch. 
An effect of negative verbal suggestions on change in skin temperature due to histamine 




autonomically controlled parameters and wheal responses [26,48], a meta-analysis of 
clinical trials demonstrating placebo effects on physical outcome parameters controlled by 
the autonomic nervous system [49], and early studies on suggestions and hypnosis [50-52]. 
Considering that either the outcome measure differed from these previous studies (i.e., skin 
temperature change rather than wheal size) or the expectation induction method was 
different (i.e., verbal suggestions given without hypnosis), caution is needed in interpreting 
these results. Moreover, the verbal suggestions in the current study did not influence wheal 
and flare areas to histamine, which is in line with most recent studies [24,29,35,53,54]. 
Our design allowed for the first time comparisons of effect sizes of positive and negative 
verbal suggestions under open- and closed-label conditions for itch. The findings 
demonstrate that positive verbal suggestions are able to significantly reduce expectations of 
itch under both open-label and closed-label conditions, with open-label verbal suggestions 
seemingly inducing larger expectancy effects. Overall, the effects of positive and negative 
verbal suggestions on itch were approximately similar sized under open-label and closed-
label conditions. However, some differences between the conditions could be seen when 
examining the within-group changes from baseline. Closed-label suggestions appeared 
slightly more effective for itch, as illustrated by the significant within-group changes in itch 
during follow-up from baseline to post-suggestions under closed-label conditions. That 
open-label placebo treatment can significantly influence expectations and, potentially, 
symptoms of itch is in line with previous findings on other outcome parameters [31,32,34-
39]. It also provides further preliminary support for the notion that concealment of 
treatment is not necessary to elicit placebo responses, and that placebo mechanisms can 
potentially be utilized in clinical practice. Small differences between the open-label 
instructions of the current study and previous work need to be noted. Previous studies [e.g., 
refs. 31-34, 40] began their open-label placebo instructions by indicating that the pill that 
was used was a placebo, prior to indicating the efficacy and mechanisms of these effects. 
The current study on the other hand began by introducing the tonic as an effective tool for 
itch reduction and explaining that it was a placebo afterwards, together with a rationale on 
why it would still be effective. Differences in the order in which this type of information is 
presented may impact the strength of open-label placebo and nocebo effects. In addition, 
previous work has incorporated the concept of learning in the open-label instructions (i.e., 
by giving the example of Pavlov’s dog). This aspect has been omitted here, as the current 
study investigates placebo responses evoked by conscious expectancy (i.e., verbal 
information) rather than associative learning mechanisms. Potentially, this may have 
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influenced the efficacy of the open-label rationale. Some caution needs to be taken in 
interpreting the effects of negative verbal suggestions under the separate open-label and 
closed-label conditions, since neither type of negative verbal suggestions was able to 
increase expectations of itch. 
Some strengths and limitations need to be taken into account. This is the first study that 
compares open- and closed-label positive and negative verbal suggestions to elicit placebo 
and nocebo effects in itch and other responses to histamine. Since the study was conducted 
single blinded, a reporting bias cannot be ruled out, as participants may have adjusted their 
answers to the experimenters’ expectations. To minimize influences of response bias on 
assessments of expectations and itch, participants used a (computerized) bar slide to 
indicate these parameters. Future research might, however, consider using a double-blinded 
approach. The effect sizes found in the current study are considerably small, which may be 
due to the itch stimulus being perceived as low by participants. As such, the study may 
have been underpowered to find small effects, which seems to be supported by finding 
more significant effects of the combined open- and closed-label groups than for the separate 
groups. Moreover, the design of the current study did not include a no-treatment group. 
This prevents an estimation of a true placebo or nocebo response, as itch may reduce from 
the first to second histamine test regardless of group allocation. Though habituation to the 
itch stimulus cannot be ruled out, its role is likely small, since the itch stimuli were 
relatively short and presented with 1 week in between. Alternatively, anxiety may have 
resulted in higher itch ratings during baseline. Including a no-treatment group to control for 
these reductions or utilizing a counterbalanced design could provide better estimates of a 
true placebo and nocebo response. Lastly, verbal suggestions were given regarding an inert 
tonic. While this approach may have worked for placebo induction, potentially, it may have 
been harder to elicit nocebo effects in this manner, as negative consequences regarding 
such a treatment method may be counterintuitive. To compare open-label and closed-label 
nocebo effects for itch, a different approach could be needed. For example, future research 
could investigate whether nocebo effects can be induced when the effects of an inert 
substance on itch are introduced as side effects of this substance, as changing to such an 
introduction of negative effects may be more closely related to how negative effects would 
be experienced in clinical practice. 
In conclusion, this study provides evidence for the first time that positive verbal 
suggestions can induce expectations for itch reduction under both open-label and closed-




histamine iontophoresis under both open-label and closed-label conditions, with closed-
label suggestions appearing more effective in reducing itch during follow-up. However, 
experienced itch during histamine iontophoresis was not influenced by suggestions. Future 
research may aim to investigate under which circumstances and with which type of attribute 
these suggestions could elicit effects for itch. Further demonstrating the efficacy of open-
label placebo effects may help facilitate the application of these effects in clinical practice. 
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Open- and closed-label placebo and nocebo 








Meeuwis, S.H., van Middendorp, H., Lavrijsen, A.P.M., Veldhuijzen, D.S., & Evers. 
A.W.M. Open- and closed-label placebo and nocebo suggestions about a sham transdermal 





Objective. Accumulating evidence indicates that placebo effects may also occur when it is 
known that a placebo is given. It is not yet clear whether these open-label placebo effects 
are similar to those of concealed (i.e. closed-label) placebo effects for somatic symptoms 
such as itch or whether nocebo effects can be induced under open-label conditions.  
Methods. Healthy volunteers (n=112) were randomized to I) an open-label positive 
suggestions group, II) a closed-label positive suggestions group, III) an open-label negative 
suggestions group, or IV) a closed-label negative suggestions group. Participants were told, 
as cover story, that a transdermal caffeine patch would be applied that positively influences 
cognitive abilities and, as a side effect, positively or negatively (depending on group 
allocation) influences itch. Participants in the open-label groups were given a rationale 
explaining placebo and nocebo effect mechanisms. Itch was induced at baseline and post-
suggestions by histamine iontophoresis. 
Results. In the positive suggestions groups, significantly lower itch was reported than in the 
negative suggestions groups for both open- and closed-label contexts (all p≤.008, Cohen’s 
d≥0.47). Self-rated skin response was rated as less severe following positive versus 
negative suggestions (all p≤.017, Cohen’s d≥0.33), but no effects on physical skin 
responses to histamine were found (all p≥.23, Cohen’s d≤0.30).  
Conclusion. Itch can be reduced by positive compared to negative suggestions under both 
open- and closed-label conditions. These findings indicate that open-label suggestions may 
potentially be a tool to utilize placebo effects for self-reported outcomes in clinical practice, 
for example by explaining role of expectancy in treatment. It needs to be investigated 
further under which circumstances an open-label rationale may impact placebo and nocebo 
effects.  






Placebo effects are beneficial effects that are not attributable to active treatment 
components such as pharmacological substances [1, 2]. Instead, these effects emerge 
through expectations about treatment outcomes, that are shaped by information that is 
provided about a treatment, learning, and environmental and social cues such as a positive 
patient-clinician interaction [1, 3-5]. Nocebo effects (i.e. adverse treatment outcomes such 
as side effects, that can be attributed to negative outcome expectations) can be similarly 
shaped by these pathways [1,6]. Experimental studies have demonstrated that placebo and 
nocebo effects can be induced in itch [7-9], although some studies show mixed or limited 
evidence [10-14]. In fact, meta-analyses show that over 30% of symptom improvement in 
clinical trials for itch and allergic symptoms can be explained by the placebo effect [15,16]. 
Itch ranks as one of the 50 most common interdisciplinary symptoms which affects an 
estimated one-fifth of the population, and that it has a debilitating impact on quality of life 
while existing treatments show limited effects [17-19]. Therefore finding ways to enhance 
existing treatments for itch becomes increasingly important. Potentially, placebo and 
nocebo effects may be used to facilitate improvement of existing treatments for itch.  
Most studies on placebo and nocebo effects for physical symptoms such as pain or itch 
have investigated concealed placebo or nocebo induction, in which participants were 
unaware of receiving a placebo (sham) treatment. Such an approach does not allow for an 
easy translation towards clinical practice, mostly due to ethical considerations [20]. In the 
past decade, accumulating evidence shows that placebo effects can also occur when patients 
are fully informed about receiving placebos. Studies have shown that providing an inert pill 
in combination with a rationale on how placebo effects can impact medical conditions can 
reduce symptoms of a variety of medical conditions, amongst which irritable bowel 
syndrome, low back pain, and symptoms of allergic rhinitis [21-30].  
There is limited literature available on whether a non-deceptive (open-label) approach can 
induce placebo effects for itch specifically, or how these effects relate to concealed (closed-
label) placebo effects. Likewise, while we do know that nocebo effects often present as side 
effects to active treatments (e.g., induced by reading the leaflet of a pharmacological 
substance) [31-33], not much is known about whether these effects can also be induced 
using an open-label approach. A single study investigated open-label and closed-label 
placebo and nocebo effects induced by verbal suggestions about sham cutaneous treatment, 
and found that both open-label and closed-label suggestions influenced itch after, but not 
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during, histamine application on the skin [34]. The current study builds on these previous 
findings and investigates whether positive and negative outcome expectations, induced by a 
novel suggestive framework (verbal suggestions regarding a transdermal caffeine patch, 
where positive or negative effects on itch were purported as side effects, provided with 
either an open-label context or a closed-label context), could influence self-reported itch 
during an experimental itch induction test using histamine. Secondary outcomes include 
self-rated and clinical (physical) skin responses to histamine as well as psychological 
outcomes such as wellbeing. We first examine differences between the combined positive 
and the combined negative suggestions groups, and next assess effects for open-label and 
closed-label contexts separately. We expect low itch following positive verbal suggestions 




The study was approved by the Medical Ethics Committee at the Leiden University 
Medical Center, The Netherlands (NL64502.058.17) and pre-registered in the Dutch Trial 
Register on May 6th 2018 (trial ID: NTR7174). The study was conducted in accordance 
with the Declaration of Helsinki. All participants provided written informed consent. Data 
for the study were collected between April 2018 and January 2019.  
 
Participants 
Healthy male and female volunteers were recruited through advertisements on sites of 
Leiden University and social media. Participants between 18 and 35 years old that had a 
good understanding of written and spoken Dutch were included. Exclusion criteria 
consisted of severe somatic or psychological morbidity (e.g., heart and lung diseases, 
Diagnostic and Statistical Manual fifth edition (DSM-V) psychiatric disorders); current 
chronic itch or pain; current use of analgesics, anti-inflammatory drugs, antihistamines, or 
antibiotics; recent vaccinations; pregnancy; and colour blindness. Participants were asked to 
refrain from caffeine or nicotine consumption and heavy meals 2h, exercising 12h, and 
alcohol and drugs 24h prior to participation in the study, which was verified at the start of 





A between-subjects, single-blinded, randomized controlled design was applied. Participants 
were allocated (by block-randomization (n=8/block), online random number generator: 
www.random.org, Dublin, Ireland) to I) an open-label positive verbal suggestions (VS), II) 
closed-label positive VS, III) open-label negative VS, or IV) closed-label negative VS 
group. Allocation was not concealed from the experimenter. Participants were invited to a 
single laboratory session at the faculty of Social and Behavioural Sciences, Leiden 
University, The Netherlands. Itch was induced at baseline and post-VS by histamine 
iontophoresis (see also Figure 1).  
 
Materials and Measures 
1. Verbal suggestions 
The study was advertised as a study that investigated the effects of a transdermal caffeine 
patch on cognitive abilities and sensitivity to physical stimuli. As part of this cover story, 
cognitive tasks3 were conducted before and following suggestions. Following baseline 
measurements, participants were told that (1) a caffeine-containing patch would be placed 
on their shoulder, (2) caffeine, like nicotine, can be delivered by this method, and (3) this 
would influence both cognitive abilities and sensitivity to physical stimuli such as itch. In 
the positive VS groups, the following suggestion was then given: “Previous research has 
shown that itch decreases strongly after applying this patch for most people, i.e. about 95% 
of people. The caffeine makes your skin less sensitive to physical stimuli. As such, we expect 
that you will experience less itch, compared to the first test”. In the open-label groups, an 
additional explanation of the placebo effect was given that stressed the following points: (1) 
the patch actually did not contain caffeine, (2) the purpose of the study was to test the 
effects of such positive suggestions, (3) previous research has shown that suggestions can 
reduce itch, (4) these effects are due to bodily processes, as the brain responds to 
information about a treatment in the same manner as to the actual treatment, and (5) this 
may also work when people know that they receive a placebo. For the negative VS groups, 
positive words were replaced by negative words (i.e. ‘more itch’ instead of ‘less itch’, and 
 
3 Considering that the verbal suggestions were not directly aimed at manipulating the outcomes of the cognitive tasks (but that 
these were rather included as part of the cover story), the detailed methodology for these tasks, their outcome measures (including 
related outcomes, e.g., expectations) and their results can be found in the Supplementary Material. 
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‘nocebo’ instead of ‘placebo’). A 10x10 cm hydrocolloid patch (Medeco B.V., Oud-
Beijerland, the Netherlands) was then placed on the non-dominant shoulder.  
 
2. Itch induction: histamine iontophoresis 
Itch was induced experimentally by histamine iontophoresis (see Meeuwis, Van 
Middendorp [13] for detailed methodology). Briefly, itch was induced for 2.5 minutes on 
the volar side of the forearm. After 2.5 minutes, iontophoresis electrodes were removed, 
after which a 3-minutes follow-up period commenced. Baseline iontophoresis was 
conducted on the dominant forearm, and post-VS iontophoresis on the non-dominant 
forearm.  
 
3. Outcome measures 
3.1. Expected itch and expected patch efficacy for skin sensitivity 
Prior to each itch induction, participants rated expected itch on a Numeric Rating Scale 
(NRS) from 0 (‘no itch’) to 10 (‘worst imaginable itch’). In addition, participants rated 
(post-VS, but prior to iontophoresis) the extent to which they believed the patch would 
influence skin sensitivity during the itch induction test on a NRS (0 ‘no effect’, 10 ‘very 
effective’).  
 
 3.2. Self-rated itch 
Self-rated itch was assessed every 30 seconds during both iontophoresis tests and their 
follow-up period, using the same NRS as described in section 3.1. Participants were asked 
to rate mean itch experienced during iontophoresis (the primary study outcome) 
immediately upon removal of the iontophoresis electrodes. Correlations between mean itch 
assessed following iontophoresis and itch scores assessed every 30 seconds during 
iontophoresis were calculated to assess reliability of the primary outcome: self-rated mean 
itch (as assessed directly following the test) was significantly associated with all other itch 





3.3. Self-rated and clinical skin response to histamine 
As a measure of self-rated skin response, participants were asked to fill in a version of the 
Sensitive Scale-10 (SS-10) questionnaire [35] that was adjusted for use with histamine 
iontophoresis (see also [13]). In the current study, Cronbach’s alphas for the post-
iontophoresis SS-10 were .85 and .86, respectively. Wheal size and flare response to 
histamine were assessed following both iontophoresis tests by tracing the outer edges on a 
transparent, 1 cm2-gridded sheet. Images were uploaded and retraced in ImageJ [36], and 
wheal and flare areas were calculated (in cm2). In addition, skin temperature measurements 
were taken with a handheld infrared digital thermometer pre- and post-iontophoresis. Rise 
in skin temperature due to iontophoresis (Δ-temperature) was calculated as an outcome 
measure by subtracting the pre- from post-iontophoresis measurements.  
 
3.4. Wellbeing: the Positive and Negative Affect Schedule 
To assess the effects of suggestions on wellbeing, participants filled out the Positive and 
Negative Affect Schedule (PANAS [37]) at four moments during the laboratory session 
(see Figure 1). In the current study, Cronbach’s alpha ranged .88 – .91 for the PANAS 
positive affect (PA) scale. Considering the scores on negative affect were very low at all 
measurement points (Mrange = 11.49–12.32; with variances between 4.09 – 9.60, while the 
scale ranges from 0–50), group differences for this scale were not analysed. Two additional 
scales for wellbeing were assessed at the same moments as the PANAS, and are discussed 
in the Supplementary Material. 
  

























































































































































































Prior to participation, volunteers filled out an online screening questionnaire. Eligible 
volunteers were invited for a single 2-hours laboratory session at the research site of the 
Social and Behavioural Sciences Department, Leiden University, The Netherlands. Upon 
arrival, the general procedures were explained and participants provided written informed 
consent (for the online screening questionnaire, separate online consent was given). Briefly, 
the in- and exclusion criteria were checked and adherence to lifestyle rules was verified. 
Next, the baseline phase started and participants filled out questionnaires for wellbeing and 
expectations. Demographics and personality factors were assessed (the latter were not 
related to the current study purpose and will be reported elsewhere). Histamine 
iontophoresis was conducted on the dominant arm, during and following which participants 
rated itch. Clinical and self-rated skin responses were assessed, followed by cognitive tests, 
and assessment of wellbeing. Verbal suggestions were given (depending on group 
allocation) and the inert patch was placed on the participant’s shoulder. Participants were 
asked to perform some neutral filler tasks (i.e., Sudoku’s, word & picture search puzzles) 
while the experimenter left the room, with a twofold purpose: 1) so that carry-over effects 
in itch could be minimized, an 2) so that the cover story of testing effects of the patch on 
cognitive tasks could be further reinforced. Thirty minutes after the baseline phase ended, 
the experimenter returned, and wellbeing and expectations were assessed. Histamine 
iontophoresis was conducted on the non-dominant forearm, followed by the cognitive tests 
and wellbeing questionnaires. Finally, participants filled out a closing questionnaire. They 
were debriefed on the true purpose of the study (in the open-label groups, the study purpose 
was reconfirmed) by the experimenter. Participants received a compensation of €20,- for 
the laboratory session.  
 
Statistical analysis 
Power analysis was conducted in G*Power [38] to determine the optimal sample size for 
detecting between-group differences in mean itch, controlled for baseline. The estimated 
effect size was based on a meta-analysis of open-label placebo [39], which found an 
average effect of d=0.88 for open-label placebo effect induction in patient samples, 
compared to a no-treatment control group. As the current study investigated effects in 
healthy volunteers rather than patients, a more conservative effect size of d=0.78 was used. 
An a priori power analysis for analysis of covariance (ANCOVA), with α=.05 and β=.80, 
indicated that, taking into account an additional 5% missing data rate, 28 participants per 
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group were needed to detect differences between the positive and negative verbal 
suggestion groups (for separate analysis of open-label and closed-label contexts).  
All analyses were conducted in SPSS 23.0 for Windows (IBM SPSS Inc., Chicago, Illinois, 
US) with an alpha level of α=.05. Normal distribution of the variables, baseline differences, 
and assumptions were checked prior to data analysis. As was a priori determined, open-
label and closed-label groups were first combined to detect differences between the effects 
of positive verbal suggestions and negative verbal suggestions and to increase power for 
these analyses. General linear model (GLM) analyses of covariance (ANCOVAs) were 
conducted for each outcome measure of itch and self-rated and clinical skin response, in 
which baseline measures were controlled. Within-group baseline-to-post-VS change was 
explored for each group by paired-sample t-tests (Bonferroni corrected: α/2=.025) to assess 
impact of each type of verbal suggestions on itch, and self-rated and clinical skin response. 
Effects of group on wellbeing were explored by mixed between-within repeated measures 
ANOVA. For itch expectations, GLM ANOVA was used. As an effect size, Cohen’s d was 
calculated from (covariate adjusted) group means and SD’s, with the following categories 
for interpretations: 0.2 small effect, 0.5 medium effect, 0.8 large effect [40]. All analyses 
were repeated for the separate open-label groups, and the separate closed-label groups. For 
these secondary analyses, a Bonferroni correction for multiple comparisons was applied 
(α/2=.025 for ANCOVA and (α/2)/2=.0125 for further within-group t-tests). Data of one 
participant was excluded from the analyses, as technical issues with the iontophoresis 
device prevented a baseline measurement of itch. Group means are described as Mean±SD, 





In total, 236 potential participants expressed interest in the study, of whom 79 volunteers 
refrained from participating for reasons unknown (e.g., no response following invitation), 
and of whom 43 were excluded (30 for somatic and/or psychological conditions, 7 for 
medication use, and 6 for having trouble understanding Dutch). Two participants dropped 
out during the laboratory session, resulting in a final sample of 112 participants (16.1% 
male) aged between 18 and 31 years old (Mage=21.88±2.77). No group differences were 




outcome parameters for either the combined open- and closed-label groups (see Table 1, all 
p≥.16) or separate groups (see Supplementary Table E1; all p≥.13).  
 
Expected itch and expected patch efficacy for skin sensitivity 
Expected itch during iontophoresis was significantly lower following suggestions in the 
combined positive VS groups (M = 4.00±1.87) compared to the combined negative VS 
groups (M = 5.69±2.16); F(1,109)=19.23, p<.001, Cohen’s d=0.84. When analyses were 
repeated for open-label and closed-label contexts separately, group differences in the same 
direction as for the combined groups were found, with larger effect sizes found for the 
open-label rather than closed-label context (open-label: F(1,53)=15.00, p<.001, Cohen’s 
d=1.04; closed-label: F(1,54)=6.67, p=.013, Cohen’s d=0.69; see Figure 2A and B). 
Expected patch efficacy for skin sensitivity was somewhat lower in the combined positive 
VS groups (M=3.43±2.11) compared to the combined negative VS groups (M=4.28±2.55), 
however, effects were marginal and small; F(1,109)=3.64, p=.059, Cohen’s d=0.36. When 
groups were separated for open-label and closed-label context, no differences were found 
(both p≥.13; see Figure 2C and D). 
 
Self-rated mean itch 
Self-rated mean itch during iontophoresis was significantly lower in the combined positive 
VS groups (M=3.29±1.53) compared to the combined negative VS groups (M=4.21±1.96); 
F(1,108)=17.14, p<.001, Cohen’s d=0.51. Similar group differences were found when 
analyses were repeated for open-label and closed-label contexts separately, with medium-
sized differences for the closed-label context (F(1,53)=9.02, p=.004, Cohen’s d=0.54), and 
small-to-medium-sized differences for the open-label context (F(1,52)=7.62, p=.008, 
Cohen’s d=0.47; see Figure 3A and B). Within-group analysis of baseline-to-post-VS-
change for itch indicated that mean itch reduced significantly following positive VS (both 
combined and separate groups: all p≤.007), while it did not change in the negative VS 
groups (all p ≥.22) (see Table 2 for the combined-groups analyses, and Supplementary 
Table E2 for the separate-groups analyses). 
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Table 1. Means ± standard deviations, and analysis of (co)variance (AN(C)OVA) outcomes for the combined open- and closed-
label positive verbal suggestions (VS) groups and the combined open- and closed-label negative VS groups.  
 
 
Note (Table 1). a Misery et al. [35]. b n=1 missing due to technical difficulties with the infrared thermometer. c calculated as post-
iontophoresis temperature – pre-iontophoresis temperature. d n=1 missing on the post-VS SS-10. e n=2 missing due to technical 
difficulties with the infrared thermometer. 
 
 
Clinical and self-rated skin response to histamine 
Participants in the combined positive VS groups rated their skin response as less severe 
compared to the combined negative VS groups, as indicated by small-to-medium-sized 
significantly lower scores on the SS-10 in the positive VS groups (M=23.60±11.88) 
compared to the negative VS groups (M=27.56±12.72); F(1,107)=13.58, p<.001, Cohen’s 
d=0.39. When open-label and closed-label contexts were separated, similar group 
differences were found, with somewhat larger effects found for the closed-label context 
(closed-label: F(1,52)=7.23, p=.010, Cohen’s d=0.45; open-label: F(1,52)=6.09, p=.017, 
Cohen’s d=0.33; see Supplementary Table E1). No differences were found for clinical 
skin response outcomes of wheal and flare area, or skin temperature change between the 
combined positive and combined negative VS groups (all p≥.24) or between the separate 
open- and closed-label groups (all p≥.23). An overview of the within-group baseline-to-
  
 Combined open- and closed-label contexts 
  AN(C)OVA 




p-value Cohen’s d 
Demographics     
Sex [male: n (%)] 8 (14.55) 10 (17.86) .64  
Age 21.89 ± 2.49 21.93 ± 3.02 .94 0.01 
     
Baseline histamine iontophoresis     
Mean itch 3.98 ± 1.43 4.00 ± 1.73 .94 0.01 
Self-rated skin response (SS-10) a 30.92 ± 13.26 29.79 ± 12.90 .65 0.09 
Wheal area [cm2] 8.92 ± 3.38 9.28 ± 3.87 .61 0.10 
Flare area [cm2] 43.36 ± 15.70 42.17 ± 13.01 .19 0.08 
Change in skin temperature [°C] b, c  1.39 ± 1.15 1.68 ± 1.00 .16 0.27 
     
Post-VS expectation outcomes for itch      
Expected itch 4.00 ± 1.87 5.69 ± 2.16 < .001 0.84 
Expected patch effectiveness for skin sensitivity 3.43 ± 2.11 4.28 ± 2.55 .059 0.36 
     
Post-VS histamine iontophoresis     
Mean itch 3.29 ± 1.53 4.21 ± 1.96 < .001 0.51 
Self-rated skin response (SS-10) a, d 23.60 ± 11.88 27.56 ± 12.71 < .001 0.39 
Wheal area [cm2] 8.19 ± 3.18 7.92 ± 3.42 .24 0.15 
Flare area [cm2] 41.66 ± 13.33 41.71 ± 13.82 .65 0.05 
Change in skin temperature [°C] c, e 1.20 ± 1.19 1.20 ± 1.09 .39 0.14 




post-VS-change for each variable is provided in Table 2 (combined groups) and 
Supplementary Table E2 (separate groups). In short, no significant within-group changes 
were found for clinical skin response in the combined groups (p≥.063), except for wheal 
area and skin temperature change in the combined negative VS groups, which decreased 
significantly from baseline (both p≤.001). When open-label and closed-label contexts were 
separated, similar decreases were demonstrated in the negative VS groups (p≤.009), except 
for change in skin temperature in the open-label context (p=.071). 
 
Wellbeing: Positive Affect (PA) 
No effect of the combined-groups x time interaction on PA was found (p=.81), indicating 
that verbal suggestions did not influence affect during the laboratory session. No main 
effect of group was found (p=.51), but PA changed significantly over time (p<.001, see 
Supplementary Figure S1). Post-hoc Bonferroni tests indicated that PA following baseline 
iontophoresis was significantly higher compared to all other measurements (all p<.002), 
and that other measurement moments did not differ significantly over time (all p>.99). 
Next, analyses were separated for open-label and closed-label contexts. In the open-label 
context, PA following baseline iontophoresis was higher compared to the two subsequent 
measurements (all p<.001), whereas in the closed-label context, PA following baseline 
iontophoresis was higher compared to the first and third (post-VS) measurements (all 
p≤.017; see also Supplementary Figure S1). Results for two additional wellbeing scales 












Table 2. Within-group baseline-to-post-verbal suggestions (VS) changes on histamine iontophoresis outcomes for the combined 
open- and closed-label positive VS groups and the combined negative VS groups. 
 
    
 Combined open- and closed- label 
positive VS groups (n=55) 
 Combined open- and closed-label 
negative VS groups (n=56) 
 n Mean 
change 
t p  n Mean 
change 
t p 
          
Mean itch 55 -0.68 4.97 < .001  56 0.22 -1.24 .22 
Self-rated skin response (SS-10) a 55 -7.32 6.92 < .001  55 -2.29 2.48 .016 
Wheal area [cm2] 55 -0.73 1.90 .063  56 -1.35 4.64 < .001 
Flare area [cm2] 55 -1.25 1.14 .26  56 -0.46 0.44 .66 
Change in skin temperature [°C] b, c 54 -0.19 1.18 .25  56 -0.47 3.46 .001 
          
 
Note (Table 2).  Mean change was calculated as post-verbal suggestions score – baseline score, with negative values indicating a 
decrease from baseline, and positive scores indicating an increase from baseline. a Misery et al. [35]. b n=2 missing due to technical 






































































































































































































































































































Figure 3. Mean Numeric Rating Scale (NRS) score for itch experienced during histamine iontophoresis for the baseline and post-
verbal suggestions (VS) measurements, with the standard error of the mean (SEM) for [A] the combined open- and closed-label 
positive and negative VS groups, and [B] the separate open-label and closed-label positive and negative VS groups. *** p<.001, ** 





The current study investigated whether positive and negative verbal suggestions regarding a 
sham transdermal patch for both open-label and closed-label contexts were able to 
influence self-reported itch during an experimental histamine test. Overall, the study 
findings illustrate that both open- and closed-label positive suggestions are able to influence 
expectations for itch and mean itch experienced during an experimental itch induction test 
compared to negative suggestions. The effects on itch expectations appear larger for the 
open-label context, whereas for self-rated perceived itch, the effects were larger when 
suggestions were given for the closed-label context. Secondary analyses indicated that itch 
decreased significantly following positive suggestions for both open-label and closed-label 
contexts, but that negative suggestions failed to increase itch. No effects on clinical skin 
response were found, but participants rated their own skin response as less severe following 
positive compared to negative suggestions for both open-label and closed-label contexts.  
That positive suggestions are able to reduce itch is in line with findings of some, but not all 
previous studies [8,10-12,14]. The discrepancies in study findings in the literature may be 
explained by the strength and duration of verbal suggestions. Most of the studies on placebo 
effects in itch induce positive expectations by using brief suggestions of low or reduced itch 
[11,12,14]. In line with this, Bartels et al. [10] demonstrated that a combination of learning 
and suggestions was able to induce placebo effects, but brief suggestions alone could not. 
On the other hand, Darragh et al. [8] combined verbal suggestions with an information 
leaflet, which may have contributed to the strength of suggestions. The current study 
combined positive suggestions about itch with the cover story that a caffeine patch would 
influence cognitive abilities. That caffeine is able to impact, for example, focus and 
attention may be commonly accepted knowledge, which may in turn have contributed to the 
believability of the suggestions for itch.  
Negative verbal suggestions did not increase experienced itch, which is not in line with 
previously conducted research [7,9,41-43]. However, previous studies have induced 
nocebo-like effects by giving suggestions directly about the itch elicitation methods. 
Potentially, suggestions regarding a sham treatment method may not elicit equally strong 
nocebo effects. A previous study, in which suggestions were given about a sham topical 
treatment, likewise failed to elicit significant increases in itch following negative 
suggestions [34]. Moreover, most participants were unfamiliar with the itch induction 
method, which may have resulted in higher itch scores during the baseline test. This may 
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complicate the estimation of the nocebo response, as the suggestions could have negated a 
naturally occurring decrease in itch. Future research may consider adding a no-suggestions 
(natural history) group to control for such effects and to more explicitly evaluate the size of 
placebo and nocebo effects.  
Self-rated skin response was rated as less severe following both open-label and closed-label 
positive suggestions compared to negative suggestions. Indications that suggestions may be 
able to influence self-rated skin response have been found in previous research [13] and are 
further supported here. Clinical – or physical – skin response to histamine on the other hand 
was generally not influenced by verbal suggestions, which is in line with existing literature 
[8,13,44]. Wheal area and skin temperature decreased significantly in the negative VS 
groups. No differences between positive and negative suggestion groups were found, 
however, making it unlikely that these decreases were related to the manipulation used in 
the current study. A single previous study showed medium-sized increases in skin 
temperature following negative suggestions [34], but these findings could not be replicated 
here. Overall, the findings further support the notion that verbal suggestions may be more 
likely to impact subjective sensations such as pain or itch, whereas learning (i.e., 
conditioning) may be needed in addition to instructions in order to induce placebo effects 
for physical or physiological parameters.  
While open-label suggestions appear particularly effective in inducing expectations for itch 
in the current study, effects on experienced itch were somewhat lower than for the closed-
label context, though still medium-sized. The current study is one of the first to investigate 
similar verbal suggestions for both an open-label and a closed-label context. A previous 
study showed mixed evidence for the effects of open-label and closed-label suggestions on 
itch, but effect sizes did indicate that verbal suggestions had lower efficacy for itch in an 
open-label context as well [34]. Findings of the current study are in line with this. Most 
open-label studies report higher effect sizes than those reported in the current study though 
[39]. These studies have often used a rationale in which placebo effects were explained as 
learned Pavlovian responses [21-30]. The rationale in the current study differs from the one 
used previously, as only placebo and nocebo effects induced by positive or negative 
information (suggestions) and conscious expectancy were explained. These differences in 
rationale may as a consequence impact expectations in a different manner. Moreover, the 
open-label rationale in the current study was added onto a concealed positive or negative 
verbal suggestion (i.e. that the patch contained caffeine that would impact perception of 




open-label rationales have either been provided immediately and without prior concealed 
suggestions [21-30], or have been added as an extended explanation of mechanisms onto a 
very succinct suggestion about to-be-expected effects [34]. Potentially, such a ‘placebo-
reveal’ (i.e., explaining that you provided deceptive information first) may have resulted in 
smaller placebo responses in the open-label context compared to the closed-label 
(concealed) context. It has been shown that conditioned analgesia persists after it is 
revealed that subjects are in fact receiving a placebo [45]. A similar mechanism (i.e., first a 
placebo effect induction, which persists after the open-label rationale) may have played a 
role in the current study. Future research could aim to investigate how variations in the 
open-label rationale could impact its efficacy, for example by immediately integrating the 
open-label rationale in the suggestions or by investigating the efficacy of various open-label 
explanations of the placebo effect. Alternatively, participants may have responded 
differently to the negative suggestions, when they are given under concealed (closed-label) 
or open-label conditions. This may explain differences in effect size found under the open-
label and closed-label contexts in the current study. There is evidence that information 
framing can influence the size of nocebo effects, with positive framing reducing the 
occurrence of (nocebo) side effects compared to negative framing [33]. Hypothetically, 
explaining how nocebo effects are formed may likewise impact how nocebo effects are 
formed, though this cannot be concluded exclusively based on data of the current study. 
Rather, future research may aim to clarify the impact of open-label information on the 
formation of nocebo effects. If it can be shown that open-label information can impact the 
formation of nocebo effects, this may be a potential method to prevent nocebo effects 
occurring in clinical practice. Moreover, an open-label rationale and suggestions may then 
be used to enhance placebo effects and inhibit nocebo effects simultaneously, for example 
by providing an explanation on the role of expectancy and context in treatment of medical 
conditions.  
Some limitations need to be taken into account for the current study. The study was 
conducted single-blinded, with the experimenter giving the suggestions also being the one 
that conducted the tests. Potentially, this may have (unconsciously) impacted the 
participants’ rating of itch during iontophoresis. Future research might consider using a 
double-blinded approach, for example, by having iontophoresis performed by a second 
experimenter who is blinded to allocated conditions. Second, participants received 
histamine iontophoresis twice within two hours, which may have caused habituation. 
However, the itch stimuli were relatively short (2.5 minutes) and presented almost one hour 
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apart. Moreover, by design, baseline iontophoresis took place on the dominant arm, and 
post-suggestions iontophoresis on the non-dominant arm. There are indications that 
handedness may affect sensory threshold and pain sensitivity, with the non-dominant arm 
being more sensitive [46,47]. It is likely that differences between both arms in sensitivity to 
itch would have negated habituation effects. Regardless, future research may aim to further 
control for these factors, including handedness. The lack of a no-treatment group in the 
current study complicates an estimation of the true placebo or nocebo response, as itch may 
have changed from baseline to post-VS regardless of suggestions. Including a no-treatment 
group, or counterbalancing the baseline and post-suggestion tests, may be a valuable 
contribution in future research to more explicitly evaluate placebo and nocebo effect sizes.  
In short, the current study provides evidence that positive verbal suggestions regarding a 
sham transdermal patch for both open-label and closed-label contexts can influence 
expectations, itch experienced during, and self-reported skin response following an 
experimental histamine test. Future research may aim to investigate how variations in open-
label rationale may impact the efficacy of positive and negative suggestions for itch. 
Potentially, open-label rationales may then be used to enhance placebo effects and inhibit 
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Materials and Measures 
1. Stroop test and Trail Making Test 
As part of the cover story of the patch positively influencing cognition, the Stroop test [1] 
and Trail Making Test [2,3] were assessed at baseline and following suggestions. Stroop 
interference scores and percentile scores were calculated controlling for age, sex, and 
education level. As a large inter-individual variability in the execution of the Trail Making 
Test was noted (e.g., on noticing and dealing with mistakes during the test – some 
participants did not correct mistakes whereas others did, thus causing differences on the 
time spent taking the test and the associated outcome measure), these data were not 
analysed.  
 
2. Expectations for the cognitive tasks   
Prior to the cognitive tasks (both baseline and post-verbal suggestions) participants were 
asked how well they expected to perform during the tasks by rating the following items on 
a Numeric Rating Scale (NRS) ranging from 0 (“not good at all”) to 10 (“very good”): 
focus, attention, performance, and speed during the tasks. In addition, expected patch 
efficacy for focus, attention, and speed was rated following the verbal suggestions using the 
same NRS.  
 
3.  Wellbeing: State Anxiety and General Wellbeing Scales 
The State Trait Anxiety Inventory – State Anxiety short scales (STAI-S-s [4]), and seven 
Numeric Rating Scales (NRS) measuring general wellbeing (relaxed, anxious, serene, 
agreeable, tense, worried, stressed, see also [5]) on a scale from 0 (‘not at all’) to 10 (‘very 
much so’) were assessed at four moments during the laboratory session: I. pre-baseline 
iontophoresis (baseline 1), II. post-baseline iontophoresis (baseline 2), III. post-verbal 
suggestions (post-VS 1), and IV. at the end of the session (post-VS 2). Of the NRS items, 
negative items were recoded and a total score was calculated by summing all items (with 
higher scores reflecting higher general wellbeing). Cronbach’s alpha for state anxiety 
ranged from .80 to .83 in the current study. For general wellbeing, Cronbach’s alpha ranged 






All analyses were conducted in SPSS 25.0 for Windows (IBM SPSS Inc., Chicago, Illinois, 
US). As was a priori determined, open-label and closed-label groups were first combined to 
detect differences between the effects of positive verbal suggestions and negative verbal 
suggestions with optimal power, and second, repeated for the separate open-label context 
and the separate closed-label context. Normal distribution of the variables, baseline 
differences, and assumptions were checked prior to data analysis. General linear model 
(GLM) analyses of covariance (ANCOVAs) were used to assess group differences in 
expectations regarding the cognitive tasks. For the expected efficacy of the patch, GLM 
analysis of variance (ANOVA) was used. Effects of suggestions on Stroop scores were 
analysed using GLM ANCOVA, and effects of group on wellbeing scales were assessed by 
mixed between-within-subject RMA. The critical alpha used was α=.05 for the combined 
group analyses. For the separate open-label and closed-label context analyses, a Bonferroni 
correction for multiple comparisons was applied (α/2=.025).  
 
SUPPLEMENTARY RESULTS  
Results 
1. Expectations and expected patch efficacy for the cognitive tasks 
At baseline, expected attention and performance during the tasks were significantly higher 
in the combined open- and closed-label negative VS groups (attention: M=7.00±1.39; 
performance: M=6.80±1.07) compared to the combined positive VS groups (attention: 
M=6.33±1.56; performance: M=6.26±1.44); Fatt..(1,109)=5.55, p=.020, Fperf.(1,109)=5.09, 
p=.026; see Supplementary Table E3. Marginal differences were found for expected focus 
(p=.052) and expected speed (p=.073), respectively. When open-label and closed-label 
contexts were separated, no baseline differences could be found (all p≥.061; see also 
Supplementary Table E4).  
When open- and closed-label groups were combined, no group differences were found for 
any of the post-suggestions expectation measures (all p>.055), with the exception of 
expected patch influence on speed; F(1,109)=4.11, p=.045, Cohen’s d=0.39 (see 
Supplementary Table E3). Participants in the combined negative VS groups expected the 
patch to be more effective for speed during the cognitive tasks (M=3.70±2.38), compared to 
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participants in the combined positive VS groups (M=2.86±1.94). No group differences were 
found in the separate open-label or closed-label context (all p≥.091; see Supplementary 
Table E4). Within-group baseline-to-post-VS-change indicated no significant changes in 
expectations regarding the cognitive tasks following suggestions after applying the 
Bonferroni correction for multiple comparisons (all p≥.042), with the exception of expected 
speed in the combined positive VS groups. Within these groups, a significant decrease in 
expected speed was noted (Mchange=-0.48, t(54)=2.54, p=.014 (see Supplementary Table 
E5). When open-label and closed-label contexts were separated, no significant changes 
from baseline to post-VS were noted (all p≥.13).  
 
2. Effects on Stroop Test  
The combined positive and the combined negative VS groups did not differ on Stroop 
interference scores or percentile scores at baseline, or following verbal suggestions (all 
p≥.10). Similar findings were demonstrated when analyses were repeated for the separate 
open-label and closed-label contexts (all p≥.044). Within-group baseline-to-post-VS-
change indicated Stroop interference and percentile scores improved in both the combined 
positive and the combined negative groups (all p<.001). When groups were separated, 
similar reductions in Stroop interference and percentile scores were found for the closed-
label negative VS and the open-label positive VS groups (all p≤.020). In the open-label 
negative VS group, no significant change in interference score was found after applying the 
Bonferroni correction for multiple comparisons (p=.039), however, the percentile score did 
reduce significantly (p=.011). Stroop interference and percentile scores did not change in 
the closed-label positive VS group (both p≥.037).  
 
3. Subjective wellbeing: State anxiety and General Wellbeing Scales 
No combined-group x time interactions, or main effects of the combined groups, were 
found for STAI total score or general wellbeing scales (p≥.22). Both state anxiety and 
general wellbeing changed significantly over time (p≤.012, see Supplementary Figure 
S2A (state anxiety) and Supplementary Figure S3A (general wellbeing)). For state 
anxiety, the baseline measurement was significantly lower than the second measurement 
(baseline post-iontophoresis; p=.006). No significant differences over time for the other 




was significantly higher compared to the second and third measurements (both p≤.015). 
When analyses were conducted for the separate open-label and closed-label contexts, no 
effects were found for state anxiety (see Supplementary Figure S2B). For general 
wellbeing, the final measurement was significantly higher compared to the baseline post-
VS measurement only for the open-label context (see Supplementary Figure S3B).  
 
Concluding note on the effects of open-label and closed-label suggestions on 
expectations regarding cognition, outcomes of the cognitive tasks and wellbeing 
Overall, verbal suggestions did not induce differences in expectations regarding the  
cognitive tasks and patch efficacy for such tasks, with the exception of expected speed 
during the tasks. The participants in the negative suggestions groups expected the patch to 
be more effective for speed during the cognitive tasks compared to the positive VS groups. 
It should be noted though that on general, both groups scored low on expected efficacy for 
speed (mean of 3.70 and 2.86, respectively, on a 0-10 scale). When groups were separated 
for open-label and closed-label contexts, no differences in expectations were found. 
Notably, expectations for the cognitive tasks generally did not reduce after suggestions, 
indicating that the positive suggestions about the tasks may not have impacted participants’ 
expectations. However, expectations were assessed at baseline before any test was 
conducted. It may be possible that participants found the Stroop test, Trail Making Test, 
and filler tasks (i.e. Sudoku’s and other puzzles) more challenging than previously 
anticipated, which may have impacted the scores given post-suggestions. In general, some 
improvement on Stroop test scores was demonstrated for all groups, which could be due to 
training effects. Regarding wellbeing, significant changes over time could be demonstrated, 
but positive and negative verbal suggestions did not significantly impact either state anxiety 
or general wellbeing. This is in line with the findings for positive affect, which are 

































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Table E5. Within-group baseline-to-post-verbal suggestions (VS) changes for expectations and outcomes of the 
cognitive tests in the combined open- and closed-label positive and negative verbal suggestions (VS) groups. 
 
    
 Combined open- and closed- label 
positive VS groups (n=55) 
 Combined open- and closed-label 
negative VS groups (n=56) 
 n Mean 
change 
t p  n Mean 
change 
t p 
          
Expectation outcomes for cognitive tasks          
Expected focus 55 -0.14 0.78 .44  56 0.03 -0.15 .89 
Expected attention 55 0.09 -0.45 .65  56 0.11 -0.70 .49 
Expected performance 55 -0.33 2.09 .042  56 -0.23 1.32 .19 
Expected speed 55 -0.48 2.54 .014  56 -0.12 0.68 .50 
          
Stroop test          
Interference score 55 5.26 -4.70 <.001  56 3.48 -3.30 .002 
Percentile score 55 10.96 3.95 < .001  56 10.41 -4.01 < .001 
          
 
Note. Mean change was calculated as post-verbal suggestions score – baseline score, with negative values indicating a decrease 



















































































































































































































































































































































































































































































































































































































































































































































































































































Supplementary Figure S1. Means + SEMs of the Positive and Negative Affect Schedule (PANAS) subscale ‘positive affect’ and 
mixed between-within repeated measures ANOVA (RMA) outcomes for (A) the combined open- and closed label positive VS 




Supplementary Figure S2. Means + SEMs of the State and Trait Anxiety Inventory (STAI) subscale ‘state anxiety’ and mixed 
between-within repeated measures ANOVA (RMA) outcomes for (A) the combined open- and closed label positive VS groups and 
the combined negative VS groups, and (B) the separate groups.  
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Supplementary Figure S3. Means + SEMs of the Numeric Rating Scales (NRS) total score for ‘general wellbeing’ and mixed 
between-within repeated measures ANOVA (RMA) outcomes for (A) the combined open- and closed label positive VS groups and 
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The aim of this dissertation was to investigate the induction of placebo and nocebo effects 
for histaminergic itch based on multiple approaches of associative and instructional 
learning. Pharmacological conditioning and positive and negative verbal suggestions were 
used to elicit effects in both open-label (i.e., with participants knowing about the placebo or 
nocebo effect induction) and closed-label (i.e., concealed, or with participants not knowing 
about the placebo or nocebo effect induction) contexts. Moreover, effects of these 
approaches on other (psycho)physiological responses to histamine were addressed.  
With regard to the dissertation aim, Chapter 2 examined the existing literature on 
experimentally elicited placebo and nocebo effects in itch, and itch-related medical 
conditions and symptoms of the dermis and mucous membranes, as well as in related 
animal and human models. The systematic literature review covers the methods used to 
elicit these effects, as well as the general study findings. Broadly, placebo and nocebo 
effects have been elicited by three techniques, or combinations thereof: verbal suggestions 
(with or without hypnosis), (classical or operant) conditioning, and social learning (e.g., 
induction of contagious itch). Overall, these methods were successful in eliciting placebo 
and nocebo effects for itch and itch-related symptoms within dermatology. However, the 
review also shows that studies are largely heterogeneous, and that the elicited placebo and 
nocebo effects are oftentimes conditional: for example, conditioned placebo and nocebo 
effects are subject to changes in the context in which effects are learned, and verbal 
suggestions seem to elicit effects only on the short term. A large variety of procedures (i.e., 
no standard ‘conditioning protocol’, or standard suggestions) for placebo and nocebo 
effects induction was found, regardless of which type of technique was used, and effects 
were investigated in very diverse patient populations, as well as in different animal and 
human models.  
 In Chapter 3, the results of a randomized controlled study on the classical 
(pharmacological) conditioning of the antipruritic effects of H1-antihistamines were 
reported. Pharmacological conditioning is one of the mechanisms by which placebo effects 
can be induced. Two previous studies have investigated conditioning of antihistamines in 
allergic patients, but were unable to distinguish between conditioned and other expectancy 
effects on self-reported allergic symptoms. The study described in this chapter aimed to fill 
this knowledge gap by investigating conditioned effects for histamine-evoked itch and other 




marginal lower itch compared with control, no differences between separate groups were 
found, nor did conditioning influence other parameters in the study under either open-label 
or closed-label conditions. Overall, the study provides limited evidence for the antipruritic 
effects of conditioning with H1-antihistamines.   
In Chapters 4, 5, and 6, three studies were described in which the effects of verbal 
suggestions on itch and other (psycho)physiological responses to histamine were examined. 
In Chapter 4, the effects of open-label positive verbal suggestions about low itch were 
compared with neutral instructions. While no differences between groups were found, 
expected and experienced itch were significantly related following verbal suggestions 
exclusively. Moreover, a trend was observed for self-assessed skin condition, with open-
label positive suggestions resulting in marginal lower self-assessed skin condition severity 
compared with neutral instructions. As a whole, these results illustrate a potential role for 
open-label placebo effects in itch (as evidenced by the association between expected and 
experienced itch following positive suggestions). 
In Chapter 5, the effects of open-label and closed-label positive and negative verbal 
suggestions about the itch-reducing (or –increasing, depending on group allocation) 
properties of an (inert) tonic on itch were compared. No effects on itch during histamine 
iontophoresis were found, but itch during a short follow-up period was lower in the positive 
compared with the negative verbal suggestions groups, both in open-label and closed-label 
contexts. Further examination of the data indicated that in the positive suggestion groups, 
itch reduced significantly, whereas in the negative suggestion groups, no changes were 
found. These results indicate that placebo and nocebo effects may be elicited for itch by 
verbal suggestions in both open-label and closed-label contexts, though future research on 
these effects is warranted.  
In Chapter 6, effects of open-label and closed-label positive and negative verbal 
suggestions were again compared for itch, with the suggestions being that itch would be 
influenced as a side effect of a (sham) transdermal caffeine patch. In short, verbal 
suggestions resulted in significant changes in the amount of itch that was experienced for 
both open-label and closed-label contexts, thus showing that these effects can be induced 
when people know about them. As in Chapter 5, further examination of baseline-to-post-
VS changes shows that itch significantly reduced in the positive VS groups, but did not 
change following negative suggestions. Taken together, these findings demonstrate 
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effective placebo and nocebo effect induction for itch under both open-label and closed-
label contexts. 
Taken together, the performed studies investigated experimental elicitation of placebo and 
nocebo effects using various methodological approaches. The studies examined the existing 
literature on this topic (Chapter 2) and whether effects could be elicited by 
pharmacological conditioning (Chapter 3) or by verbal suggestions (Chapter 4-6). Finally, 
they examined the potential of eliciting effects with participants’ awareness. In the 
following section, we discuss the results of this dissertation, mention limitations that may 
be addressed in future research, and discuss several clinical implications and the scientific 
relevance of the work. 
 
GENERAL DISCUSSION 
The systematic review in Chapter 2 indicated that placebo and nocebo effects have been 
investigated in itch and itch-related medical conditions and symptoms of the dermis and 
mucous membranes using a wide range of induction methods in patient samples, and in 
relevant animal and human (i.e., healthy participants) models. Three main categories of 
placebo and nocebo effects induction could be identified: associative learning (i.e., 
conditioning), instructional learning (i.e., verbal suggestions), and social learning (i.e., 
social cues). Verbal suggestions were used to investigate placebo and nocebo effects in 
human trials  with study groups of patients, healthy participants, or both. From the 
systematic literature review, we concluded that there  is evidence for the efficacy of verbal 
suggestions for eliciting both placebo effects and nocebo effects, however, the methods 
often differ between studies, and effects of suggestions on physiological outcomes are by 
and large lacking. Secondly, animal and human studies (in healthy participants and 
patients) showed both placebo (e.g., immunosuppression) and nocebo (e.g., exacerbation of 
allergic responses, or scratching behavior) effects on physiological and behavioral 
parameters through classical conditioning. For self-reported outcomes such as allergic 
symptoms and self-rated itch in human trials, conditioning of negative (nocebo) effects 
could be demonstrated. However, conditioning of positive (placebo) responses appeared 
more complicated. One explanation for such a phenomenon may be that learning of 
negative associations could be more potent and therefore needs less acquisition trials than 




would be sensible, considering that rapid learning of and responding to negative stimuli 
(i.e., threats) might be directly linked to an individual’s and species’ survival [1-4]. Finally, 
itch may also be prone to be influenced by social factors, as evidenced by successful 
induction of contagious itch and the impact that advertisements for different brands of 
antihistamines were demonstrated to have on reporting of allergic symptoms during 
antihistamine treatment.  
Overall, the existing literature demonstrates ample evidence for placebo and nocebo effects 
in itch and itch-related conditions and symptoms. However, the body of evidence currently 
available is also characterized by a large heterogeneity in both methodology and chosen 
outcome parameters – which makes it challenging to extend findings across dermatological 
conditions. The current dissertation builds on these previous findings and investigates 
placebo and nocebo effects for histamine-induced itch in healthy volunteers using 
conditioning and verbal suggestions. Previous studies used pharmacological conditioning to 
elicit placebo effects to enhance clinical outcomes in patients diagnosed with psoriasis [5] 
or allergic rhinitis [6,7]. However, these studies have investigated the efficacy of 
conditioning for a multitude of symptoms, including itch. This may complicate an exact 
interpretation of study findings, since symptoms could be susceptible to changes caused by 
multiple factors that are unrelated to the study aim (e.g., regression to the mean, 
spontaneous recovery). Moreover, symptoms may be elicited through various pathways 
(e.g., both histaminergic and non-histaminergic itch pathways). It may then be challenging 
to ascribe symptom change to a single isolated mechanism such as conditioning with, for 
example, antihistamines. The effects of pharmacological conditioning of antihistamines 
have not yet been tested in experimental models that exclusively induce histaminergic itch 
in healthy volunteers.  
Previous work with healthy volunteers also shows that itch may be reduced by providing 
positive verbal suggestions [8], and that negative verbal suggestions could increase itch [9-
11], but itch induction methods differ between studies and it may be challenging to translate 
study findings to clinical practice. This dissertation extends the previous findings by 
investigating the efficacy of conditioning and verbal suggestions for itch under open-label 
conditions (i.e. non-concealed). Potentially, eliciting placebo effects while patients are 
aware of this may lead to new therapeutic possibilities aimed at maximizing treatment 




Experimental induction of placebo and nocebo effects for itch  
Associative learning: antipruritic conditioning of H1-antihistamines 
Previous work shows that allergic responses can be exacerbated by conditioning in patients 
[12-14], and that immunosuppressive properties of medications may be sensitive to 
conditioning effects as well. Studies find that the effects of general immunosuppressive 
agents – for instance, of cyclosporine-A (CsA) – can be mimicked using conditioning 
mechanisms in humans: when only a conditioned stimulus (CS) is presented, similar effects 
are found compared with previous exposures, where the CS was presented together with 
CsA as unconditioned stimulus (UCS) [3,15,16]. For example, conditioning with CsA has 
been found to result in reduced levels of interleukin-2 and, in some studies, also reductions 
of IFN-γ [3,17,18]. Considering that exacerbation of allergic responses can also be 
conditioned, and considering the potential of conditioned (general) immunosuppression, it 
stood to reason that a reduction of allergic symptoms may also be conditioned. Two studies 
investigated this hypothesis by classically conditioning the effects of antihistamines in 
allergic patients, and reported mixed results: although a unique physiological conditioned 
response (i.e. reduced basophil activation) was found in one study [6], no distinctive effects 
for self-reported allergic symptoms and physical skin responses were identified [6,7]. It 
should be noted that one study showed these subjective outcomes reduced over time in both 
the conditioned and sham-conditioned groups, compared with a natural history group – thus 
implying that other factors, for example conscious expectancy, could have impacted 
outcomes [7]. For example, natural fluctuations in allergic symptoms may have been 
interpreted as medication effects and may thus have potentially interfered with the study 
protocol.  
The study reported in Chapter 3 builds on the findings of these two studies and 
investigated whether conditioning with H1-antihistamines could influence itch that was 
experimentally elicited by histamine and other (psycho)physiological parameters in healthy 
volunteers. In addition, the study investigated the efficacy of conditioning when 
participants were aware of the conditioning procedures (open-label). A conditioning 
protocol was applied with three acquisition moments and three evocation moments. Effects 
of conditioning on psychological and physiological parameters were examined, as were 
effects of conditioning during a short term histamine challenge, in which itch was 
experimentally elicited on the skin of the forearm during a short period of time. Limited 




found, while no effects of conditioning were found for any of the other parameters in the 
study. Potentially, conditioned responses may have been small, as the sample consisted of 
healthy participants who did not experience allergic symptoms prior to enrolment in the 
study – this may have led to a situation in which the unconditioned response (effects of 
levocetirizine) may not have been easily noticeable. Consequently, learned responses would 
also be small, or associations between the CS and UCS may not have readily formed (as 
previously discussed in Chapter 3). This would be in line with theoretical models that 
place expectancy at the center of placebo effects as they state that, in order to learn, 
awareness (of both causes and effects) is needed [19]. There is some evidence that 
challenges such models, however, as conditioning has been found to result in hyperalgesia 
and analgesia when the CS was presented on a subliminal (i.e. subconscious) level [19,20]. 
This would imply that it may hypothetically be possible to unconsciously condition 
endogenous responses through pharmacological means as well. This notion is supported by 
the marginal reduction in itch that was found in the conditioned groups of the study in 
Chapter 3. It should be noted though that this reduction in itch was not significant – for 
clinically relevant effects, awareness may be needed regardless. Alternatively, it may be 
possible that immunosuppressive conditioning needs more acquisition trials for stronger 
effects compared to the conditioning of negative events (e.g., allergic responses, other 
enhanced immune reactions), as immunosuppression may be less sensitive to conditioning 
[21]. From an evolutionary perspective, rapid learning of negative associations helps in the 
survival of organisms whereas positive associations may be less relevant and thus less 
salient for behavioral conditioning [1-4]. Moreover, measures of itch were taken on the 
third evocation day. It may be possible that (partial) extinction of the conditioned response 
had already taken place at that moment. For example, this has been shown in a study on 
conditioned endocrine responses, that used a similar design [22]. Future research could 
investigate whether antipruritic conditioned effects of antihistamines may be stronger at 
earlier evocation moments, or investigate what factors could help strengthen placebo effects 
elicited by antipruritic conditioning of antihistamines (e.g., a longer acquisition phase, itch 
induction during acquisition to boost learning). 
 
Instructional learning: verbal suggestions about itch and itch-related treatments 
Instructional learning, for example by verbal suggestions, may also be a potential 
mechanism by which placebo (and nocebo) effects could be elicited. As described in 
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Chapter 2, verbal suggestions can influence levels of itch, but some uncertainty exists 
about under which circumstances verbal suggestions may induce placebo or nocebo effects. 
In most experimental studies, the verbal suggestions are modelled after a situation in the 
clinic. Broadly, three different categories of information modelling can be discerned (see 
also Table 1): I. information about symptoms elicited by a test (Chapter 4 – as these 
suggestions are open-label exclusively, this category will be discussed in the following 
section), II. information about the intentional effects of a treatment method (Chapter 5), or 
III. information about the unintentional effects of a treatment method (e.g., side effects; 
Chapter 6).  
In Chapters 5 and 6, effects of concealed positive and negative verbal suggestions on itch 
elicited by a short-term histamine challenge were examined using different categories of 
information modelling. In Chapter 5, participants were told that the effects of a tonic on 
sensitivity of the skin to itch would be examined. Depending on group allocation, 
participants were then told that itch would either increase or decrease following the 
application of a (sham) tonic, making the proposed effects on itch a direct consequence of 
the intended treatment (Table 1: ‘model 2’). In Chapter 6, participants were told that the 
study investigated effects of a transdermal caffeine patch on cognitive functioning, and that 
as a side effect, this would impact sensitivity to somatic symptoms such as itch. As such, 
proposed positive or negative effects on itch were introduced as an inadvertent consequence 
of a treatment rather than the intended effects (Table 1: ‘model 3’). Overall, both types of 
suggestions were found to impact itch either during histamine application, or in a short 
follow-up period after the test. The two ways in which information was provided mirror 
those often used in consults with patients, where health care providers explain effects of a 
treatment as well as potential side effects that may be expected. 
For itch specifically, there are relatively few studies that have investigated effects of 
positive verbal suggestions about a treatment on itch. A single study showed that 
suggestions about a cream were able to elicit placebo effects for itch [8]. The study 
described in Chapter 5 is in line with this work and extends these previous findings by 
showing that verbal information about a different type of topical treatment (i.e., a ‘tonic’) 
can also influence itch in a short follow-up period to histamine iontophoresis. It should be 
noted though that itch during iontophoresis was not significantly influenced by positive and 
negative verbal suggestions. Potentially, the suggestions may not have been convincing 
enough to significantly influence itch during the test (e.g., participants were told that the 




component in the tonic would cause this). Nonetheless, the results of this study as a whole 
highlight a potential role of verbal suggestions in eliciting placebo and nocebo effects for 
itch.  
In Chapter 6, placebo and nocebo effects were elicited by providing information about itch 
as a side effect of a transdermal caffeine patch. Relatively few studies investigate whether 
nocebo effects can be elicited by providing side effect information in experimental settings. 
However, it has been demonstrated that the manner in which side effect information is 
framed can impact the frequency and severity of several drug-related side effects (see, for 
example, [34-38]). Although information framing has not been formally investigated for 
itch yet, the study findings described in Chapter 6 appear consistent with this line of 
research. For instance, it is shown that directional (i.e., positive or negative) information 
about itch as a side effect can directly impact the intensity of itch experienced by 
participants. Noticeably, significantly reduced itch was found following positive 
suggestions in Chapter 6, but itch did not increase following negative suggestions. This 
may be explained by the specific study procedures however (i.e., repeated itch provocations 
may result in lower itch by itself). Overall, the findings in Chapter 6 show that information 
about itch as a side effect may impact itch experience.  
Taken together, the studies described in Chapter 5 and 6 demonstrate that providing 
positive and negative verbal information can influence the experience of itch in 
experimental settings. This emphasizes that the type and manner in which information is 
provided could potentially be used to maximize treatment efficacy, by enhancing positive 
expectations about treatments and eliciting placebo effects. It furthermore shows that it is 
important to carefully consider the manner in which negative information should be 
provided in the clinic. Finally, the findings demonstrate that healthcare providers may be 
able to actively contribute to treatment efficacy by the manner in which they communicate 
about treatment. However, future research is needed in order to more precisely estimate 
placebo and nocebo effect sizes, and to investigate whether variations in instructions may 







































































































































































































































































































































































































































































































































































































































































































































































































































































































Open-label placebo and nocebo effects 
There has been a lot of debate on how to ethically use the knowledge of placebo and 
nocebo effects in clinical practice [39-42]. Central to this debate is the concept of 
deception: the notion that the deceptive nature of experimental placebo and nocebo effects 
induction would complicate direct application of this knowledge in clinical practice, as 
patients need to be fully informed about treatments for ethical medical treatment [39-42]. 
Over the years, various solutions to this conundrum have been proposed, including having 
patients provide consent for informed deception during treatment (e.g., so conditioning 
mechanisms can be used to enhance placebo effects), or providing patients with minimal 
information about side effects during consults, and offering them the option to look up 
information elsewhere (to minimize nocebo effects) [43]. Another promising angle of 
approach is through eliciting placebo effects without deception [39,44].  
Studies have found that open-label placebo effects can be elicited for symptoms of various 
conditions, including irritable bowel syndrome, allergic rhinitis, chronic low back pain, 
ADHD, and depression [28,29,45-55]. Central to most of these studies is the combination 
of giving inert pills and providing a rationale with four key arguments: 1) that placebo 
effects may be powerful, 2) that these effects may be learned through Pavlovian 
conditioning, 3) that positive attitudes are not necessary, but may be helpful to induce 
effects, and 4) that pills need to be taken faithfully (i.e., adherence) [45]. Overall, the 
studies show promising effects, but with regard to the type of open-label placebo effect 
induction, little is still known about the underlying mechanisms. A single study has teased 
apart the effects of the open-label placebo rationale and the inert pills, and found that the 
inert pills seemed to elicit effects, whereas the added rationale did not significantly 
contribute to placebo effects [28]. This would imply that effects may be mostly due to 
previous associations between the medical ritual of ingesting a pill and reduction of 
symptoms. Another study has shown that only groups that receive a rationale appear to 
benefit on subjective symptoms, at least when a cream is used as inert substance [52]. 
These discrepancies may be influenced by previously learned associations between 
application routes and efficacy for certain types of symptoms [57]. Relatively little is 
known about how variations in instructions and instruments (i.e., pills, creams, or other 
medication types) may impact open-label placebo effects, and effects have rarely been 
investigated for itch or itch-related conditions [28,29]. In the current dissertation, open-
label placebo and nocebo effects were induced using various methods, which will be 
discussed below.  
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Associative learning: antipruritic conditioning under open-label conditions 
The study described in Chapter 3 aimed to investigate whether pharmacological 
conditioning of antihistamines could also be effective when participants knew about the 
conditioning procedure. While in general, participants in the open-label arm of this trial 
expected less itch during the histamine challenge compared with the other groups (who 
were not told about the conditioning procedure, and who were blinded to whether they 
received active medication), conditioning was able to only marginally influence itch levels. 
This complicates interpretations of the impact that the open-label rationale may have had on 
the efficacy of the conditioning procedure. Previous studies show that open-label pills may 
be used as a dose-extender. For example, Sandler and colleagues [56] showed that 
subclinical doses (50% decrease) of extended-release mixed amphetamine salts (MAS-XR) 
could reduce ADHD symptoms in children to a level comparable with a full dose, when 
MAS-XR was given together with open-label placebo pills as ‘dose extenders’. For the 
open-label placebo pills, an explanation was given to participants of how they may impact 
treatment by eliciting placebo effects. While no classical conditioning procedure was used 
in this study, the information it yields may be used for future studies: making use of 
subclinical doses could potentially strengthen conditioned responses for itch as well. 
Finally, Schafer and colleagues [58] investigated whether revealing the conditioning 
procedure to participants would impact conditioned analgesia. They demonstrated that 
analgesia persisted, even when it was revealed that participants received a placebo, thus 
indicating that learned placebo effects can be robust. It should be noted though that these 
instructions were aimed at revealing deception, whereas the instructions used in Chapter 3 
of this dissertation were aimed at convincing participants of the efficacy of conditioning, 
with the purpose of strengthening expectancy effects and investigating whether placebo 
effects may be elicited by conditioning under open-label conditions. Revealing previously 
used deception may impede conditioning (i.e., conditioned effects were halved following 
the reveal in Schafer and colleagues’ experiment [58]), may have the potential to elicit 
negative thoughts or emotions, and may perhaps erode trust in health care practice in the 
long term. When conditioning is transparently and adequately explained prior to starting a 
treatment in which these mechanisms are utilized, such negative consequences could 





To our knowledge, the study described in Chapter 3 was the first to combine classical 
conditioning with open-label instructions. Variations in the frequency and what type of 
open-label instructions about conditioning should be provided naturally need to be further 
investigated, in order to fully gauge the impact of such instructions on the efficacy of 
conditioning of antipruritic effects. For example, the open-label instructions in Chapter 3 
were repeated with every administration of the CS and UCS or placebo pill. Future research 
may examine whether this repetition of instructions is necessary. In addition, the current 
open-label rationale did not specifically touch upon the biological underpinnings of 
conditioned placebo effects. The level of detail needed to maximize both comprehensibility 
of the conditioning mechanisms and positive outcome expectations may be examined in 
future research as well.  
 
Instructional learning: verbal suggestions about itch under open-label conditions 
As described above, few studies on open-label placebo effects have made the distinction 
between effects of the open-label placebo rationale and the inert pills, and the ones that did 
show that the effects may depend on the type of instrument (e.g., inert pills or creams) used. 
For example, in one study placebo effects elicited for allergic symptoms were found to be 
induced by an inert pill, while an added open-label rationale (i.e., explanation of placebo 
effects) did not elicit effects [28]. Another study reported contradictory findings, however, 
with an open-label rationale that did elicit placebo effects for pain and an inert cream that 
did not [52]. Hypothetically, one would imply that associative learning could underlie 
effects (i.e., placebo effects elicited by performing ritualistic medicinal practices that are 
strongly associated with symptom relief, for example, taking pills for pain reduction), 
whereas the other would imply that the explanation of placebo effects underlies the effects 
(i.e., cognitively modulating expectancies for treatment by explaining the working 
mechanisms involved and the to-be-expected effects). There are too few studies conducted 
in this field – with too little variation in instructions and instruments – to draw any firm 
conclusion on the underlying mechanisms of open-label placebo effects. Moreover, the 
medical conditions that are studied in this field vary, and little is known about whether 
open-label instructions can impact itch. The studies described in the current dissertation 
aimed to investigate whether information provided in an open-label context, modelled after 
three types of settings in the clinic (see also Table 1), could influence the experience of itch 
in an experimental setting.  
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In Chapter 4, open-label positive suggestions about an itch induction test were compared 
with neutral instructions. Participants were told that a histamine challenge would elicit little 
itch in most healthy people, and were given an explanation about how such suggestions 
may impact experienced itch. This type of information modelling (i.e., providing 
information about a method that elicits symptoms) has been previously used to test whether 
(concealed) nocebo or nocebo-like effects can be elicited (see for example, [11,23,25,59]). 
The study described in Chapter 4 is, to our knowledge, the first to examine whether this 
type of modelling could elicit placebo effects in an open-label context. While no direct 
effects of open-label positive suggestions were found, strong associations between 
participants’ post-suggestions expectations and experienced itch were observed exclusively 
when open-label suggestions were given. This indicated that participants reported levels of 
experienced itch close to those that they expected a priori, after open-label suggestions 
were given. Potentially, giving this type of information, and pointing out the role of 
expectations in the experience of symptoms, may be helpful when participants or patients 
already have positive expectations about a treatment. When expectations that patients have 
prior to treatment are negative however, providing information about the role of these 
expectations becomes more problematic, as this might only validate that the treatment will 
likely not work for them. In these cases, interventions aimed at optimizing expectations or 
at taking away the causes of negative expectations could be more helpful instead. Future 
research may aim to investigate whether such an approach may be useful to optimize 
treatment outcomes for itch.  
In Chapters 5 and 6, positive and negative suggestions were given under open-label 
conditions as well as closed-label (concealed) conditions. Effects of suggestions on 
expectations were stronger for the open-label condition, whereas for experienced itch, 
effects of suggestions under concealed conditions were larger. This apparent contradiction 
may be explained by the contents of the open-label rationale. In both studies, expectancy is 
central in the open-label rationale: participants are clearly told that expecting little (or a lot 
of) itch will influence the intensity of itch that they experience, also when they know about 
it. This may have primed them to report more profound levels of expected itch when 
subsequently questioned about their expectations. Regardless of this priming effect 
however, the studies in Chapter 5 and 6 show similar patterns in outcomes under both 
open-label and closed-label contexts. This implies that placebo and nocebo effects occur 
regardless of whether or not participants were informed about them, and that explicitly 




outcomes. However, some caution is needed in drawing this conclusion, as this infers that 
providing this type of information – that is, explaining the underlying mechanisms of 
placebo effects – has little actual impact on the formation of expectations about treatment. 
In Chapter 5 and 6, effects of suggestions on expectations were larger in an open-label 
context however. This suggests that an alternative explanation may be possible: the open-
label rationale may have helped in actively shaping placebo and nocebo effects by 
influencing expectations in a manner that is distinct from concealed placebo and nocebo 
induction. Speculatively, this would also be in line with previous studies that found that an 
open-label rationale may (partially) explain placebo effects independently of a previous 
placebo induction [52,60]. 
For nocebo effects it is particularly interesting that similar patterns were found for the 
open-label and closed-label groups. After all, informing patients about nocebo effects has 
previously been proposed as a potential approach to limit nocebo effects from occurring in 
clinical practice [61]. This implies that informing about nocebo effects could theoretically 
have a protective function. However, previous open-label studies [44] show that it does not 
appear to matter that participants are informed, at least when eliciting placebo effects. This 
would imply a facilitative (or neutral) role of informing about these effects, which is in 
contrast with the goal of informing about nocebo effects to prevent them. Findings of the 
current dissertation likewise support a facilitative (or neutral) role of explaining nocebo 
effects: the effects of negative suggestions were similar for both open-label and closed-
label (concealed) contexts in both Chapter 5 and 6. In future research, careful 
consideration of the manner in which patients or participants can be informed about nocebo 
effects is necessary, and it should be examined how variations of open-label explanations of 
nocebo effects may impact the induction of such effects, for example, by comparing 
different ways of framing this information. It might be especially relevant to examine how 
variations in explanations of the nature of placebo and nocebo effects in the open-label 
rationale may impact their effects. Both the current dissertation and previous literature have 
used an open-label rationale in which an automatic nature for placebo effects is 
emphasized. While this may be helpful for placebo effects (i.e., they occur regardless of 
whether you know about them), this may not be the case for nocebo effects. Hypothetically, 
an explanation of nocebo effects could emphasize active rather than passive components: 
instead of having these effects be described as automatic responses, focus could be on what 
can be done about them (e.g., which strategies can be employed to prevent nocebo effects 
from forming [62-66]). Future research may investigate such strategies.  
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On a final note, recent findings highlight that open-label placebo effects may depend on a 
patient’s beliefs about placebo effects [47,51]. As described in Chapter 5, participants in 
the open-label groups of this study rated the likelihood that their own experience of itch 
was influenced by the instructions as rather low. Moreover, effect sizes reported in the 
current dissertation were generally smaller than in other open-label studies, though this may 
be due to the other studies being conducted with patient populations rather than healthy 
volunteers [44]. Future research may aim to investigate for which (patient) subgroups open-
label placebos are most likely to be beneficial.  
 
Placebo and nocebo effects in physiological responses to histamine 
In line with most previous research [67], no effects of verbal suggestions on physiological 
responses to histamine were found in the studies described in Chapter 4, 5 and 6, with the 
exception of skin temperature, which changed following suggestions in the study described 
in Chapter 5 (i.e., less increase in skin temperature following positive suggestions 
compared with negative). These findings were not replicated in the study reported in 
Chapter 6, however. It is of note that previous studies found effects of suggestions under 
hypnosis on skin temperature [68-70]. Moreover, placebo effects have been found for 
physiological parameters (including skin temperature) that are usually associated with 
autonomic nervous system (ANS) functioning [71-73]. Indeed, in Chapter 3, the only 
physiological parameter for which group effects were found was heart rate. Any 
interpretation needs to be made very carefully however, considering that in previous studies 
suggestions were often made with the intent of changing these parameters (e.g., [68,70]), 
whereas for the studies in the current dissertation any effect of suggestions (or 
conditioning) on physiological parameters was treated as a by-product of a placebo 
response (i.e., the verbal suggestions did not explicitly mention effects on physiological 
parameters, although effects on other parameters were implied: “you will respond less to 
the histamine test”). This type of response generalization has been noted before, for 
example when suggestions of pain were given and skin temperature increased as a results 
[69], or when suggestions about exaggerated itch following skin prick tests were given and 
skin reactions were modulated as a result [10].  
Generally, placebo and nocebo effects were found more often for subjective symptoms such 
as itch in the current dissertation, whereas effects on physiological symptoms were more 




other than conditioning. This is in line with most previous literature and suggests that 
learning may be necessary in order to facilitate long-term and physiological effects, 
whereas for subjective symptoms, verbal suggestions may suffice. It has previously been 
suggested that placebo effects may be elicited by conditioning for unconscious 
physiological responses, and by expectancy for conscious psychophysiological responses 
(i.e., pain or itch) [74]. Distinct mechanisms for these effects elicited by conditioning and 
suggestions have been proposed, but have not been studied extensively so far [19]. For 
physiological responses to histamine, no comparisons between conditioning and 




The current dissertation provides novel evidence about placebo and nocebo effect induction 
for itch and other (psycho)physiological responses to histamine. However, several 
limitations of the research should be discussed. First, no optimal conditioning protocol 
could be identified in previous literature (see Chapter 2) because the study protocols 
showed large heterogeneity (related to the specific physiological mechanisms of the used 
stimuli). This complicated the study design for the study described in Chapter 3. It was 
opted that three acquisition sessions would be sufficient for conditioning to take place. 
Although stronger learning may occur with an increase of learning trials, gustatory learning 
is thought to be strongly linked to evolutionary processes and may therefore occur after a 
single exposure [75]. The decision to measure itch at the end of a three-days evocation 
phase means that (some) extinction of learned responses could have already occurred. 
Including histamine tests at earlier time points could potentially have interfered with 
conditioning effects for other parameters however.  
Healthy volunteers were examined in all studies of this dissertation in order to limit the 
amount of factors that could impact the effects of suggestions and learning on itch. For 
example, patient groups may have a larger variability in previously learned expectations. 
These expectations may be especially influenced in patient groups by duration of illness 
and by previous positive or negative experiences with treatments or the health care system. 
In addition, by including healthy volunteers only, natural fluctuations in symptom severity 
or other complications often seen in patient samples were excluded. This may have 
influenced the study results, as effect sizes could potentially have been smaller due to lower 
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expected benefit experienced by healthy volunteers. Indeed, participants knew that induced 
symptoms would be short-term and that they would be able to stop the induction of 
symptoms at any point in time. This considerably lowers benefits of participating in a 
study, and patient samples may arguably have a higher wish or desire for improvements in 
their symptoms, especially when complaints are chronic. Future research may therefore 
consider investigating placebo and nocebo effects in patient populations for whom itch is a 
relevant symptom, as placebo and nocebo effects may be more impactful there.  
The studies in which suggestions about itch were given were mostly proof of concept 
studies, in which especially new open-label instructions were tested. Comparisons with 
previous open-label studies were made in the current dissertation, but some caution is 
needed, especially given that the content of the rationale differs across studies. For 
example, it was not possible to use one of the key arguments in previous open-label 
rationales (i.e., that placebo effects are learned) for the studies described in Chapter 4-6. 
Given that verbal suggestions were used to elicit placebo and nocebo effects, together with 
instruments (e.g., tonic, transdermal caffeine patch) unlikely to have been associated with 
itch treatment in the past, providing a rationale about learned placebo effects would have 
been redundant – learning was simply not relevant for the studies described in Chapter 4-6 
and the studies show that open-label effects may also occur without mentioning that 
placebo effects are learned. However, interpretations need to be made carefully, as demand 
characteristics may play a role in such studies. The findings of the current studies should 
therefore be confirmed by future studies, preferably with a double-blind study design. 
Moreover, future research may consider including a neutral control group, as in the current 
dissertation positive and negative suggestions were often compared. While this does allow 
for assessment of the impact of suggestions on itch and other parameters, no estimation of 
the ‘true placebo effect’ or the ‘true nocebo effect’ can be made, as the normal course of 
repeated tests is unknown.  
Finally, limitations concern the power calculations for the secondary hypotheses in the 
studies described in this dissertation. The effect sizes used as input for these calculations 
were derived from previous work on placebo and nocebo effects in itch, and resulted in a 
sample size adequate to test group differences under the separate open-label and closed-
label contexts. However, analyses for the secondary outcome measures, such as wellbeing, 
self-rated and physical skin response to histamine (Chapter 3-6), and heart rate, skin 
conductance, and pulmonary functioning (Chapter 3), may have been underpowered. 




of personality traits, for example, optimism or neuroticism. Previous work shows 
indications that personality traits like these may be related to placebo and nocebo 
responding [10,76,77], but this was not confirmed by the studies described in the current 
dissertation.  
 
Future research directions 
The current dissertation raises several relevant questions that may be further investigated in 
future research. First, as demonstrated in the systematic review, the field of classical 
conditioning of immune responses relevant to dermatology has been investigated 
extensively with animal models. Human trials have focused most on conditioned 
exacerbation of allergic symptoms, whereas comparatively little is known about how to use 
classical conditioning mechanisms to enhance treatment efficacy. At the moment, only two 
studies focused on suppression of allergic symptoms using conditioning mechanisms, but 
these were unable to distinguish between conditioning and expectancy effects for subjective 
symptoms. The study described in Chapter 3 extends these findings by investigating 
pharmacological conditioning of antihistamine in healthy volunteers. It was demonstrated 
that conditioning marginally improved itch in response to a histamine challenge. 
Theoretical implications from this study are that classical conditioning indeed may result in 
learned suppression of itch or other markers of allergic symptoms, but that, hypothetically, 
conscious learning (i.e., experiencing reduced symptoms during acquisition) may 
strengthen these effects. Therefore, effects may be stronger in case of patient studies, as 
patients could rapidly notice changes in their symptoms, whereas for studies with healthy 
volunteers, symptoms first need to be deliberately induced. As a first step however, future 
research may consider strengthening the design used to test pharmacological conditioning 
with H1-antihistamines. For example, future research may consider including multiple 
histamine tests, especially given that the timing of conditioned responses for itch, and 
specifically antipruritic conditioning with antihistamines, has not been investigated 
systematically. Moreover, including histamine tests in the acquisition phase may help 
strengthen associative learning for itch in healthy volunteers. It could be possible that in the 
current, study participants may not have noticed effects of the medication, which would set 
them up for insufficient learning of associations between CS and UCS. Including multiple 
tests, or including patients who experience symptoms during acquisition for which they can 
notice improvements, would help strengthen this type of associative learning. Alternatively, 
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other outcome parameters could be considered in the future, for example, measuring 
immune markers related specifically to antihistamine in the blood (e.g., interleukins) 
[78,79]. These parameters may potentially be more sensitive to relatively smaller 
conditioned effects compared to subjective or clinical parameters (e.g., itch, pulmonary 
functioning), but were not measured in the current study.  
The conditioning study described in Chapter 3 showed that conditioning marginally 
reduced itch for both open-label and closed-label contexts. This raises the question whether 
deception is necessary for conditioning to occur. Potentially, the conditioning procedure 
may be explained to participants without losing effects for itch. This needs support of future 
research, however, as conditioned effects in the current study were marginal and not 
significant, which hampered assessment of the impact of the open-label rationale. It would 
be relevant for future studies to further focus on whether and under which circumstances 
open-label conditioning could reduce itch, as non-deceptive placebo induction may be 
promising to apply in clinical practice. Regarding open-label placebo effects, another 
interesting question was raised in Chapter 4. It was demonstrated that instructions about 
low itch and about how participants’ expectations impact itch experience led to higher 
positive associations between expected and experienced itch. However, emphasizing such a 
relation between expectations and symptomatology may become problematic for nocebo 
effects, specifically in populations-at-risk, for example, individuals who are highly anxious 
about receiving medical treatment or have a high fear of side effects. The impact of 
negative information in these subpopulations may be investigated more thoroughly in future 
research, for example, by comparing the effects of such instructions across groups with 
high or low fear of side effects.  
Future research may also consider investigating effects of learning and instructions on 
scratching or other behaviors related to itch. In the systematic literature search in Chapter 
2, studies are described that show that social cues can impact not only itch (i.e., contagious 
itch) but also the frequency of spontaneous scratching behavior [80-82]. Scratching has 
been found to exacerbate itch in skin conditions, and to result in a vicious itch-scratch cycle 
that can lead to significant impairments for patients (e.g., loss of control, feelings of shame, 
social isolation) [83]. Therefore, investigating whether placebo and nocebo effects can 
significantly influence scratching behavior may be a worthwhile approach for future 
research. So far, a single study investigated whether nocebo effects could generalize from 
itch to scratching in healthy volunteers, and found no evidence for such response 




effects for itch can also result in reduction of scratching behavior (i.e., response 
generalization). If it can be demonstrated that placebo effects can generalize from itch to 
scratching behaviour, this may lead towards new therapeutic possibilities that could target, 
for example, the itch-scratch cycle. 
Finally, the studies described in Chapter 5 and 6 show that placebo and nocebo effects 
elicited by verbal suggestions are similar across open-label and closed-label contexts. This 
raises another theoretical question on the similarity of such open-label and closed-label 
placebo and nocebo effects. In these chapters, the open-label rationale was provided as an 
add-on for verbal suggestions about a treatment tool (tonic or caffeine patch). In general, 
the elicited effects were similar under open-label and closed-label conditions, which has 
some important implications for research. Careful consideration of the type of information 
to be provided is necessary. Moreover, the goal that is to be achieved by providing 
information needs to be considered: if the intention is, for instance, to prevent side effects 
from occurring, it may not be sufficient to only explain that negative expectations can result 
in nocebo effects. Hypothetically, such a method could just as likely facilitate nocebo 
effects (especially when the information about nocebo effects is negatively framed). Rather 
than explaining that nocebo effects occur through conditioning as a passive, automatic 
process, it may be more beneficial instead to explain that expectations can be actively used 
to modulate experience of symptoms [62-66]. Future research could examine whether such 
an approach can be used to prevent nocebo effects, as well as how this would relate to 
placebo effects. For instance, it may be worthwhile to investigate whether an open-label 
rationale that promotes empowerment and active modulation of expectations can enhance 
placebo effects, or whether it is more prudent for open-label placebo effects to emphasize 
automaticity of learned responses.   
 
Implications for clinical practice 
The results of the current dissertation show that placebo and nocebo effects can be induced 
for itch and itch-related conditions and symptoms of the mucous membranes using a 
multitude of methods, including verbal suggestions and conditioning. The information this 
provides may be used to enhance patients’ expectations regarding treatment outcomes in 
clinical practice, for example, by emphasizing positive information when explaining to-be-
expected treatment outcomes to patients and by positive framing of potential adverse 
effects. For example, when explaining side effects occurrence, it may be useful to discuss 
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the percentage of people that do not experience them rather than the percentage that do [34-
38], or to change the manner of informing about side effects of a treatment (e.g., fostering a 
mindset that side effects may signal that therapies such as immunotherapy work; [85]). 
Moreover, conditioning mechanisms could be used to maximize placebo effects. For 
example, by varying the doses of medication, without changing any of the attributes (e.g., 
the amount, color and shape of pills), conditioned effects could be used to potentially 
achieve similarly or more effective treatment with lower doses of medication. Several 
studies already show that this method of conditioned dose reduction can lower medication 
intake without loss of treatment efficacy for various medical and psychological conditions 
[5,56]. Findings of the study described in Chapter 3 indicate that such an approach may 
potentially be useful to support pharmacological treatment of itch-related conditions as 
well, however, this needs to be investigated more thoroughly before it can be applied in 
clinical practice.  
In Chapter 4, it is demonstrated that open-label positive suggestions about an itch-inducing 
method can result in positive outcome expectations, and that these in turn are associated 
with lower itch experience during an experimental itch induction test. This shows that it 
may be relevant to consider in which ways potentially unpleasant tests and proceedings in 
health care settings are introduced to patients. Though more research is needed, these 
findings provide a first indication that it may be helpful to address patients’ own 
expectations and to discuss the impact that these expectations could have on, for example, 
recovery from medical proceedings, or pain levels during such procedures, especially when 
patients are highly anxious for invasive procedures. To illustrate, there are studies that show 
that communication interventions, informational preparation and positive suggestions can 
influence pain levels [86]. This could potentially be the case for itch as well. Moreover, 
next to negative emotions (e.g., stress and anxiety), high levels of ruminating (as a chronic 
negative expectation) have been found to be a predictor for itch in clinical settings as well 
[87-89]. The findings described in Chapter 4-6 show that suggestions can impact itch 
experience, and suggest that providing information about placebo (and nocebo) effects 
could be a useful way to enhance expectancy effects for itch. In clinical practice this may 
translate, for example, to psychoeducation regarding the role that expectancy has in 
harnessing placebo effects for somatic symptoms. Finally, the current studies give some 
indications that open-label conditioning may potentially be a worthwhile method to 
facilitate the use of placebo effect mechanisms in clinical practice. If this can be replicated 




populations), this may then translate into therapies that utilize conditioned dose reduction in 
an open-label context. Conditioned dose reduction has already been found effective in 
psoriasis in a closed-label (i.e., concealed) context [5]. If it is proven effective in an open-
label context, medication use could be reduced, and the full potential benefits of placebo 
effect mechanisms could be reaped in clinical practice as a result.  
 
Conclusion 
In the current dissertation, we investigated the experimental elicitation of placebo and 
nocebo effects for histamine-induced itch and other psychophysiological responses to 
histamine. Placebo and nocebo effects were examined in a systematic review of the 
literature, as well as in a series of studies that used multiple induction methods (i.e., 
classical conditioning, verbal suggestions) for placebo and nocebo effects under both open-
label and closed-label (i.e. non-concealed and concealed) conditions. Overall, the 
dissertation demonstrates that placebo and nocebo effects can be elicited for itch and itch-
related parameters by several means. It is shown that histamine-induced itch may be 
influenced by suggestions under both open-label and closed-label conditions. Moreover, the 
dissertation shows that potentially, antipruritic effects of antihistamines may be sensitive to 
conditioning to some extent, though this needs to be investigated further in future research. 
Placebo (and nocebo) effects can be elicited by conditioning and suggestions with 
participants’ knowledge as well, which is a first step in opening new pathways towards 
therapeutically applying placebo and nocebo effect knowledge without deception or 
concealment of methods. Using associative and instructional learning in medical treatments 
with participants’ knowledge may be a promising strategy to maximize placebo effects, 
minimize nocebo effects, and help in reducing medication use for (chronic) itch and other 
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Placebo-effecten zijn positieve behandeluitkomsten die niet kunnen worden toegeschreven 
aan actieve behandelonderdelen van bijvoorbeeld farmacotherapie of niet-medicamenteuze 
therapieën. Zo kunnen placebo-effecten ook ontstaan wanneer een inactieve stof wordt 
toegediend (d.w.z., een suikerpil oftewel placebopil), en degene die de pil neemt daarbij 
verwacht dat het een actieve behandeling is, die zal helpen bij het verminderen van 
klachten. Direct tegenover placebo-effecten staan zogeheten nocebo-effecten, dat wil 
zeggen, negatieve behandeluitkomsten die niet aan actieve behandelonderdelen 
toegeschreven kunnen worden. Nocebo-effecten ontstaan door (bewuste of onbewuste) 
negatieve verwachtingen. Dit kan bijvoorbeeld gebeuren wanneer iemand verwacht dat 
medicijnen voor vervelende bijwerkingen gaan zorgen (een negatieve behandeluitkomst), 
omdat ze hierover geïnformeerd zijn of in het verleden vervelende ervaringen mee hebben 
gehad. Het is ook mogelijk dat negatieve verwachtingen de werking van effectieve 
behandelingen verminderen. Dit gebeurt bijvoorbeeld wanneer men twijfelt over de 
effectiviteit van een gegeven behandeling. Er is al veel onderzoek gedaan naar placebo- en 
nocebo-effecten bij lichamelijke symptomen zoals pijn en er zijn indicaties dat andere 
lichamelijke symptomen, zoals vermoeidheid, misselijkheid en jeuk, ook onderhevig 
kunnen zijn aan dit soort effecten. Studies laten bijvoorbeeld zien dat biopsychosociale 
factoren een grote rol kunnen spelen bij de ervaring van jeuk. Zo is er aangetoond dat enkel 
praten over jeuk dit symptoom kan opwekken (dit wordt ook wel ‘besmettelijke jeuk’ 
genoemd). Door deze grote invloed van biopsychosociale factoren is het mogelijk dat 
placebo- en nocebo-effecten bij jeuk bijzonder relevant zijn.  
Onderzoek toont aan dat placebo- en nocebo-effecten kunnen worden opgewekt door 
verschillende leermechanismen, waaronder associatief leren en instructieleren. Bij 
associatief leren worden verbanden tussen stimuli en daaropvolgende gebeurtenissen 
aangeleerd. Meer specifiek wordt dit ook wel klassieke conditionering genoemd. Bij 
medicijngebruik bijvoorbeeld kan het nemen van een pil (stimulus) leiden tot  een 
vermindering van hoofdpijn (de daaropvolgende gebeurtenis). De pil (ongeconditioneerde 
stimulus) heeft farmacologische eigenschappen die leiden tot vermindering van hoofdpijn; 
dit noemen we de ongeconditioneerde respons. Het kan zo zijn dat (na verloop van tijd) ook 
andere eigenschappen van de pil, bijvoorbeeld de vorm of kleur hiervan, in de hersenen 
geassocieerd worden met pijnvermindering. Dit (de vorm of kleur van de pil) heet de 
geconditioneerde stimulus. Wanneer alleen de aanblik of het nemen van een pil met 
dezelfde vorm of kleur leidt tot een vermindering in pijn, spreken we van een aangeleerde 




binnen dit proefschrift is toegepast is instructieleren. Deze vorm van leren omvat het leren 
doordat informatie of instructies gegeven worden, die de verwachtingen die mensen hebben 
over toekomstige gebeurtenissen beïnvloeden. In het kader van placebo-effecten kan hier 
bijvoorbeeld gedacht worden aan verbale suggesties over hoe effectief een procedure of 
behandeling zal zijn. Wanneer aangegeven wordt dat een procedure tot weinig pijn of jeuk 
zal leiden, wordt hierdoor een positieve verwachting gevormd. Deze kan er vervolgens toe 
leiden dat mensen minder pijn of jeuk ervaren dan wanneer verteld wordt dat deze 
procedure veel pijn of jeuk kan opwekken. De extra pijn- of jeukvermindering die enkel 
door het geven van deze instructies optreedt wordt ook toegeschreven aan placebo-effecten.  
Het primaire doel van dit proefschrift was om te onderzoeken of placebo- en nocebo-
effecten opgeroepen kunnen worden voor jeuk (die werd opgewekt door de toediening van 
histamine op de huid) met behulp van de bovengenoemde leertechnieken. Tevens zijn 
effecten op andere (psycho)fysiologische reacties op histamine onderzocht. Hierbij zijn 
placebo- en nocebo-effecten binnen twee verschillende contexten onderzocht. Een van de 
contexten is hoe onderzoek naar placebo-effecten traditioneel verricht wordt: wanneer 
mensen niet weten dat er placebo- of nocebo-effecten worden opgewekt en een werkzaam 
middel verwachten (verborgen inductie van deze effecten; dat wil zeggen, in een gesloten-
label context). In een andere context werd onderzocht wanneer men op de hoogte was van 
de inductie van placebo- of nocebo-effecten (een zogeheten open-label context). In een 
dergelijke situatie worden placebo- of nocebo-effecten expliciet aan deelnemers uitgelegd 
en wordt verteld hoe en waarom deze effecten kunnen bijdragen aan een behandeling van 
jeuk. Studies naar deze open-label inductie van placebo-effecten zijn relatief nieuw: er is 
nog weinig bekend over open-label placebo-effecten en voor welke symptomen deze 
kunnen worden geïnduceerd. Wanneer open-label placebo- en nocebo-effecten geïnduceerd 
kunnen worden voor jeuk, kan onderzoek hiernaar bijdragen aan een vernieuwende en 
ethische toepassing van de achterliggende mechanismen in de klinische praktijk, 
bijvoorbeeld door de effectiviteit van bestaande behandelingen te vergroten. Samenvattend 
werd in dit proefschrift het opwekken van placebo- en nocebo-effecten onderzocht met 
behulp van verschillende leermechanismen. Hierbij lag de focus in het bijzonder op het 
lichamelijke symptoom jeuk. De beschreven studies onderzochten de bestaande literatuur 
over dit thema (Hoofdstuk 2), evenals de vraag of placebo- en nocebo-effecten 
experimenteel opgewekt kunnen worden door (farmacologische) conditionering (associatief 
leren; Hoofdstuk 3) en verbale suggesties (instructieleren; Hoofstukken 4–6). Bovendien 
werd onderzocht of deze effecten al dan niet opgewekt konden worden wanneer deelnemers 
e  verbale suggesties (instructielere ; oofdstu ken 4-6). ien 
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zich bewust waren van de conditionering of betreffende verwachtingsinductie (d.w.z. in een 
open-label context).  
In Hoofdstuk 2 is de bestaande literatuur over experimenteel geïnduceerde placebo- en 
nocebo-effecten bij jeuk, jeuk-gerelateerde aandoeningen en symptomen van de huid en 
slijmvliezen onderzocht. In deze systematische literatuurstudie werden naast studies bij 
patiëntpopulaties ook studies naar relevante diermodellen en experimentele studies met 
gezonde participanten geïncludeerd. De literatuurstudie beschrijft methoden die doorgaans 
gebruikt worden om placebo- en nocebo-effecten op te wekken. Daarnaast wordt een 
samenvatting van de onderzoeksresultaten gegeven. In grote lijnen kan worden gesteld dat 
in de literatuur gebruik is gemaakt van drie leertechnieken (of combinaties hiervan) om 
placebo- en nocebo-effecten op te wekken: associatief leren (klassieke of operante 
conditionering), instructieleren (met behulp van verbale suggesties, al dan niet aangeboden 
met hypnose) en sociaal observatieleren (bijvoorbeeld inductie van ‘besmettelijke jeuk’). 
Over het algemeen konden deze technieken placebo- en nocebo-effecten opwekken voor 
jeuk en jeuk-gerelateerde symptomen van de huid (zoals zwellingen of laesies). Wel waren 
de gevonden studies vaak heterogeen in de gekozen inductietechnieken (bijv. 
conditionering en suggesties), en bleken de geïnduceerde placebo- en nocebo-effecten vaak 
voorwaardelijk te zijn: zo waren geconditioneerde effecten bijvoorbeeld vaak afhankelijk 
van de context waarin effecten werden geleerd, en leidden veranderingen in 
omgevingsfactoren ertoe dat effecten verminderden of verdwenen. Bovendien waren 
verbale suggesties vaak enkel effectief op korte termijn. Samenvattend laat de 
systematische literatuurstudie zien dat een grote verscheidenheid aan experimentele 
procedures is gebruikt binnen de studies; dat wil zeggen, er is geen standaard 
‘conditioneringsprotocol’ of standaard set van verbale suggesties voor het oproepen van 
placebo- en nocebo effecten te onderscheiden. Bovendien zijn effecten onderzocht in zeer 
diverse patiëntenpopulaties, en zijn verscheidene diermodellen en experimentele modellen 
met gezonde participanten gebruikt.  
In Hoofdstuk 3 zijn de resultaten van een gerandomiseerd gecontroleerd onderzoek naar 
klassieke (farmacologische) conditionering van de jeuk-remmende eigenschappen van 
antiallergische medicijnen (antihistaminica) gerapporteerd. Twee eerdere studies hebben 
farmacologische conditionering met antihistaminica bij patiënten met een 
huisstofmijtallergie onderzocht. Deze studies konden geen onderscheid maken tussen 
geconditioneerde effecten en anderszins aan verwachting gerelateerde effecten 




effectiviteit van antihistaminica, nog voordat zij deelnamen aan het onderzoek) op zelf-
gerapporteerde allergische symptomen. De studie uit Hoofdstuk 3 was bedoeld om de 
kennis opgedaan uit eerdere studies aan te vullen, door geconditioneerde effecten voor jeuk 
(experimenteel opgewekt door histamine toe te dienen op de huid) bij gezonde vrijwilligers 
te onderzoeken. Conditionering werd bovendien onderzocht binnen twee verschillende 
contexten: een open-label context, waarin deelnemers uitleg over conditionering ontvingen 
en verteld werd dat de effecten van conditionering met antihistaminica in deze studie getest 
werden; en een gesloten-label context, waarin deelnemers niet wisten dat zij 
geconditioneerd werden. Deze twee groepen werden vergeleken met twee controlegroepen. 
Ondanks dat conditionering (in de gecombineerde open- en gesloten-label context groepen) 
leidde tot een marginale vermindering van jeuk vergeleken met de controlegroepen, werden 
geen significante verschillen tussen de afzonderlijke groepen gevonden. Tevens werden 
andere parameters binnen de studie niet tot weinig beïnvloed door conditionering. Over het 
algemeen biedt de studie beperkt bewijs voor de jeuk-remmende effecten van 
conditionering met antihistaminica bij gezonde vrijwilligers.  
In de hoofdstukken 4, 5 en 6 worden drie gerandomiseerde gecontroleerde onderzoeken 
beschreven, waarin de effecten van verbale suggesties op jeuk en andere 
(psycho)fysiologische reacties op histamine werden onderzocht. In Hoofdstuk 4 werden de 
effecten van open-label positieve verbale suggesties (over het ervaren van weinig jeuk na 
een histamine-applicatie op de huid) vergeleken met neutrale instructies. Hoewel er geen 
significante verschillen in jeuk tussen de groepen zijn gevonden, waren de verwachtingen 
over jeuk van deelnemers wel significant beïnvloed door de instructies. Zo verwachtten 
deelnemers na de suggesties minder jeuk te ervaren vergeleken met deelnemers die neutrale 
instructies kregen. Deze verwachtingen van deelnemers waren significant gerelateerd aan 
de hoeveelheid jeuk die ervaren werd: hoe minder jeuk deelnemers verwachtten, hoe 
minder jeuk zij uiteindelijk rapporteerden. Dit werd uitsluitend binnen de positieve 
suggestie groep gevonden; na neutrale instructies was dit verband niet aanwezig. 
Bovendien kon een trend worden waargenomen voor zelf-beoordeelde conditie van de huid 
na toediening van histamine: na open-label positieve verbale suggesties werd de 
huidconditie door deelnemers marginaal beter beoordeeld vergeleken met de neutrale 
instructie groep. Samenvattend illustreren deze resultaten een potentiële rol voor open-label 
placebo effecten bij jeuk.  
In Hoofstuk 5 werden de effecten van open-label en gesloten-label positieve en negatieve 
verbale suggesties over de jeuk-verminderende of -verhogende eigenschappen van een 
dstuk 5 werden de effecten   d iti  
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(niet-werkzame) tonic op jeuk vergeleken. Deelnemers in de open-label groepen ontvingen 
naast suggesties een extra uitleg over hoe informatie en verwachtingen de ervaring van jeuk 
kunnen beïnvloeden. Hoewel er geen effect van suggesties op de ervaren jeuk tijdens het 
toedienen van histamine op de huid (de primaire uitkomstmaat van het onderzoek) werd 
gevonden, was jeuk tijdens een korte follow-up periode lager in de positieve vergeleken 
met de negatieve verbale suggestie groepen (zowel voor de open- als gesloten-label 
contexten). Exploratieve nadere analyse van de data liet zien dat jeuk in de positieve 
suggestiegroepen aanzienlijk verminderde van de baseline tot post-suggestie test, terwijl in 
de negatieve suggestiegroepen geen significante veranderingen over tijd werden 
geobserveerd. De resultaten van deze studie laten zien dat positieve suggesties jeuk kunnen 
verminderen in vergelijking met negatieve suggesties, zowel wanneer men op de hoogte is 
van het ontvangen van suggesties (open-label) als wanneer dit niet zo is (gesloten-label).  
Hoofdstuk 6 beschrijft de bevindingen van een studie waarin de effecten van open-label en 
gesloten-label positieve en negatieve suggesties op jeuk opnieuw vergeleken werden, 
ditmaal met de suggestie dat jeuk wordt beïnvloed als bijwerking van het toebrengen van 
een transdermale pleister. Deelnemers werd verteld dat deze pleister cafeïne bevatte (terwijl 
het in feite een niet-medicamenteuze, dat wil zeggen een niet-werkzame, pleister betrof). 
Verteld werd dat, als bijwerking van deze pleister, ook de gevoeligheid voor lichamelijke 
prikkels beïnvloed zou worden (in de positieve verbale suggestiegroepen werd verteld dat 
dit tot minder jeuk zou leiden, en in de negatieve verbale suggestiegroepen werd verteld dat 
dit tot meer jeuk zou leiden). Net zoals in de studie uit Hoofdstuk 5 ontvingen deelnemers 
in de open-label groepen extra informatie over de invloed van informatie en verwachtingen 
op de ervaring van jeuk. Kort samengevat leidden positieve verbale suggesties vergeleken 
met negatieve verbale suggesties tot een significante afname van de hoeveelheid jeuk die 
tijdens histamine-applicatie werd ervaren, zowel in een open-label als in een gesloten-label 
context. Net zoals in het onderzoek uit Hoofdstuk 5 blijkt jeuk aanzienlijk te verminderen 
in de positieve verbale suggestiegroepen, terwijl in de negatieve suggestiegroepen jeuk 
onveranderd blijkt. Samengevat tonen deze bevindingen aan dat bepaalde verbale 
suggesties jeuk kunnen beïnvloeden, ongeacht of men van de verwachtingsinductie door 
suggesties afweet (open-label) of niet (gesloten-label).  
In Hoofdstuk 7 worden de bevindingen uit het proefschrift besproken aan de hand van de 
wetenschappelijke literatuur. Samenvattend wordt in de literatuur bewijs voor placebo- en 
nocebo-effecten bij jeuk (en jeuk-gerelateerde parameters) gevonden. Daarnaast is 




wordt, hoewel meer onderzoek nodig is om te bepalen hoe deze leerprocessen werken en 
dergelijke effecten versterkt zouden kunnen worden. De in het proefschrift besproken 
studies dragen bij aan kennis ten aanzien van het kunnen opwekken van placebo- en 
nocebo-effecten, ook wanneer men hiervan weet. De ethische overwegingen die een rol 
spelen binnen de geneeskunde, bijvoorbeeld de noodzakelijkheid van het zo volledig 
mogelijk informeren van patiënten over behandelingen en behandelopties, maakt dit type 
onderzoek bijzonder relevant in de zoektocht naar strategieën om kennis over placebo-
effecten toe te passen in de klinische praktijk. Onderzoek naar (met name open-label) 
placebo- en nocebo-effecten bij jeuk en andere symptomen kan op deze manier bijdragen 
aan het op een ethische en verantwoorde manier verbeteren van bestaande behandelingen, 
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